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SUMMARY
CR1 is the receptor for the activated third component 
of complement C3h. It is present on the cell membranes of 
human erythrocytes, lymphocytes, polymorphonuclear leucocytes, 
mononuclear phagocytes, mast cells, B lymphocytes, some T 
lymphocytes and kidney podocytes.
Purification of CR1 from human erythrocytes using cation 
exchange and affinity chromatography revealed a single protein 
with a molecular weight of 230000 daltons. This protein was 
used to raise a polyclonal antiserum in rabbits, which was 
then utilised in the development of a radioimmunoassay to 
quantitate the number of CR1 on human peripheral blood cells.
This assay was used successfully to quantitate CR1 levels on 
erythrocytes. However, it could not be adapted to assess CR1 
levels on monocytes, lymphocytes or polymorphonuclear leuco­
cytes .
CR1 levels have previously been reported to be reduced 
on erythrocytes from patients with systemic lupus erythematosus 
(SLE). However, there has been no agreement in the literature 
as to whether the reduced erythrocyte CR1 levels observed 
are acquired as a consequence of the pathological process 
of the disease or are an inherited defect. The aim of the 
experiments performed in this thesis was to establish whether 
CR1 levels are inherited or acquired. To examine this erythro­
cyte CR1 levels were studied in normal individuals and SLE 
patients. In addition, patients with rheumatoid arthritis 
(RA) were investigated. Serial studies were performed on normal 
individuals, SLE and RA patients to see whether there were
XXI11
temporal changes in CR1 levels. CR1 levels were also 
assessed in normal families and in families where one or 
more individuals had SLE to ascertain whether receptor levels 
were inherited.
CR1 levels were quantitated using a radioimmunoassay,
125
which measured the amount of I-FCab')^ anti-CR1 binding 
to the erythrocytes. From this the number of binding sites 
per erythrocyte for the F/ab')^ anti-CR1 moiety was calculated 
(CR1 sites/erythrocyte).
Seventy normal erythrocyte specimens were studied; the 
mean was 3320 CR1 sites/erythrocyte (range 0 to 21692 CR1 sites/ 
erythrocyte) whilst the mean for the SLE patients was 1541 
(n=41, range 0 to 15766 CR1 sites/erythrocyte), significantly 
lower (p <0.001) than the normals. Likewise the mean (1410 
CR1 sites/erythrocyte, n=25) for the RA patients was also 
significantly lower (p <0.05). A striking observation was 
that many of the SLE patients had no receptors (27% as opposed 
to 1.5% in the normals and 0% in the RA group). When the 
SLE patients were further subdivided into those who were in 
an active disease phase or an inactive disease phase, the 
majority of patients with zero receptors were in an active 
disease state. When analysed further the mean CR1 level for 
the patients with active disease (356 CR1 sites/erythrocyte) 
was significantly lower (p <0.001) than those with inactive 
disease (2428 CR1 sites/erythrocyte). These levels were not 
related to any of the serological parameters studied. Serial 
studies on SLE patients showed that in some individuals the 
CR1 levels varied with disease activity, decreasing during 
exacerbations and increasing during remission.
XXIV
Family studies showed a clustering of low, medium 
or high CR1 levels in individual families. However, 
where a member of a family had SLE their CR1 levels 
were not akin to their families suggesting acquisition 
and not inheritance. Studies of two sets of identical twins 
showed that they did not have identical CR1 suggesting that 
they had acquired different levels..
Two main conclusions may be drawn from these studies,* 
firstly, genetic factors probably do influence CR1 levels as 
supported by the clustering of CR1 levels in the families 
studied and secondly, in some patients with SLE the CR1 levels 
were acquired, as indicated by the change in CR1 levels with 
disease activity and the lower levels found in patients with 
disease exacerbations.
Two possible explanations could account for the acquisition 
of reduced receptor levels, receptor removal or receptor 
blockade. In support of the latter it was observed that large 
opsonized immune complexes (formed with thyroglobulin or DNA, 
with specific antiserum) bound to and totally or partially 
blocked the erythrocyte CR1. Thus in vivo blockade of CR1 
by circulating immune complexes could account for the reduced 
CR1 levels seen in some SLE patients when their disease is in 
exacerbation.
C H A P T E R  1
INTRODUCTION
1.1 The Complement System
The immune system, as it is known today is complex. The 
original simple concept, that the body's immune system was a self 
protective mechanism against disease, is still the central tenet, 
but the multitude of means employed to fulfil this role is be­
wildering. Importantly, the number of diseases associated with 
a failure of one or more aspects of the immune system is also 
enormous.
The complement system is an integral part of the immune system. 
Composed of fourteen distinct proteins together with six known 
direct regulatory factors and a growing number of membrane receptors 
for a variety of these proteins, the complement system is itself 
complex.
The presence of complement in serum was discovered before the 
turn of the century. Many decades later with the introduction of 
new biochemical methods of protein separation, the complement system 
was demonstrated to be a cascade of self-assembling plasma proteins, 
the activation of which, causes a series of molecular interactions 
ending in the formation of a terminal membrane attack complex, to­
gether with by-products exhibiting a variety of biological activities
The complement system can be divided into three pathways; 
the classical, the alternative and the membrane attack. These are 
schematically represented in Fig. 1. The proteins of the classical 
(C1q, C1r, C1s, 04 and 02, Table 1) and the alternative (B, D, C3b 
and P, Table 2) pathways are concerned with the generation of 
enzymes which cleave 03 and 05. Whilst the proteins of the membrane 
attack pathway (C5b, 06, 07, 08 and 09, Table 3) form a multi- 
molecular complex which brings about complement-mediated cytolysis. 
There are in addition, a group of regulatory proteins (Table 4) 
which control the activation and turnover of the complement system.
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Figure 1. SCHEMATIC REPRESENTATION 
OF THE COMPLEMENT SYSTEM.
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Activation of the classical pathway is antibody-dependent.
The antigen to which the antibody is directed can be soluble or 
cellular. But in humans, for C1 activation the antibody which 
combines with the antigen must be IgM or one of the following IgG 
subclasses, IgG^, IgG^ , IgG^ (Augener et al, 1971) with IgG^ 
being the most potent activator followed by IgG^ j then IgG^
(ishizaka et al, 19/0).
The first component of the classical pathway Cl is a macro- 
molecular complex composed of three peptides Clq, 01r and CIs, the 
stability and reactivity of which is maintained by the continual 
presence of calcium ions.
The C1q moiety provides the classical pathway recognition unit 
for the immunoglobulins. The binding site for Clq is located 
within the 0^2 domain of IgG or the Cp4 domain of IgM. The con­
version of Cl to Cl after the interaction of Clq with the approp­
riate immunoglobulin, involves the other two sub-components C1r 
and C1s. C1q after interaction with antibody undergoes a critical 
conformational change which in turn induces the proenzyme Cir 
to convert to the active form C1r, which sequentially cleaves C1s 
to CIs. C1s is a serine protease and cleaves its two natural sub­
strates C4 and C2.
C4 is cleaved by C1s to C4a and C4b (Schreiber and Müller- 
Eberhard, 1974). C4a is released into the fluid phase, leaving the 
major product C4b which possesses a labile binding site in the oC' 
chain. This binding site depends upon the presence of an internal 
thiolester group in the c< chain and upon activation, a reactive 
acyl group is transferred from the thiol to a hydroxyl or an amino 
group on the acceptor molecule to form an ester or an amide bond 
(Campbell, Gagnon and Porter, 1981). By this means C4b can bind 
covalently to the antigen or the antibody of the immune complex.
This covalent binding of C4b localises further complement acti­
vation. Most of the C4b which is formed fails to bind as the 
binding site is extremely short-lived. This lability is due 
to the reaction with water, and so most C4b becomes inactive 
C4b which plays no further role in the activation of the classical 
pathway. Similarly C2 which can bind reversibly to bound or 
fluid phase C4b is cleaved >^3 C1s. Cleavage of C2 yields C2a 
and C2b, these remain attached and bind to C4b via the C2b 
moiety although the enzymatic site resides in C2a (Nagasawa and
Stroud, 1977). The formed complex C4b2a with the enzymatic activity 
located within the C2a moiety is the classical pathway C3 convertase, 
cleaving C3 to C3a and C3b. This convertase is however unstable 
having a very short half-life at 37°C. After the formation of 
the classical pathway C3 convertase the presence of C1 or antibody 
are no longer required for the completion of the classical pathway.
The regulation of the classical pathway, preventing excessive 
or unnecessary turnover is controlled by three proteins; C1-INH,
C4BP and I.
C1-INH stoichiometrically inhibits the action of a number of 
serine proteases which are present in plasma, but with respect to 
the classical pathway, C1- INH binds near or at the active enzymatic 
site of 01r and CTs (Ziccardi and Cooper, 1976; Harpel and Cooper,
1975) thereby limiting C4 and C2 cleavage. Binding of Cl-INH 
to C1 dissociates the molecule leaving Clq bound to antibody and 
releasing a cTr:CTs:C1-INH complex into the fluid phase, the molar 
ratio being 1:1:2 (Sim, Arlaud and Colpmb, 1979; Ziccardi and 
Cooper, 1979).
C4BP alone can accelerate the decay of the C3 convertase by
10.
displacing C2 (Gigli, Fujita and Nussenzweig, 1980), or can act 
as a cofactor to I facilitating the cleavage of the C4b c<' chain.
In this way the formation of the convertase is regulated and the 
stability of the preformed convertase is decreased. Both of 
these actions will limit the breakdown of C3.
Activation of the alternative pathway unlike the classical 
pathway is not confined to immune complexes comprised of certain 
immunoglobulin classes and subclasses. In fact a diverse range of 
agents can mediate activation of this pathway including yeast cell 
walls, endotoxins, the surfaces of certain intact bacteria and 
fungi to name but a few. Clearly, this pathway may provide a.first 
line defence against certain organisms in the absence of specific 
antibodies, as well as mediating inflammation and tissue injury in 
the absence of infection. Thus the alternative pathway has been 
implicated as the original primitive complement system forming a 
natural and non-specific defence mechanism.
The manner of activation of the alternative pathway is probably 
still not completely understood. There is no molecule which 
initiates the turnover of the alternative pathway. The proteins 
C3b, B, D and P are involved in the assembly of the alternative 
pathway 03 and 05 convertases, and their turnover is controlled by 
I and H. The convertase formation depends upon the complexing of 
03b with B in the presence of magnesium ions. D then cleaves B 
to Ba and Bb, Ba is released into the fluid phase and Bb remains
complexed to 03b, giving 03bBb. This convertase is said to be 
unstable because of the rapid temperature-dependent dissociation of 
Bb. However, the enzyme is stabilized by the binding of P to 03b
(Fig. 2). The resulting enzyme, 03bBbP is termed the P-stabilized 
alternative pathway 03 convertase, which cleaves 03 at the same
site as 04b2a, to form 03a and 03b. 03b as well as being a con­
stituent of the alternative pathway 03 convertase, is also a product
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ACTIVATION.
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of the enzyme on its substrate. Thus a positive-feedback 
loop (the alternative pathway amplification loop) is formed, 
which in the absence of regulatory mechanisms would continue to 
be activated until the supply of C3 or B was exhausted. Limit­
ation of turnover depends upon the presence of two control proteins, 
the enzyme I and its cofactor H. I, in the presence of the co­
factor H, cleaves the oC' chain of C3b to form iC3b; this can no 
longer bind B and therefore stops convertase formation. In
addition H alone can compete with B (Conrad, Carlo and Ruddy, 1978) 
for the binding site on C3b (Whaley and Ruddy, 1976a) and accel­
erate the decay of C3bBb (Whaley and Ruddy 1976b; Weller et al,
1976) and this re-exposes C3b to the proteolytic activities of I. 
Spontaneous hydrolysis of the thiolester bond of C3 occurs, which 
converts C3 to "C3b-like " C3 (Pangburn and Müller-Eberhard, 1980). 
C3b-like C3 has the capacity to bind B before acquiring suscept­
ibility to the regulating actions of H. Thus low-grade fluid 
phase turnover of the alternative pathway occurs, but C3b which is 
formed is rapidly degraded by H and I.
The ability of certain surfaces to activate the alternative 
pathway is a result of the protection they confer on C3b from the 
controlling effects of I and H. Thus uncontrolled assembly of 
C3bBbP on the cell surface can occur (Pearon and Austen, 1977a, b). 
Consequently microorganisms, for example, can be covered with 
large quantities of C3b and be phagocytosed or lysed via the 
terminal pathway. Thus alternate pathway activators shift the low- 
grade C3b turnover to rapid solid-phase turnover, therefore 
amplifying the whole system.
It is apparent that the carbohydrate composition of cell 
surfaces affects their ability to activate the alternative pathway. 
For example, surfaces low in sialic acid, e.g. zymosan, rabbit
13.
erythrocytes and neuraminidase treated sheep erythrocytes acti­
vate the alternative pathway in human serum (Fearon, 1978;
Pangburn and Müller-Eberhard, 1978). These surfaces reduce 
the affinity of H for C3b therefore favouring the binding of B 
to C3b (Kazatchkine, Fearon and Austen, 1979). Other factors can 
also affect convertase formation. Nephritic factor is an auto­
antibody found in the serum of some patients with mesangiocapillary
glomerulonephritis. This autoantibody binds to C3bBb and stabilizes 
the enzyme (Daha, Austen and Fearon, 1978), and this becomes 
resistant to decay-dissociation by H (Weiler et al, 1976).
Cobra venom factor is isolated from the saliva of two snakes 
Naja naja and Naja Naje, in mammalian serum this causes exhaustive 
activation of the alternative pathway by complexing with B in the 
presence of D. This forms a stable convertase which is unsuscept­
ible to H mediated decay-dissociation (Nagaki, lida and Okerbo, 1978) 
It is clear that activation of both the classical and alter­
native pathways leads to the cleavage of C3. C3 constitutes the 
bulk protein of the complement system, with normal serum concen­
trations ranging from 768 ^ g/ml to 1700 pg/ml. It has a molecular 
weight of 190,000 daltons and is composed of two polypeptide chains 
designated (110,000 daltons) and ^  (75,000 daltons) which are 
held together by disulphide bridges plus non-covalent forces 
(Fig. 3, Table 5)-
The cleavage of 03 to C3a and C3b by the C3 convertase is the 
major event of the complement system. Both convertases cleave 
C3 at the same point, between arginine 77 and serine 78 at the N- 
terminus of the chain. The first 77 aminoacids of the chain 
constitute C3a which is released into the fluid phase and is a 
potent anaphylotoxin. C3b consists of the remaining cX ' chain
and an intact chain and as a result of the cleavage a labile
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15
CQIu(M
I0u
A
A
O
44
O
raÜ
•HA
CQ
•H
U0
AÜ
oj
s
g
lA
0
A
•§
A
ra
0
X
0
1—1
A A SS O
3>5
0 O Um Ü 44cd cd
!>5
1—1 IS A 44 m
cd A Sh O
A Ü A 0
•H •H Cd > rl A
> m A o
•H ra o •H 44
A cd 0 Ü A O
Ü ü A > cd
cd •H Ü •H LT\ N Ü
X A O •H o
1—1 o 44 Cd A •H
cd A o Ü A •H •H A
Ü O S4 Ü A cd•H A A 0 o d N
bû b ’ i4 A ra 1—1 •HO A cd A tA A O A
1—1 A. Ph Cd O O CO •H
O cd A
•H d O
pq <5 CM lA P- O' a
0 w
bO A
cd Ü
> pi
cd A
0 O
1—1 in
o A
0
A•H 0
a  B
0 A
R.S ;
A  cd P-i 
O A  A  Ph Ü ra
1
m
Ü
d o
O •H
Ü A 1—1
Cd S
U
A bO
{4 pi
0 0
CO Ü
1|0 bO
I—I ‘H 
O 0
a 12
I
g
I
O
g
e
0
g
A
cd A Ü A 0
tA lA CA lA lA
o O O O O
CM
O
OlA
O
OO
O
tA
O
16.
thiolester bond is exposed in the oc' chain. This allows 
C3b to bind to cell surfaces or immune complexes. However, the 
labile binding site is short-lived, with an approximated half- 
life of 50 milliseconds, after which the C3b decays, probably 
because of the interaction of the thiolester with water to form 
inactive fluid-phase C3b and conformational changes to a more 
stable molecular configuration. A consequence of this is that 
only about 10% of the available C3b binds to targets, the remainder 
becoming inactive fluid-phase C3b. This form, despite being unable 
to take any further part in the complement cascade sequence, still 
retains its ability to bind to 03 receptors, although Arnaout et al 
(1981) present experimental evidence indicating that monomeric 
C3b does not bind to 03 receptors. This molecular form can, 
however, enter into the alternative pathway feedback cycle.
03b which does bind close to the alternative or classical 
03 convertases alters the specificities of these enzymes from 03
to 05. The classical pathway 05 convertase (04b2a3b) still has 
the active enzymatic site in 02a, and likewise the alternative path­
way 05 convertase (03bBbP03b) enzymatic site resides still in Bb, 
however they have altered molecular specificities cleaving 05 to 
05a and 05b instead of 03. This change in specificity occurs
because 03b acts as a binding site for 05 and presents to the enzyme 
for cleavage. 05 cleavage allows the commencement of the terminal 
attack pathway.
The terminal attack pathway, unlike the classical or alternative 
pathway, has no proteolytic steps, but is a sequential series of 
self-assembling proteins. 05 is very similar to 03 consisting of 
two polypeptide chains linked by disulphide bridges and non- 
covalent forces (Nilsson, Tomar and Taylor, 1972; Tack, Morris and
Prahl, 1979). On cleavage 05a, a potent chemotaxin and anaphylo- 
toxin, is released from the N-terminus of the chain (Fernandez
17.
and Hugli, 1978), leaving C5b composed of the remaining o< ' chain 
and an intact ^chain. C5b now contains a newly exposed labile 
binding site in the x.' chain, allowing it to bind to cell membranes. 
The half-life of this labile binding site is approximately the same 
as that of C3b, but about 4% of C5b becomes membrane associated 
(Cooper and Müller-Eberhard, 1970) compared to 10% of C3b. Once 
membrane bound the functional activity of C5b decays and this is 
inhibited by its further interaction with 06. The binding of C6
to C5b (C5b6) imparts stability and this complex has the capacity 
to travel considerable distances, consequently allowing binding: 
to bystander cells. 06 is thought to bind 05b by adsorption and 
probably as a result of a conformational change in 05b, 07 can bind
to give an equimolar trimolecular complex 05bp7(Podack et al, 1978). 
The configuration of this complex is essential for the binding of 
08, which is thought to bind to all three components 05b, 06 and
07 at the centre of the triangular shaped complex (Kolb et al, 1972)
08 binds on a one-to-one basis with the trimolecular complex to 
give a tetrahedral complex. It is via 08 that several molecules
of 09 can bind to the 05b-8 complex. This complex 05b6789 has a 
molecular weight of 995,000 daltons (Kolb and Müller-Eberhard, 1975) 
and in a dimeric form it is inserted into the lipid bilayer of the 
cell. In fact, as the complex forms it attains a greater ability 
to insert into the cell membrane, however it only maintains this 
for about 0.1 seconds, after which the binding site is lost. Molecular 
re-arrangement may account for this, or two serum proteins, S protein 
and very low density lipoprotein (VLDL) can compete with the labile 
binding site and prevent complex insertion (Lint, Behrends and 
Gewur.z'>, 1977; Podack, Kolb and Müller-Eberhard, 1978).
The insertion of the terminal complex C5b6789 into the cell 
membrane is as a dimer and this forms the characteristic 'holes' 
seen in electron micrograms. These holes have a diameter of 10 pn
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and appear as hollow cylinders projecting outwards from the cell 
membrane and into the lipid bilayer. The formed channel allows 
the passage of water and electrolytes finally bringing about osmotic 
lysis of the cell. The nature of the channel is still not fully 
resolved, leaking of cell contents maybe through the centre of the 
channel or the complex may cause such gross distortion of the lipid 
bilayer that the contents leak around the periphery of the complex. 
Whatever the exact mechanism, the membrane attack pathway results 
in the cytolysis of nucleated and unnucleated mammalian cells, 
bacteria,platelets, mycoplasmae and viruses, in addition the mobility
of C5b6 can result in the complexes forming on bystander cells and 
hence causing inappropriate lysis.
1.2. Biological activities of complement.
The lytic effect of the terminal membrane attack complex is 
now well established. However,during the turnover of the pathway, 
a variety of fragments are produced which have biological activities 
of their own, and these will be discussed in turn.
C4a, C3a and C5a are anaphylotoxins; ranked in order,C5a 
is most potent, then C3a then C4a. Both C3a and C5a act on mast 
cells and basophils causing histamine release, C3a also releases 
serotonin from platelets (Johnson, Hugli and Müller-Eberhard, 1975). 
C3a and C5a can induce smooth muscle contractions independent of 
histamine release, and similarly such an action on endothelial cells 
of the post-capillary venules would open up gap-junctions and increase 
vascular permeability. These effects are inhibited by the inacti­
vation of the anaphylotoxin by carboxypeptidase N, which cleaves 
the carboxy terminal arginine residue (Damerau, G-runefeld and Vogt, 
1978), to give C4a des arg and C3a des arg and C5a des arg.
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C5a and C5a des arg are potent chemotactic agents 
attracting neutrophils, eosinophils and monocytes (Fernandez 
et al, 1978; Damerau et al, 1978). The activity of C5 des arg 
seems to require some serum cofactor for the expression of its 
activity (Perez et al, 1980).
036 causes leukocytosis, although this is usually preceded 
hy an initial phase of leucopenia. C3e probably causes this 
effect by mobilizing leucocytes from the bone marrow (McCall et 
al, 1974; Bother, 1972).
The role of C3b as an opsonin is well known. C3b-coated 
immune complexes or particles adhere to 03 receptors on phagocytic 
cell membranes and together with the interaction of IgG- with the 
Fc^ receptors, thesq complexes can be phagocytosed, facilitating 
their removal from the circulation.
Complement also plays a vital role in the solubilization of 
immune complexes within the circulation. The solubilization pheno­
menon was first described in 1975 by Miller and Nussenzweig.
This process alters the physical and biological properties of 
complexes probably by disrupting the original antigen-antibody 
lattice (Takahashi, Tack and Nussenzweig, 1977), thus making the 
immune complexes more soluble.
The effects of the complement system are multiple and its 
importance is stressed and clearly demonstrated in patients with 
complement deficiencies. There are reported deficiencies of all 
complement components and Schifferli and Peters (1983) recently 
reviewed the literature. It is clear that complement deficiencies 
lead to an increase in infections and defects particularly of the 
classical pathway and 03 is associated with immune complex diseases 
(Table 6). A possible reason for this is the failure of the 
complement system to prevent immune complex precipitation, and 
rather than be removed by the fixed mononuclear phagocytic system
20
Table 6. Human disorders associated with complement deficiencies
Component Disorder
01q SLE or similar syndrome, hypogammaglobulinaemia.
01 r Renal disease, SLE or similar syndrome, recurrent
infections, rheumatoid disease.
01s SLE
04 SLE
02 Arthralgia, SLE or similar syndrome, nephritis, 
susceptibility to infections.
03 Recurrent infections with pyogenic bacteria.
05 SLE, recurrent infections, recurrent gonococcal 
infections.
06 Recurrent gonococcal and meningococcal infections, 
Raynaud’s phenomenon.
07 Recurrent gonococcal and meningococcal infections, 
Raynaud's phenomenon, glomerulonephritis.
08 Recurrent gonococcal infections, SLE
OÏ-INH Hereditary angioedema.
I Repeated infections, recurrent infections with
pyogenic infections.
(From Cooper, 1984)
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they become trapped in extravascular spaces and hence initiate 
tissue damage. Therefore in the immune complex diseases, systemic 
lupus erythematosus (SLE) and rheumatoid arthritis (RA) low com­
plement levels may contribute significantly to the disease process. 
Low haemolytic complement levels are found in patients with SLE 
and RA, however, many have normal complement levels. Thus, this 
implie.î that some other facet of the complement system may be at 
fault in these patients. Recently, increasing importance has been 
placed on the role of complement receptors (OR) in the immune 
system. For example, a defect in the C^b receptor (CRT) on phago­
cytes, could have a drastic effect on the removal of immune 
complexes from the circulation and this may increase the propensity 
to immune complex diseases.
1.3 . Membrane receptors.
The nature of the plasma membrane of mammalian cells is such 
that it is impermeable to molecules of high molecular weight, each 
cell therefore becomes an isolated specialized chemical environment. 
To enable communication between cellular compartments, mechanisms 
are present which allow extra-cellular macromolecules to be presented 
to the cell interior. One such mechanism is fluid phase pinocytosis, 
where uptake is non-selective, linear and solely dependent upon the 
extra-cellular macromolecular concentration. Slightly more select­
ive is the process of endocytosis, where fluid is entrapped by a 
fold in the plasma membrane; this can then be expelled from the cell 
or taken into the cell as a cytoplasmic vesicle. However,
Kaplan (1981) suggests that this is probably a mechanism for ter­
mination (i.e. expulsion of cell contents) rather than initiation 
(i.e. internalization of extra-cellular fluids) of information 
transfer.
22.
To overcome the lack of specificity of information trans­
fer imparted by these two mechanisms, cells have developed plasma 
membrane receptors. Such receptors have the capacity to form high 
affinity complexes with specific extra-cellular ligands, allowing 
Tigand to impart information to the cell via the receptor. In 
this way a wide variety of ligands such as hormones, neuro^ 
transmitters, chemotactic agents, viruses and drugs can elicit 
their biological activities.
The discovery of a diverse range of receptors on circulating 
immune effector cells has been of great interest, in particular 
their possible involvement in abnormal immune responses. Circulating 
immune effector cells have been shown to have receptors for the 
Fc portion of immunoglobulins, interleukines,leukotrienes etc.
To date, receptors have been described for five complement components; 
C1q, 04-, 03, 03 and H (Ross, 1980; Ross, 1982; Arnaout and Oolten, 
1984; Fearon;,, 1984). It is plausible that these receptors play 
a vital role in linking the humoral arm of the system
with the cellular effector mechanisms of the immune system. The 
distribution and characteristics of these receptors are summarized 
in Tables 7 and 8.
At present the best characterized complement receptors are 
0R1, 0R2 and 0R3 (Table 8). Unlike conventional nomenclature 
where the receptor is named after the ligand, the multi-ligand 
specificity of these receptors precludes this", thus they have been 
designated complement receptors (OR) and are numbered in their order 
of discovery. The subject of this thesis is 0R1, the receptor 
for the ligand 03b,' however, a brief discourse about 0R2 and 0R3 
the receptors for 03d-g and i03b respectively is warranted. It is 
fair to point out that early studies on these receptors were dogged 
with problems, consequently this has led to many conflicting 
experimental results in earlier papers. Two of the main reasons 
for this were the lack of knowledge of the physiological breakdown
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Table 7 The specificity and distribution 
of receptors for C1q, 05 and H.
Receptor Ligand Distribution
C1q C1q B lymphocytes, monocytes, 
neutrophils.
H receptor H B lympho cytes, mono cytes, 
neutrophils
C5a receptor C5a Mast cells, granulocytes, 
monocyte macrophages, 
platelets.
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Table 8. The specificity and distribution 
of receptors for C3 fragments.
Receptor Ligand Distribution
CR1 C3b, iC3b, C4b Erythrocytes, granulocytes, 
monocytes, macrophages,
B lymphocytes, some T 
lymphocytes, glomerular 
podocytes, mast cells.
CR2 C3d-g, C3d,
iC3b, C3b (weak) ^ lymphocytes
CR3 iC3b, C3d-g? Neutrophils, monocytes, 
macrophages, large 
granular lymphocytes
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of 03 and the insensitivity of the assay techniques used to 
investigate the receptors.
Before introducing CR1 and describing in brief CR2 and CR3 
an appreciation of the 03 cleavage is necessary.
1-4. 03 and the generation of 03 breakdown fragments.
The series of proteolytic cleavages leading to the formation 
of a variety of 03 breakdown fragments, some of which are ligands 
for the complement receptors 0R1, 0R2 and 0R3, is illustrated 
in Pig. 4.
As previously described, 03 is cleaved by either the classical 
or alternative pathway 03 convertase yielding 03a and 03b. 03a
is released into the fluid phase and the labile thiolester bond 
located in the o< ' chain of 03b then becomes exposed. This thiol­
ester bond can a) undergo spontaneous hydrolysis rendering it non­
functional or b) allow the binding of the 03b molecule to a cell 
surface or immune complex bearing the 03 convertase.
03b, whether bound to an immune complex or a cell surface, is 
next converted to the haemolytically inactive form i03b by the 
actions of I. I is a serine protease and together with the co­
factor H cleaves the ex' chain of 03b at two sites. Released into 
the fluid phase is a small fragment 03f (3,000 daltons) and remain­
ing covalently bound to the cell or immune complex are the two 
o<. ' chain fragments (68,000 and 43,000 daltons) attached to an 
intact chain, this comprises i03b. This cleavage can also be 
mediated by I but with 0R1 as the cofactor (Medof et al, 1982;
Ross et al, 1982; Medicus, Melamed and Arnaout, 1983).
Further cleavage of i03b by I requires 0R1 as an obligate 
cofactor (Medof et al, 1982; Medicus and Arnaout, 1982; Ross 
et al, 1982; Medicus et al, 1983) as no known fluid phase counterpart
Fig. 4. THE SEQUENTIAL CLEAVAGE OF 03 :
(1) cleavage by the 03 convertase,
(2) cleavage by I and H or I and CR1,
(3) cleavage by I and 0R1.
(4) cleavage by non-specific
proteases.
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has yet been discovered. This results in the cleavage of the
chain at a third site generating C3d-g (42,000 daltons) which 
remains covalently attached to the cell surface or immune complex 
whilst C3c (140,000 daltons) is released into the fluid phase.
The in vivo sequence of proteolytic cleavages probably terminates 
in the formation of C3c and C3d-g (Ross et al, 1982; Lachmann , 
Pangburn and Oldroyd, 1982; Medicus et al, 1983). Further cleavage 
of C3d-g can however be brought about in vitro using non-specific 
proteases such as trypsin, plasmin and leukocyte elastases, which 
split C3d-g to C3d (31,000 daltons) and C3g (8,000 daltons)
(Davis, Harrison and Lachmann, 1983).
Finally C3e (10,000 daltons) is probably derived from C3c 
(Gherbrehiwet and Müller-Eberhard, 1979) by an as yet unidentified 
plasma enzyme. C3d-K is derived from proteolysis of iC3b by 
kallikrein. Its N-terminus aminoacid sequence overlaps the C- 
terminal sequence of 03© (Meuth et al, 1983). Thus the 03 break­
down fragments 03b, i03b and C3d-g covalently attached to an 
immune complex or cell surface are the primary ligands for the 03 
receptors 0R1, 0R3 and 0R2 respectively.
1.5 . Complement receptors.
The first description of complement receptors was by Duke and 
Wallace in 1930,* they observed the adherence of human erythrocytes 
to trypanosomes in the presence of antibody and complement. In 
1968 the presence and properties of complement receptors were further 
examined by Lay and Nussenzweig. They used resetting assays to 
study the complement receptors on mouse macrophages, polymorpho­
nuclear leukocytes (PMNs) and lymphocytes. This technique utilises 
as indicator cells sheep red blood cells (SRBO) coated with anti­
body (IgM or IgG, EA) and complement (EAO), and it is this technique
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which has been most frequently used to detect complement receptors. 
However, at the time when Lay and Nussenzweig (1968) performed 
these experiments the exact nature of the complement components 
on the indicator cells was unknown. They demonstrated first the 
necessity to use IgM to make EACs as EAs made with IgG formed 
spontaneous rosettes with the cells under study, and they consequently 
showed resetting of EACs (made with IgM) with peritoneal macrophages, 
PMNs, some monocytes, 10 to 25% of lymph node cells but not thymus 
cells. By using C5 deficient mouse serum they concluded that the 
first four components of the classical pathway were required for 
rosette formation, with resetting being minimal at 4°C. (The obser­
vation of reduced ligand binding at 4°C can probably be attributed 
to reduced receptor levels as Fearon and Collins (1983) have shown 
PMNs to have seven-fold more receptors at 37°C than at 4°C.) By 
performing the experiments in the presence or absence of divalent 
cations, they suggested there were two types of receptors, with 
receptors on monocytes, macrophages and PMNs requiring divalent 
cations for EAC binding but not those on lymphocytes.
In 1953 Nelson documented the complement receptor on human 
erythrocytes. He was studying the phagocytosis of the virulent 
spirochaete Treponema pallidum, which had been sensitized with 
syphilitic serum. In control preparations where the spirochaete 
suspension was incubated with erythrocytes alone as opposed to whole 
blood, he observed that instead of remaining in suspension, the 
spirochaetes within five minutes adhered to the erythrocytes. As 
lysis of the erythrocytes returned the spirochaetes into suspension 
he presumed they had adhered to the cell membrane and as the reaction 
was heat sensitive he assumed it to be mediated by complement. He 
called this phenomenon immune adherence (lA), a term still commonly 
used.
Pursuing this work further Nelson (1956) showed using complement
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sensitized starch granules the dependency of lA on the classical 
pathway components and particularly 03.
An important step towards the elucidation of the complement 
receptor ligands was finding that 04 and 03 complexed to indicator 
cells were in the cleaved forms 04h and 03b (Dalmasso and Müller- 
Eberhard, 1967). With this knowledge, Ross et al (1973) made 
indicator cells using as a complement source purified human com­
plement components (EAChu) or 05 deficient mouse serum (EACmo) and 
compared their ability to form rosettes with human erythrocytes 
or lymphoblastoid cell lines. The EAOhu demonstrated enhanced 
binding to the erythrocytes, while the EAOmo bound more effectively 
to the lymphoblastoid cells. Theoretically both types of indicator 
cells bore 03b, however the observed differential binding did not 
support this supposition. Further use of crude antiserum prepar­
ations raised against the two cell types in a rosette inhibition 
assay indicated the presence of two different complement receptors. 
Firstly 0R1, the erythrocyte lA receptor binding 03b (EAChu) and 
secondly 0R2, the receptor on lymphoid cells for 03d (now known to 
be i03b, EAOmo), formed by the actions of I (in the 05 deficient 
mouse serum) on 03b. The ability of EAOhu treated with I to behave 
in a similar manner to EAOmo confirmed this proposal.
Ross et al (1973) cites 0R2 as binding 03d, based on the 
assumption that I mediated cleavage of 03b yielded C3c and C3d. 
However, in 1977, Pangburn, Schreiber and Müller-Eberhard elucidated 
the cleavage pattern of C3b. They showed that I together with the 
cofactor H cleaved 03b to an intermediate form i03b and that further 
in vitro cleavage of iC3b to 03c and 03d required the action of 
enzymes such as plasmin or trypsin. Thus prior to 1977 all refer­
ences to 0R2 binding 03d are actually referring to i03b binding to 
a third receptor 0R3-
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1.6 CR1
CR1 is now known to bind C3b, C #  (Bokisch and Sobel,
1974; Cooper, 1969; Ross and Polley, 1975) and iC3b (Ross and 
Polley, 1975; although in this paper it is cited as C3d because 
of the unknown cleavage pattern of 03).
The cellular distribution of 0R1 on cells other than erythro­
cytes has been evaluated using the resetting technique. Lay and 
Nussenzweig (1968) demonstrated resetting with mouse peritoneal 
macrophages, PMNs, monocytes and a proportion of lymph node derived 
lymphocytes but not thymocytes. The presence of 0R1 on human 
monocytes and PMNs was also demonstrated in 1968 (Gigli and 
Nelson; Huber et al) and in 1973 Ross et al showed the identity 
of the lymphocyte 0R1 with the erythrocyte lA receptor. However 
neither Ross et al (1973) nor Bianco, Patrick and Nussenzweig 
(1970) could detect 0R1 on T lymphocytes. More recently using 
an indirect immunofluorescence technique with an anti-CRl anti­
serum Wilson, Tedder and Fearon (1983) have identified a population 
of T lymphocytes (approximately 14% of the total T lymphocyte 
population) expressing CR1. CR1 has also been detected on mast 
cells (Sher and McIntyre 1977) and human kidney glomerular cells 
(Gelfand, Frank and Green, 1975; Fischer, Appay and Kazatchkine, 
1984).
1.7 . CR2.
In present classification schemes of complement receptors 
(Arnaout and Colten, 1984; Fearon, 1984) CR2 binds the ligand 
C3d but like CR1, CR2 can bind more than one ligand, if the assay 
conditions are specifically adjusted or sufficiently sensitive to
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demonstrate this. Lambris and Ross (1982) have analysed the 
ligand specificity and distribution of CR2 with 03 coated fluo­
rescent microspheres,a technique more sensitive than resetting 
assays. This has shown CR2 to be restricted to B lymphocytes 
but having the ability to bind C3d, C3d-g and iC3b. They could 
not demonstrate the binding of C3b, although it has since been 
shown that even this ligand will bind to CR2, albeit rather weakly 
(Fearon, 1984; Weis, Tedder and Fearon, 1984).
Various workers have examined the molecular structure of CR2 
on B cells and lymphoblastoid cell lines. In 1981 Lambris, Dobson 
and Ross isolated from the culture medium of a Raji cell line a 
glycoprotein of molecular weight 72,000 daltons. This glyco­
protein was presumed to be CR2 (shed from the cell during membrane 
turnover) because of its ability to bind EAC3d and not EAC3b.
Likewise in 1981 Nadler et al using a monoclonal antibody 
identified a human lymphocytic antigen designated B^. The 
expression of B^ was confined to B lymphocytes and by surface 
labelling followed by immunoprécipitation the B^ antigen with a 
molecular weight of 140,000 daltons was isolated.
In 1983 lida, Nadler and Nussenzweig linked the B^ antigen 
(Nadler et al 1981) with CR2 based on their dual presence on B 
cells and distribution similarities on lymphoblastoid cell lines. 
Additional evidence of identity was attained with rosette inhibition 
assays where the anti-B^ monoclonal antibody inhibited EAC3d 
resetting with B lymphocytes.
Weis et al (1984) have also identified and purified a membrane 
protein of molecular weight 145,000 daltons from B lymphocytes 
and lymphoblastoid cell lines using a monoclonal antibody HB-5.
They also presume this antigen to be synonymous with CR2, as the
32.
purified antigen can bind EC3bi, EC3d, EC3d-g and they also cite 
the very weak binding of EC3b. When the monoclonal antibody is 
cross-linked with a second antibody resetting is inhibited.
The relationship between the three putative CR2 molecules 
described by Nadler et al (1984), Lambris et al (1981) and Weis 
et al (1984) is unclear. It seems probable that the antigens 
with molecular weights of 145,000 and 140,000 daltons are the 
same, with the molecular weight variation due to the different 
experimental techniques. However, their relationship to the
72,000 dalton glycoprotein described by Lambris et al (1981) is 
not clear, but it is possibly a result of proteolysis of the 
complete molecule.
The functional attributes of CR2 have caused much speculation. 
The restriction of CR2 to B lymphocytes implies a possible role 
in B lymphocyte activities. Lambris et al (1982) looked at the 
effects of anti-CR2 antiserum (F(ab')2 and Fab'), EAC3d and C3d 
on the B lymphocyte response to mitogens, antigens and allogenic 
cells. B lymphocyte proliferation in response to allogenic 
cells, pokeweed mitogen and tetanus toxoid was inhibited by these 
ligands. However they did not affect the response to concanavalin A 
or phytohaemagglutinin. These data imply that binding of CR2 
specific ligands in some way regulate B lymphyocyte responses.
The strong expression of Bg (CR2) on B lymphocytes particularly 
in the germinal centres of lymphoid follicles has led lida et al 
(1983) to propose a possible role for CR2 in antigen retention 
and development of B cell memory which is known to be antibody 
and 03, dependent.
A number of studies have suggested a relation between the 
Epstein-Barr Virus (EBV) receptor site on lymphocytes and CR2.
By using double immunofluorescence and capping experiments.
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Yefenof et al (1976) demonstrated that both these receptors 
stained and redistributed as one unit within the lymphocyte 
membrane, suggesting they were closely linked or the same (Yefenof 
et al, 1976; Klein et al, 1978). More recently the EBV receptor 
on lymphocytes has been purified (150,000 daltons) and as a 
result of inhibition assays performed with specific receptor anti­
sera it was concluded that CR2 is probably not the binding site 
for EBV (Simmons et al, 1983; Hutt-Fletcher et al, 1983).
As yet there is no clear role for GR2, but the use of specific 
monoclonal antibodies may resolve this in the future.
1.8. CR3.
CR3 imlike CR1 and GR2 binds only one ligand iG3b (Arnaout 
and Golten, 1984; Fearon, 1984) although there is some evidence 
to support G3d-g binding (Ross et al, I983). The ability of iG3b 
to bind to GR1 and GR2 as well as GR3 has caused considerable 
difficulties in studying GR3-iG3b interactions, however the binding 
is now distinguishable by its divalent cation dependency (Ross et 
al, 1983) and by utilizing monoclonal antibodies to the receptors.
GR3 is found on monocytes, macrophages, PMNs (Garlo et al 
1979; Ross and Rabellino, 1979; Ross et al, 1983) and large 
granular lymphocytes (Nocera et al, 1982). Like GR2 the structural 
characteristics of GR3 have been examined using monoclonal antibodies.
Beller, Springer and Schreiber (1982) raised a rat monoclonal 
antibody to a mouse macrophage antigen designated Mad. This antigen 
was composed of two non-covalently linked polypeptide chains 
( oc 170,000 and X 95,000 daltons) and found additionally on mouse 
PMNs and natural killer cells, as well as cross-reacting with the 
counterpart human cells. As a result of the monoclonal antibody's 
ability to selectively inhibit EAG3bi resetting with murine
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macrophages and human PMNs as well as the distribution similarities 
of M a d  and CR3, M a d  was thought to be GR3. However Beller 
et al (1982) have not excluded the possibility that M a d  could 
be distinct but intimately associated with GR3 or perhaps has 
a GR3 promoting function.
The antigen M a d  seems to be synonymous with the antigen 
recognised by 0KM10 (Wright et al, 1983). 0KM10,like anti-Mad, 
can block EAG3bi binding to human monocytes and macrophages and 
immunoprecipitates two polypeptides (185,000 and 105,000 daltons) 
retaining their i03b binding activity.
Arnaout et al (1983a) have also detected a monocyte-granulocyte 
glycoprotein termed Mo1 using a monoclonal antibody. Like anti- 
MacI and 0KM10, anti-Mo1 inhibits EAG3bi resetting to granulocytes 
and immunoprecipitates two polypeptides with molecular weights of
155,000 and 94,000 daltons.
Three groups, Beller et al (1982), Wright et al (1983) and 
Arnaout et al (1983a), have detected and isolated two surface 
membrane polypeptides of similar molecular weights, i03b binding 
properties and cellular distribution. Thus it seems probable, 
that the surface antigens recognised by anti-MacI, 0KM10 and 
anti-Mol are the same and synonymous with GR3-
The functional role of GR3 like GR2 has aroused much specula­
tion and as yet there seems to be no clear indications about its 
relation to cellular functions in the cells on which it is found. 
Work on patients with a putative GR3 molecule defect has shed some 
light on this area. Arnaout et al (1982) have investigated a young 
male patient who suffered from recurrent pyogenic infections. They 
found this boy to have defective receptor PMN functions, such as 
phagocytosis of immunoglobulin coated particles, superoxide gener­
ation and reduced de-granulation induced by opsonized zymosan.
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The only defect found was a 50% reduction in the levels of the
150,000 dalton polypeptide chain and they proposed this to be 
causing the defective cellular functions and thus its possible 
role in triggering normal neutrophil functions.
Arnaout et al (1985) has also studied Mol levels on neutro­
phils with a view to understanding the mechanism causing haemo- 
dialysis-induced granulocytopenia. Eight patients were studied 
and after 15 minutes of haemodialysis there was a five-fold 
increase in the mean cell-surface expression of Mol. This co­
incided with the maximal drop in neutrophils and the peak in the 
complement activation products C3a des arg and C5a des arg. From 
these data they suggested that Mol may provide a mechanism for 
initiating leucoaggregation, sequestration of granulocytes and 
neutropenia during haemodialysis.
Interestingly it has also been shown that the ^  subunit of 
Mol is shared with another surface structure; lymphocyte function 
associated antigen (LFA-1). By performing functional studies on 
lymphocytes it has been shown that LFA-1 is involved in promoting 
adherence between LFA-1 positive cells and targets (Arnaout and 
Colten, 1984).
The relationship between CR3 and LFA-1 is unclear, their role 
in affecting cellular immune functions has been touched on, and 
further investigation will be required to determine their possible 
association for example with phagocytic defects.
1.9 . The structure of CRI.
CRI was first isolated from the membranes of pooled human 
erythrocytes in 1979 by Fearon. Prior to this the physiochemical 
characterization of CRI was limited to the demonstration of its
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trypsin sensitivity (Lay and Nussenzweig, I968; Huber et al,
1968) which suggested it was a protein.
Fearon (1979) initially set about purifying an alternative 
pathway C3 convertase inhibitory protein. This was based on the 
observation that human erythrocytes did not activate the alter­
native pathway, even after the removal of the membrane-associated 
sialic acid residues which promote high affinity binding of H to
C3b inhibiting C3bBb formation. This inhibitory protein was 
intrinsic to the cell membrane and by solubilizing the membranes 
with a non-ionic detergent Nonidet P-40 (NP-40) followed by 
chromatographic procedures (anion exchange, gel filtration and 
affinity chromatography) a protein displaying the observed inhib­
itory effect on the alternative pathway 03 convertase was purified 
to homogenicity. On sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) both reduced and non-reduced, the protein 
presented as a single band with a molecular weight of 205,000 
daltons. However prior to affinity chromatography the molecular 
weight was 1 to 1.2x10^ daltons, thus indicating its possible 
existence in the cell membrane as an oligomer.
This inhibitory protein could impair the function of C3bBbP 
by displaying Bb and promoting I mediated cleavage of C3b and 
binding reversibly to Sepharose-C3 and Sepharose-lentil lectin, 
thus indicating it to be a glycoprotein (gp) with an affinity for 
03. These data all suggested its possible identity with 03 and 
this was further investigated by Fearon (1980) using rosetting 
assays with E03b, E03bi and E03d, and rosette inhibition-assays 
with an anti-gp 205 antiserum raised in rabbits. F(ab')g anti- 
gp 205 only inhibited E03b rosetting with human erythrocytes, PMNs, 
B lymphocytes and monocytes in a dose-dependent fashion. In 
addition this specific antiserum could be used to immunoprecipitate 
the gp 205 from the previously mentioned cell types, thus giving
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direct evidence for the identity of gp 205 with CR1.
A similar result was obtained by Dobson, Lambris and Ross
(1981) who also isolated CRI from human erythrocytes. The 
isolated protein consisted of a single band with a molecular 
weight of 195,000 daltons and bound EAC14b and EC3b.
Mussel et al (1982) and Gerdes and Stein (1980) have attempted 
to isolate human erythrocyte CRI by using 2M KBr to solubilize the 
cell membranes. Gerdes and Stein (1980) purified three bands of 
molecular weights 1 to 1.3x10^, 80,000 and 60,000 daltons, the 
latter two bands being reduced to 38,000 and 18,000 daltons. These 
bands were immunoprecipitated from the cell lysates by a crude anti- 
CRl antiserum (Gerdes, Klatt and Stein, 1980) and they bear no 
relation to the CRI protein isolated by Fearon (1979) or Dobson 
et al (1981).
Mussel et al (1982) purified a band of molecular weight
55,000 to 60,000 daltons from C3-sepharose treated 2M KBr lysates. 
This material did not agglutinate EAC14°^^23b, but inhibited ery­
throcytes coated with C3b from binding to human erythrocytes.
They designated this monovalent CRI and concluded that it repre­
sented the head region of CRI.
Neither of these results attained by Mussel et al (1982) or 
Gerdes and Stein (1980) have been repeated, and their true relation 
to CRI is unknown nor been investigated further.
Recently more careful studies of the structure of CRI in 
individual donors have been carried out and this has led to some 
very interesting discoveries.
Dykman et al (1983a) first examined CRI on the erythrocytes
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of individual donors, using cell surface-labelling with I, then 
cell lysis with NP-40 followed by affinity chromatography (Sepharose- 
03 or Sepharose**C4) or immunoprécipitation (monoclonal anti—human 
CRI) SDS-PAGE and finally autoradiography. With this combination
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of techniques they demonstrated that the structure of CR1 within 
the population is polymorphic, expressing itself in three patterns, 
types A, B and C. In a group of 33 normal people, on non­
reduced gels, 70% had a major band of molecular weight 190,000 
daltons (type A), 33% had a major band of 220,000 daltons (type B) 
and 27% expressed both bands (type C). In all three types a minor 
band, with a molecular weight 15,000 daltons larger than the 
major band was also seen. Further studies of the three receptor 
patterns within four families provided evidence to support the 
transmission of the CRI structural phenotypes by two codominant 
alleles designed A and B, coding respectively for the 190,000 
and 220,000 dalton CRI proteins.
Similar polymorphisms exist in the CRI molecules purified 
from leucocytes. By examining the CRI profiles on the erythrocytes 
and leucocytes of three donors, Dykman et al (1983b) found that 
within an individual donor the CRI phenotype on the erythrocytes 
and leucocytes was identical. However two cell specific differences 
in CRI were found; 1) a 5,000 dalton increase in the molecular 
weight of CRI on PMNs and 2) minor bands were only found on ery­
throcytes .
Wong, Wilson and Fearon (1983) have also examined CRI poly­
morphism on human erythrocytes and leucocytes using similar tech­
niques to Dykman et al (1983a, b). Likewise they have found two 
major bands but with a molecular weight of 250,000 (F=fast migrating) 
and 260,000 (S=slow migrating) daltons on reduced gels. In a 
study of 111 unrelated individuals the following phenotype 
frequencies were found: 64.9% were homozygous for F, 1.8% were
homozygous for S and 33.3% heterozygotes. In addition a study of 
15 families gave further evidence to support the inheritance of 
F and S by two autosomal codominant alleles.
Dykman et al (1983a, b) and Wong et al (1983) are obviously
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both studying CR1, with the differences in molecular weights 
probably arising from the different analytical systems used.
This may also account for the discrepancy in the molecular weights 
of CR1 as observed by these two groups and the 205,000 daltons 
CR1 molecule isolated by Fearon (1979). Both groups' data 
on the observed frequencies of the CR1 phenotypes within the 
population do not differ significantly from those predicted by 
the Hardy-Weinberg equilibrium for two codominant alleles, and this 
is further supported by family studies. Both groups also observed 
that the ratio of the two bands in heterozygotes was variable but 
characteristic for an individual. The major difference between 
the two groups was the inability of Wong et al (1983) to demonstrate 
the minor band found on erythrocyte membranes and the increased 
molecular weight of CR1 derived from PMNs . However, the pub­
lished gels of Wong et al (1983) have a heavy background staining 
which may have prevented the identification of these minor molecular 
differences.
Further investigations by Dykman ' s group have led to the dis­
covery of two additional CR1 phenotypes (C and D), based on their 
structural and ligand binding characteristics, cellular distribution 
and familial transmission. In 1984 Dykman, Hatch and Atkinson 
described a third band with a molecular weight of 160,000 daltons 
(G) which co-existed with A or B. In a study of 104 unrelated, 
normal individuals, the observed phenotype frequencies were AA 69.2%, 
AB 25%, BB 3.8%, AC 2.9% and CO 0%. These results were compat- 
ible with the Hardy-Weinberg equilibrium for three codominant 
alleles at a single locus. In their most recent paper Dykman et 
al (1985) describe a fourth structural variant (D) with a molecular 
weight of 250,000 daltons. This was found in only one person out 
of a total of 200 studied and existed in the heterozygous state 
with A (190,000 daltons).
40.
Thus to date four alleles coding for structural variants 
of CR1 have been described. Both groups point out that structural 
polymorphisms apparent by moleculgrweight differences are very 
unusual, the more normal case being a difference in net charge 
as is seen with the polymorphic complement components, for example 
02 (Alper, 1976; Meo et al, 1977), 04 (Teisberg et al, 1976),
04 (Azen and Smithies,1968), 05 (Hobart, vaz Guedes and Lachmann, 
1981) and B (Alper, Boenisch and Watson, 1972). Nor is this 
difference in molecular weight small, the extreme being 90,000 
daltons between 0 and D; this cannot be accounted for by post- 
transcriptional modification. Wong et al (1983) also rule out 
the possibility of N-linked carbohydrate differences as the cause. 
Although 0-linked carbohydrate differences have not been ruled out, 
it seems more likely that differences in the primary peptide 
sequences are giving rise to the polymorphism of 0R1.
With such vast differences in the molecular weights of 0R1, 
it poses the question as to whether the polymorphisms are beneficial 
or arise solely as a result of non-advantageous mutations. There 
is no apparent linkage of the CR1 phenotype with HLA (Hatch et al, 
1984), 0R1 numbers (Wong et al, 1983; Medof, lida and Nussenzweig, 
1983), functional ability to bind dimeric 03b (Wong et al, 1983) 
or the ability to serve as a cofactor to I (Medof et al, 1983). 
However, the ability of the different phenotypes to mediate such 
functions as phagocytosis and adsorptive endocytosis by PMNs and 
monocytes has not been investigated.
1.10. The functions of 0R1.
The number of 0R1 receptors on immune effector cells have
been quantitated using ^I-labelled dimeric 03b (Arnaout et al,
1981) or ^^^l-labell0d polyclonal F(ab')g anti-CRl (Fearon, 1980)
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and the results are expressed in Table 9. Clearly the cellular 
distribution and density of CRI on the different cell types poses 
the question: What is the function of CRI?
Many functions of CRI are cited in the literature. Generally 
these functions can be divided into two categories, those which 
influence an individual cell population or those affecting all 
cells bearing CRI. This division is broad but allows a clearer 
discussion of the universal role of CRI as a potent inhibitor of 
complement turnover and its individual effects on the cellular 
function of kidney podocytes, lymphocytes, phagocytic cells and 
erythrocytes within the immune system.
Obviously if CRI plays a role in the induction and/or reg­
ulation of the immune system, it must be sensitive to modulations 
in the levels of the ligands ; C3b, iC3b and C4b. There has been 
controversy as to whether C3 binds to CRI. This would be detri­
mental to the sensitivity of CHI, as the receptor would be con­
tinually swamped with C3 due to its high serum concentration.
It is now apparent that native C3 does not bind to CRI (Berger 
et al, 1981; Schreiber, Pangburn and Müller-Eberhard, 1981;
Berger and Pleisher, 1983) and only binds after cleavage of the 
internal thiolester bond of the chain (Dixit et al, 1982;
Berger et al, 1981; Schreiber et al, 1981). Nor does monomeric 
C3b bind under normal physiological conditions, with the receptor 
having a higher affinity for dimeric or oligomeric C3b (Arnaout 
et al, 1983b). This is contrary to the results obtained by 
workers such as Tack, Segal and Schechter (1978), Newman and John­
ston (1979) and Sim and Sim (1981), who all report 03 binding to 
CR1. It seems likely that the 03 preparations used in these 
experiments were either contaminated with 03b-like haemolytically 
inactive 03 or the 03 may have been cleaved by cell associated
Table 9* Density of CR1 on human immune effector
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cells as determined by I-dimer C3b (Arnaout et 
125
al, 1981^or I-F(ab')  ^ anti-CR1 (Fearon, 1980).
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C3b dimer F/ab')^ anti-CRl
Erythrocytes 360 930
PMNs 21,000 37,000
B cells 20,000 21,000
Monocytes 30,000 48,000
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proteases released during the time course of the experiments
(Frade and Strominger, 1980). However this does not explain the
results attained by Sim and Sim (1981) who showed the binding of 
5 125
5x10 I-labelled 03 molecules to human lymphocytes; the reasons 
for this are unclear.
1.11. CRI, a potent inhibitor of complement turnover.
There is now strong evidence to support the proposal that 
CRI on all immune effector cells, functions as a potent in vivo 
inhibitor of complement turnover. This inhibitory activity was 
first described by Fearon (1979) who demonstrated the ability of 
purified CRI to accelerate the decay of the properdin stabilized 
alternative pathway C3 convertase, in a dose-dependent fashion.
CRI mediates this activity by displacing Bb from the convertase by 
competing for the C3b binding site. Normally this role is per­
formed by the plasma protein H. H, as well as functioning in­
dependently, acts as a cofactor to the serine protease I, together 
they control the alternative pathway C3 convertase by cleaving C3b 
to the inactive form iC3b. Fearon (1979) has further shown the 
ability of CRI to replace H as a cofactor in this cleavage step.
However, H cannot normally act as a cofactor to I to bring about
the further cleavage of iC3b to C3c and C3d-g. It is evident 
that C3c and C3d-g are the terminal cleavage products of C3, as 
the erythrocytes from patients with cold-agglutinating disease 
bear C3d-g on their surface and not iC3b or C3d (Lachmann, 1981).
Ross et al (1982) have demonstrated the ability of H and I to
cleave iC3b but only in low ionic strength buffer (4mS at room 
temperature) not physiological buffer strength (12mS at room temp­
erature). It is now clear that purified CRI or membrane bound CRI
44.
can act as a cofactor to I to bring about the cleavage of iC3b to 
C3d.~g and C3c (Medof et al, 1982; Ross et al, 1982; Medicus et al, 
1983).
C4b is also a ligand for CR1 and this led lida and Nussenz­
weig (1981) to examine the possible controlling influences of CR1
on the classical pathway enzymes containing C4b, namely C4b2a and
C4b2a3b, the C3 and C5 convertases. As with the alternative path­
way purified CRI can decay-dissociate the classical pathway C3 
convertase by competing with C2a for the C4b binding site. This 
function is also mediated by C4BP and like C4BP, CR1 can act as a 
cofactor to I to bring about further cleavage of C4b (lida and 
Nussenzweig, 1981; Gigli and Fearon,. 1981). The ability of CRI 
to inhibit the C5 convertase is probably similar to its effects on 
both C3 convertases, but in this case the CRI competes with C5 for 
the binding site on the C3b molecule in the C3 convertase (lida 
and Nussenzweig, 1981).
CRI, whether in a purified form or as a constituent of a cell 
membrane, can perform these regulatory functions (summarized in 
Table 10 along with the plasma proteins, where applicable, whose 
functions CRI mimics).
Clearly CRI in vitro has the potential to inhibit all the 
amplifying enzymes of the complement system and researchers in 
this field have speculated about its in vivo role.
It is postulated that CRI operates as an inhibitory protein 
at two levels. Firstly, CRI may prevent inappropriate self lysis
by complement. Such situations may arise due to deposition of C3b 
on self cells as a result of the low spontaneous turnover of C3 by 
the alternative pathway or during periods of inflammation. For 
example, C3b or C4b bearing substrates may interact with phagocytes 
via CRI . Subsequently this may lead to the activation and depos­
ition of complement components on or in close proximity to host
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cells which may lead eventually to self lysis. The ability of 
some immune effector cells to produce complement components may
aggravate this situation further. Therefore a strong local con­
centration of inhibitor, namely CR1, would be vital to stop 
excess tissue damage especially during infections or situations of 
high complement turnover. Secondly, CR1 can interact with C3b 
or C4b bearing substrates and bring about C3b and C4b degradation 
so they can no longer take part in complement activation and this 
will also generate the ligands for CR2 and CR3.
These inhibitory roles described for CR1 are very much simpli­
fied and in vivo the situation is probably more complex. For 
example, it has been shown that larger quantities of CR1 are re­
quired for I mediated cleavage of iC3b as opposed to C3b (Medicus 
et al, 1983). This may be of physiological importance, allowing 
the preferential formation of iC3b as opposed to C3d-g bearing 
substrates which will interact with CR3 on phagocytic cells and 
eventually be phagocytosed. Another possible subtlety has been 
described by Medof and Nussenzweig (1984), who found that the inhib­
itory effects of CR1 on C4b or C3b bearing substrates was modulated 
by C3b or C4b in the vicinity. They showed that C4b enhanced 
CR1 and I mediated cleavage of C3b and vice versa. Clearly the sit­
uation is complex.
It must also be pointed out that CR1 is not the only cell sur­
face constituent with a controlling influence on the classical 
pathway 03 convertase. A membrane protein called Decay Accelerating 
Pactor-Stroma (DAF-S) has been purified from human erythrocytes. 
Although it is structurally and antigenically distinct from CR1, 
it also accelerates the decay of the classical pathway 03 convertase. 
However, this action of DAF—S is more potent than that of 0R1 
(Nicholson-Weller et al, 1982; lida and Nussenzweig, 1983).
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DAF-S therefore may also have a role in controlling in vivo 
complement activation and turnover.
1*12. The function of CR1 on kidney podocytes.
There is very little known about the function of CR1 
on kidney podocytes. Obviously it may play a part in protect­
ing the cells from damage due to complement activation.
Recently Fischer et al (1984) has implicated a role for 
the receptor in the adsorptive endocytosis of soluble ligands 
bearing C3b, because of experimental findings which show the 
internalization of Ffab')^ anti-CR1 by kidney podocytes. 
However, there is no other known work to support this.
1.13. The function of CR1 on lymphocytes.
As yet there is no concrete evidence to support a particular 
function for CR1 on lymphocytes, particularly B cells. Results 
obtained from experiments performed on animals implicate its 
role in humoral immune responses; for example, lymphokine pro­
duction, antibody synthesis and generation of B cell memory. Some 
of the data is supported by in vitro studies on human lymphocytes.
Sandberg, Wahl and Mergenhagen (1973) and Koopman et al 
(1976) have examined the production of a macrophage chemotactic 
lymphokine by guinea-pig spleen cells in response to G3b stimula­
tion. This could not be reproduced using other 03 fragments 
and C3b aggregates were thought to be cross-linking the receptors 
and consequently eliciting the lymphokine release.
The effects of C3b on antibody production has also been
examined. There seems to be general agreement from the results 
attained in animals, that mitogens and T-dependent antigens can 
activate B cells in the absence of complement (Pepys, I976). 
However, T-dependent antigens require C3 to initiate antibody 
production. This has been demonstrated in mice depleted of 
03 by cobra venom factor and anti-C3 antiserum. Primary immun­
ization of these mice with a T-dependent antigen induces only low 
levels of IgM, and this production could be attributed to CR1 
negative B cells (Lewis et al, 1976; Lewis, Ranken and Goodman, 
1977). Using an in vitro human system Lobo and Burger (1982) 
enhanced by 78% the differentiation of adult B cells into plasma- 
cytoid cells by their incubation with EAC142.‘»3b as opposed to EAs.
In a murine system, Daha, Bloem and Ballieux (1984) induced IgM,
IgG and IgA antibody synthesis in a lymphocyte culture treated with 
P(ab')2 anti-CR1 and sub-optimal doses of pokeweed mitogen. For 
an optimal response cross-linking of CR1 was required as seen by 
the diminished antibody synthesis with monovalent Fab' anti-CR1 . 
However, these results could not be repeated with C3b or C3b bound 
to fragments of sheep erythrocyte membranes and this does question 
their validity. In contrast, Berger and Fleisher (1983) found 
C3b to inhibit antibody production. Nariuchi, Kakiuchi and Ueno 
(1985) support this finding and, in addition, found cross-linked 
C3b enhanced antibody production.
From these results one can propose a role for CR1 in con­
trolling antibody production. With antibody production being 
increased when there are circulating C3b-coated antigen-antibody 
complexes and decreased when there is C3b alone in the circulation. 
It must be stressed that in all the aforementioned experiments 
the presence of T cells was obligatory.
Finally, both Pepys (1976) and Klaus and Humphrey (1977)
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have demonstrated the inability of 03 depleted mice to localize
immune complexes, aggregated IgG or T-dependent and independent 
antigens in lymphoid follicles. Lymphoid follicles are pre­
dominantly B cell areas with dendritic reticular cells. This 
cellular combination allows the trapping of immune complexes via 
the interaction of IgG Fc and C3b with the cellular Fey receptors 
and CR1, or in the case of T-independent antigens which activate 
the alternative pathway by the interaction of C3b with CR1 . The 
close contact between B cells and dendritic reticular cells in this 
area suggests that they play an important role in the initiation 
of B cell memory and antibody responses^ based on the inability 
of 03 depleted mice to elicit these two functions. However, 
with respect to antibody responses it now seems that the observed 
reduction in response was mediated by 03a and possibly other 
chain fragments generated as a result of 03 activation by 
cobra venom factor and it was these fragments which suppressed 
antibody production (Weiler et al, 1982).
1.14. The function of 0R1 on phagocytic cells.
Olassically the role of CR1 in the phagocytic responses 
of human monocytes and neutrophils was one of enhancing the adher­
ence of these cells to 03b-bearing particles. Research has
shown that C3b-bearing complexes bind to phagocytic cells, but 
do not elicit phagocytosis unless accompanied by IgG. Together 
the interaction of IgG and 03b with Fc y  receptors and 0R1 respect­
ively, stimulates ingestion and accompanying biological reactions 
such as the release of superoxide ions, -glucuronidase and 
lysozyme (Huber et al, 1968; Ehlenberger and Nussenzweig, 1977> 
Newman and Johnston, 1979)* These results suggested that 0R1 
and Fey receptors have separate but complementary functions in
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the phagocytic process.
However, there is now accumulating experimental evidence 
from in vivo and in vitro studies to support the notion that 
under certain circumstances CR1 alone can mediate phagocytosis. 
Wright, Craigmyle and Silverstein (1983) proposed the existence 
of CR1 on phagocytic cells in two states, inactive and active, 
where cells with CR1 in an inactive state cannot phagocytose via 
CR1, whereas in an active state binding to CR1 induces phagocyt­
osis. Griffin (1980) has put forward the hypothesis that once 
macrophages have phagocytosed an immune complex, they then contact 
T cells which release an 'activating factor' (Griffin and Griffin,
1979). This factor, in turn, enhances CR1 mediated phagocytosis 
by macrophages. Such activation of macrophages can be demon­
strated in vivo. Mouse resident peritoneal macrophages cannot 
phagocytose complexes when CR1 alone is engaged, whilst thiogly- 
collate-elicited peritoneal macrophages are able to perform this 
function (Griffin and Mullinax, 1981). Other agents which have 
been shown to augment phagocytosis are the oligopeptides tuftsin 
and angiotensin II (Foris, Ftist and Medgyesi, 1983), F(ab')g anti- 
CR1 and multimeric C3b (Fearon, Kaneko and Thompson, 1981). There 
are obvious physiological advantages in being able to phagocytose 
via CR1 alone. These have been highlighted by Griffin (1980).
He stresses that when there is a large antigen load on the body 
(e.g. during an infection) there will consequently be high levels 
of circulating antibody and immune complexes. These may bind to 
the phagocytic cell Fc y receptors and either block the receptor 
or saturate the phagocytic process. Thus the selective maintenance 
of another receptor, i.e. CR1, which could mediate phagocytosis 
in addition to Fc y receptors would be advantageous.
An interesting feature which may relate to this last 
point is the ability of phagocytic cells to greatly increase the
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number of CR1 on their cell surface. Fearon and Collins (1983) 
found at 37°C PMNs to have 38,000 CR1 and this could be increased
8- to 10-fold with the chemotactic agent C5a. des arg or f-met-leu- 
phe. Similar results have been cited by Kay, Glass and Salter 
(1979) using N-formyl-methionyl peptides, casein and supernatants 
from cultured 0. parvum or human lymphocytes (Glass and Kay,
1980), and this enhancement is also reversible. Increased GR1 
numbers on phagocytic cells is not an in vitro artefact. Lee, 
Hakim and Fearon (1984) have examined CR1 levels on the neutrophils 
of patients undergoing haemodialysis. In these patients the 
haemodialysis membrane causes complement activation. For example, 
after 10 minutes (mins) of haemodialysis complement activation has 
increased by 225% and after 120 mins 160%. There are correspond­
ing changes in CR1 levels, a 127% increase in 10 mins and 296% 
increase in 120 mins.
Thus phagocytic cells have an internal CR1 pool which may 
possibly allow for: a) increased phagocytosis, b) increased
adhesion to opsonised particles or c) concentrated source of 
complement turnover inhibitor. Therefore up-regulating CR1 
may be a means of augmenting the capacity to respond to C3b 
opsonised material.
1.15. The function of CR1 on erythrocytes.
Cells of the circulatory system are traditionally and 
conveniently colour coded; the red cells transporting oxygen 
to the tissues, the white cells performing immunological functions. 
Yet the presence of CR1 on human erythrocytes poses the possibility 
that erythrocytes are, in some way, involved in immune responses.
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This was first suggested by Nelson (1953). He demonstrated 
that adherence of sensitized bacteria to erythrocytes led to 
enhanced phagocytosis of the bacteria by the leucocytes. Thus 
he concluded that the erythrocytes were acting as 'carriers' 
enabling immune complexes to be presented to phagocytic cells 
and subsequently removing them from the circulation.
These early experimental findings which proposed a role for 
erythrocytes in the immune response have now been supported by 
recent experimental evidence. Brown and Nelson (1973) examining 
the phenomenon of erythrocyte spherocytosis, argued that the loss 
of their characteristic biconcave shape was due to a reduction in 
cell surface area and volume. They noticed that EACs which inter­
acted with monocytes or macrophages became contracted and spherical, 
with the erythrocyte membrane becoming indented by cytoplasmic 
processes from the mononuclear cells. They further examined 
this process in vivo by injecting rabbits with EACs. These 
animals were subsequently killed at various time intervals and 
the liver sections were examined using electron microscopy. This 
showed the binding of the EACs to the Kupffer cells within two 
minutes of injection with accompanying cell membrane distortion, 
with pieces being pinched off. Subsequently these erythrocytes 
were released back into the circulation.
In 1982 Medof and Oger using an in vitro system demonstrated
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the preferential binding of serum coated I-labelled bovine 
serum albumin (BSA) anti-BSA complexes to the erythrocytes in 
whole human blood, with greater than 80% of the bound immune 
complexes being found on the erythrocytes. They confirmed the 
binding to be via CR1 as it did not occur in heat—inactivated 
serum. Furthermore, the complexes could not bind to non—primate 
erythrocytes which do not possess CR1. Binding was also
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dependent upon the ratio of serum to immune complex. By using 
diluted serum or serum from a hypocomplementemic patient binding 
was delayed and sustained. However, using undiluted serum maximal 
binding occurred within 2 to 4 mins and decreased thereafter.
The reason for the immune complex dissociation with increases in 
serum concentration could be due to one or all of the following:
a) cleavage of C3b due to increased concentrations of I and H,
b) solubilization of the immune complexes or c) competition
for the receptor by free G3b and C3b breakdown products.
A similar type of experiment has been performed in vivo
125using baboons (Cornacoff et al, 1983). Using preformed I- 
labelled BSA-anti-BSA complexes opsonized with baboon serum, they 
examined their fate after infusion into the baboons. Within 60 
to 180 seconds the infused immune complexes had bound to the erythro­
cytes and after 5 minutes 73% were removed from the circulation.
These were removed primarily during passage through the liver 
and, to a lesser extent, the spleen. The erythrocytes themselves 
did not become trapped but remained in the circulation. However, 
when antigen and antibody were infused separately they could not 
detect binding of the labelled BSA anti-BSA complexes to the baboon 
erythrocytes. The possible reasons which they gave for this 
observation were that either the binding occurred but was too rapid 
to record, or alternatively, the immune complexes which formed were 
too small to bind to the erythrocyte. It had been shown previously 
that the preformed complexes used were between 10S and 28S, which 
suggests that size may be a critical factor in determining whether 
a complex will bind to erythrocyte CR1 in vivo.
Thus these experiments demonstrate the ability of immune 
complexes to bind preferentially to erythrocytes via CR1 and 
consequently resulting in their removal from the circulation.
54.
However, the question which still remains to be answered 
is "What is the significance of the binding of immune com­
plexes to CR1 on human erythrocytes?"
Researchers in this field have put forward various pro­
posals in an attempt to answer this question. It has been 
calculated that 95% of CR1 in the circulatory system is present 
on the surface of erythrocytes and because of the high red cell 
to white cell ratio, a circulating opsonized immune complex is 
500 to 1,000 times more likely to bind to CR1 on an erythrocyte 
than a white cell (Siegel, Liu and G-leicher, 1981). Thus 
erythrocytes may serve as a high capacity buffer competing with 
other CR1 bearing cells for circulating opsonized immune com­
plexes. This would prevent unnecessary activation of CR1 on 
leucocytes and enable the erythrocytes to 'carry' the complexes 
to the mononuclear phagocytic system for phagocytosis. Erythro­
cyte CR1 may function by preferentially binding large com­
plexes, therefore preventing their deposition in organs, tissues 
and blood vessels where they could produce tissue injury or pre­
vent further complement activation in the blood. Finally, 
erythrocyte CR1 may act as a large ubiquitous and readily 
available pool of complement turnover inhibitor.
All this tends to support the view that erythrocyte CR1 is 
important in the handling and influencing the fate of immune 
complexes in the circulation. It is therefore possible to 
conceive that a breakdown or defect in this mechanism may cause 
abnormal handling of immune complexes, which may lead to 
increased immune complex loads and consequently aberrant immune 
responses. The relationship between erythrocyte CR1 levels and 
immune complex diseases will be discussed in the next section.
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1.16 CRI levels in immune complex diseases
It is now widely accepted that the deposition, or the 
formation of antigen-antibody complexes in tissues produces 
disease. In 1977 the World Health Organization proposed a means 
of classification in which immune complex diseases were divided 
into three groups based on the nature and origin of the antigens 
involved. To briefly summarize, the first group includes dis­
eases in which the major antigens of the immune complex are 
endogenous in origin. The second group is comprised of antigens 
which are exogenous and in the third group, the nature of the 
antigens is unknown.
In this thesis two groups of patients with immune complex 
diseases were studied and both diseases fit into the first group 
as described above. They are systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (RA).
SLE is a chronic systemic inflammatory disease which follows 
a pattern of alternating exacerbations and remissions. During 
periods of exacerbation there is multi-organ involvement with 
the disease affecting many parts of the body including the skin, 
lungs, central nervous system, joints, muscles and frequently 
the kidneys. The antigen-antibody complexes present in the 
glomeruli of SLE patients are believed to contain 3>0JA and anti- 
DNA antibodies (Koffler, Schur and Kunkel, 1967; Milgrom,
Campbell and Andres, 1976). This is supported by the obser­
vation that circulating complexes contain DNA and anti-DNA 
antibodies (Bluestone et al, 1970; Winfield, Koffler and 
Kunkel, 1975). Hypocomplementaemia also often occurs in
patients with active SLE (Schur, 1975) and using immunofluorescence 
the deposition of complement components within the glomerular 
and skin lesions of SLE patients has been demonstrated (Rothfield 
et al, 1972).
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RA is a chronic recurrent systemic inflammatory disease 
primarily involving the joints. This disease characteristically 
begins in the small joints of the hands and feet and progresses 
in a centripetal and symmetrical fashion. Extra-articular 
manifestations include vasculitis, atrophy of the skin and muscles, 
subcutaneous nodules, lymphoadenopathy, splenomegaly and leuco- 
penia. The serum and synovial fluid of RA patients contain 
rheumatoid factors (Rf ) which are antibodies directed against the 
Fc piece of IgG (Egeland and Munthe, 1983) and these can be of any 
immunoglobulin class with IgM being the type detected in convent­
ional agglutination assays. Complexes containing IgG-rheumatoid 
factor (self-associated IgG) are present in the synovial fluids of 
patients with RA (Hannestad and Melbye, 1967; Winchester, Agnello 
and Kunkel.s 1970; Munthe and Natvig, 1971; Male, Roitt and
Hay, 1979)• Similar complexes have also been detected in the 
sera of RA patients with systemic vasculitis (Stage and Mannik,
1971, Theofilopoulos et al, 1974). It is unknown whether all the 
IgG rheumatoid factor-IgG complexes represent the vast majority 
of immune complexes in RA, as it is possible that some of the IgG 
exists as antibody to an unknown antigen. In RA patients comple­
ment activation does occur in the synovial fluid (Ruddy and Austen, 
1973) and in the serum of those patients with systemic vasculitis 
(Schur, 1975).
Very little is known about the stimuli which causes the auto­
antibody production, namely anti-DNA antibodies in SLE and anti- 
IgG Fc antibodies in RA, nor why this production is not successfully 
controlled by the immune system. There is now growing evidence 
which also suggests that the mechanism for handling the formed 
immune complexes within the circulation and mononuclear phagocytic 
system of these patients is in some way inefficient. As mentioned
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previously it is probable that CR1 on erythrocytes are 
important in the handling of immune complexes within the 
circulation. This assumption has led researchers to look 
for CR1 defects on the erythrocytes from patients with SLE or 
RA.
Prior to the commencement of this project, four studies 
examining erythrocyte CR1 levels predominantly in SLE, had been 
performed.
Miyakawa et al (1981) examined CR1 levels on the erythrocytes 
from SLE patients. The 56 patients studied all satisfied the 
diagnostic criteria proposed by the American Rheumatism Assoc­
iation (ARA), all had anti-nuclear antibodies in their sera and 
all were receiving maintenance dosages of steroids. The assay 
used to examine the erythrocyte CR1 levels was a modified lA 
reaction called immune-adherence haemagglutination (IAEA) where 
test erythrocytes were incubated in a microtitre plate with 
doubling dilutions of aggregated human gamma-globulin and com­
plement. No agglutination represented no receptors on the 
erythrocytes.
Those showing agglutination had receptors and the higher 
the titre the more CR1 per erythrocyte. With this technique 
Miyakawa et al (1981) showed 66% of their SLE patients to be IAEA 
negative compared to 4% of the controls. The low CR1 levels in 
the SLE patients were not due to the steroid therapy, nor had 
the receptors been blocked with immune complexes as most of the 
patients were in remission at the time of the study. It was 
therefore proposed that the observed low CR1 levels were an 
intrinsic defect. This view was further supported by serial 
measurements of IAEA titres in individual patients. These results 
showed that the IAEA titre remained virtually unchanged during
58
periods of exacerbation and remission of disease. The exam­
ination of the relatives of SLE patients showed a higher 
frequency of low CR1 levels than in normal families. Thus 
they concluded that low erythrocyte CR1 levels are an inherited 
defect rather than a secondary manifestation of the disease.
Wilson et al (1982) examined erythrocyte CR1 levels in 38 SLE
patients (all of whom fulfilled ARA criteria, Cohen et al, 1971)
and 113 normals. The receptor numbers were initially quanti- 
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fled using both ^I-labelled dimeric G3b and F(ab') anti-CR1, 
with the former being used to determine if antigenically reactive 
receptors were also functionally reactive. This was found to be 
the case with approximately 9 F^ab')^ anti-CRt molecules binding 
per C3b dimer*, thus the remaining experiments were performed using 
F(ab')2 anti-CR1 and the results expressed as the number of 
antigenic sites per erythrocyte (sites per erythrocyte). The 
mean number of sites per erythrocyte in 113 normals was 5014+155 
compared to 2804+_241 in the SLE patients. The difference was 
significant, persistent with time and was not due to steroid 
therapy, autoantibodies to CR1 or blockage by immune complexes.
By constructing a histogram of the normal CR1 values (Fig. 5) 
they demonstrated a bimodal distribution of CR1 numbers. One 
group represented 34% of the population with a range of 5500 
to 8500 sites per erythrocyte, the second group represented 54% 
with a range of 3000 to 5499 sites per erythrocyte. This second 
group had a shoulder extending into the lower range and represented 
12% of the population (1000-2999 sites per erythrocyte). They 
proposed that a genetic basis may account for the observed 
trimodal distribution, with two codominant alleles determining 
high (H) and low (L) receptor numbers. Therefore HH would rep­
resent group one, HL group two and LL group three. By calculating
Fig. 5. HISTOGRAM SHOWING THE FREQUENCY 
DISTRIBUTION OF THE NUMBER OF
BINDING SITES ON ERYTHROCYTES
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FOR I-FCab')^ ANTI-CR1 AMONG 
NORMAL SUBJECTS.
(FROM WILSON ET AL, 1982)
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the Hardy-Weinberg equilibrium for two codominant alleles the 
expected values did not differ significantly from the observed 
frequencies. This was also supported by the pattern of inheri­
tance of receptor numbers in normal and SLE families; with the 
SLE families having a three to four times increase in the preval­
ence of the LL phenotype. Thus Wilson et al (1982) proposed 
that the CR1 phenotypes were genetically determined, but they 
stress that the wide variations in numbers in each group 
suggests the existence of modifying factors.
lida, Mornaghi and Nussenzweig (1982) examined, using I- 
labelled monoclonal anti-CR1, the CR3. numbers on the erythrocytes 
of 34 SLE patients, 10 RA patients and 52 normals. The normals 
had 1410_+620 receptors per cell and there were no differences with 
sex, age or blood groups. The SLE patients had 600+^30? receptors 
per cell and the RA patients 903+.417 receptors per cell. Both 
these values were significantly lower than the mean for the normals. 
This could not be attributed to the steroid therapy, but there was 
a correlation between low haemolytic C4 levels, high immune 
complex levels and low CR1 numbers. They showed that despite 
the stability of CR1 numbers in normals with time, the CR1 
numbers in two out of four SLE patients increased during a remission 
in their disease. These results also showed that low CR1 
numbers are not confined to the disease SLE and that the deficiency 
is reversible which tends to support the idea the low CR1 numbers 
are acquired according to the disease process.
Inada et al (1982) using a modified IAEA showed in four SLE 
patients that erythrocyte CR1 levels were not constant with time 
and correlated inversely with circulating immune complex (GIG) 
levels, that is, as GIG levels increased receptor numbers dropped 
and vice versa. They suggest that CR1 levels in SLE are not
61
inherited but related to disease activity, particularly CIO 
levels, and they indicate that such GIG may even be blocking 
receptor expression.
These results from geographically widespread areas all 
find a significant decrease in the erythrocyte GIG levels
I/'
in SLE patients, and in one study^RA patients, compared to 
normal controls. However, the interpretation of the data 
by each group differs. lida et al (1982) and Inada et al
(1982) favour the acquisition of low erythrocyte GR1 levels 
secondary to the pathophysiological manifestations of the 
disease; contrary to this Miyakawa et al (1981) and Wilson 
et al (1982) favour the inheritance of GR1 levels.
In view of these results the aim of the proposed study 
was to examine whether GR1 numbers on human peripheral blood 
cells are inherited or acquired. This was to be investigated 
by quantifying the GR1 numbers on the blood cells from normal 
individuals and patients with SLE and RA. If GR1 numbers 
appeared to be acquired the possible reasons for this would 
be investigated.
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C H A P T E R  2
MATERIALS AND GENERAL METHODS
63
INTRODUCTION
The chapter describes all materials and general methods used, 
with subsequent chapters describing in detail more specific 
methods employed.
2.1 MATERIALS
With the exception of those listed below chemicals were of Analar 
quality from British Drug Houses Ltd., Poole, Dorset.
Materials obtained from Sigma Chemical Co. Ltd. Fancy Road,
Poole, Dorset, were:
Bovine serum albumin 
<5-amino-n-caproic acid 
Thyroglobulin 
Calf thymus DNA 
Porcine pepsin 
Trypsin
Soya bean trypsin inhibitor
Folin and Ciocalteu's phenol reagent
Dextran
Bromophenyl blue
High molecular weight markers (SDS-6)
Ammonium persulphate
N, N, N ', N '-Tetramethylethylenediamine (TEMED)
2-mercaptoethanol
Phenylmethylsulfonyl fluoride
L-tyrosine
Dowex 100-200 mesh chloride form 
Caprylic acid 
Zymosan 
<oC -methyl-D-mannoside 
Ethanolamine 
Triethanolamine
Sodium dodecyl sulphate (lauryl sulfate)
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Materials obtained from Pharmacia Ltd., Pharmacia House, 
Midsummer Boulevard, Central Milton Keynes, were:
Diethylaminoethyl (DEAE) Sephacel 
Sephadex GI50 Superfine 
Sephadex G200 Superfine 
CNBr-activated Sepharose 4B 
Lentil lectin Sepharose 4B 
Picoll 400
Materials obtained from the Scottish Antibody Production 
Unit were:
Normal sheep serum
Sheep anti-Human IgG antiserum
Donkey anti-rabbit IgG antiserum ;
Sheep anti-whole rabbit serum antiserum
Materials obtained from Cappel Laboratories, Daux Road, 
Billingshurst, Sussex, were:
Goat anti-rabbit IgG
Sheep anti-mouse IgG
PITC conjugated swine anti-goat IgG
PITC conjugated rabbit anti-sheep IgG
Sheep anti-rabbit IgG (Pfab')^ fragment specific)
Materials obtained from Gibco Europe Ltd., Trident House, 
PO Box 35, Renfrew Road, Paisley, were:
Poetal calf serum 
L-glutamine 
Penicillin 
Pungazone 
Streptomycin
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Materials obtained from Plow Laboratories, Irvine, Ayrshire, 
were :
RPMI-I64O medium without sodium bicarbonate, 
without glutamine with Hepes 
Hanks buffered salt solution
Materials obtained from Aldrich Chemical Co. Ltd., Old Brickyard, 
New Road, Gillingham, Dorset, were:
Dimethyl sulphoxide 
Benzamidine hydrochloride hydrate
Materials obtained from Bio-Rad Laboratories Ltd., Caxton Way, 
Watford, Hertfordshire, were:
Silver staining kit 
Hydroxylapatite (Bio-Gel HT)
Biorex 70 100-200 mesh sodium free
Materials obtained from Berhing Diagnostics, Hoechst House, 
Salisbury Road, Hounslow, were:
Rabbit anti-human 03 
Rabbit anti-human C4 
Rabbit anti-human C5
Materials obtained from Difco Laboratories Ltd., PO Box 14B, 
Central Avenue, East Molesey, Surrey, were:
Preund’s complete adjuvant 
Preund's incomplete adjuvant
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Materials obtained from Amicon Ltd., Upper Mill, Storehouse,
Glos. were:
YM30 and PM30 filtration membranes 
Pellicon cassette
Sources of the following materials were:
Mouse monoclonal anti-CR1: Dako Ltd., 22 The Arcade,
The Octagon, High Wycombe, Bucks
Dimethyl suberimidate: Pierce and Warriner, 44 Upper Northgate,
Chester
Dithiobissuccinyl propionate: was a kind gift of Dr. Coggins,
Department of Biochemistry, University of Glasgow
Millex-GS 0.22pm filter units : Millipore UK Ltd., Millipore
Giysem, 11-15 Peterborough Road, Harrow, Middlesex
Antrypol and Mannitol, Hypaque and preservative free sodium
heparin: were supplied by the Pharmacy, Western Infirmary, 
Glasgow
Methanol: May and Baker Ltd., Liverpool Road, Barton Moss,
Ecoles, Manchester
Diethylaminoethyl (DE52): Whatman Ltd., Springfield Mill,
Maidstone, Kent
Ethanol: James Burrough, 60 Montford Place, London
Anti-human factor I (KAF C3ê inactivator): Seward Laboratory,
Norse Road, Bedford
Goat anti-human ^  IH globulin (factor H): Atlantic Antibodies,
American Hospital Supply (UK) Ltd., Station Road,
Didcot, Oxfordshire.
Rabbit anti-human P : was a kind gift of Prof. K. Whaley,
Department of Pathology, Glasgow University
El 1, mouse monoclonal anti-human CR1: was a kind gift of 
Dr. N. Hogg, Imperial Cancer Research Fund,
Lincoln's Inn Fields, London
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2.2 BUFFERS
Deionised water was used to make up all buffers and for methods 
employing water.
Veronal buffered saline (5 x VBS) pH 7.4 
85g NaCl
3.75g Barbitone sodium 
5.75g Barbitone
These were added together, dissolved in 1 litre of hot water 
and then made up to a final volume of 2 litres with water.
GVB'^ '^  pH 7.4
200 ml 5 X VBS 
5 ml 0.03M CaCl 
10 ml O.IM MgCl 
10 ml 10% gelatin 
Made up to 1 litre with water
GVB pH 7.4
200 ml 3 X VBS 
10 ml 10% gelatin 
Made up to 1 litre with water
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Isotonie dextrose containing cations (D5W^^) pH 3.3 
50 g D-glucose 
5 ml 0.03M CaCl 
10 ml 0.1M MgCl 
Made up to 1 litre with water
Isotonic 0.086m EDTA pH 7 .2-7.6
197.7 ml of O.3M NaOH was added to 500 ml of 0.12M EDTA 
to give a final pH between 7*2 and 7.6
0.04M EDTA GVB'
230 ml of isotonic 0.086M EDTA pH 7.4 was made up to 
500 ml with GVB
0.01M EDTA GVB'
57.5 ml of isotonic 0.086M EDTA pH 7.4 was made up 
to 500 ml with GVB
D50S
50g D-glucose 
5.95g NaCl
Made up to 100 ml with water
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++
Mannitol GVB
9 ml 20% mannitol 
3 ml GVB"^ "^
Phosphate buffered saline (PBS) 130 mM
8.0g NaCl 
1.21g KgHPO^ 
0.34g KHgPO^
Mg EGTA
38.04g EGTA was made up to 500ml in distilled water, 
concentrated NaOH was added until the pH was 7-4. The final 
volume was made up to 1 litre with distilled water.
To 10ml of the O.IM EGTA, 7ml of MgCl^ (0.1M) was added 
to give O.IM Mg EGTA
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2.3 Measurement of pH and conductivity.
pH : The pH of samples and column fractions were measured
using a Pye-Unicam pH meter, Model 292.
Conductivity: The conductivity of samples and column fractions
was measured at 0°C using a conductivity meter model 
CDM3, Radiometer, Copenhagen.
2.4 Measurement of protein
Absorbance at 280 nm: The absorbance at 280 nm of samples and
column fractions was read using a Shimadzu UV-120-02 
spectrophotometer, with the buffer in which they were 
suspended being used to zero the spectrophotometer.
Folin assay: Protein was measured according to the method of
Lowry et al (1951)> using Folin and Ciocalteu’s phenol 
reagent and known concentrations of bovine serum albumin 
(BSA) as standards.
The method employed is as follows:
Reagent A: 2g NagCO Plus 20mg NaK tartarate made up to 100 ml
with 0.1M NaOH 
Reagent B: 0.15% CuSO^. 515^ 0
Reagent C: 5ml of A plus 0.1ml B made freshly on day of use.
Reagent D: Commercial Folin and Ciocalteu’s phenol reagent diluted 
with an equal volume of water.
Into a series of test tubes 2ml of C was placed, to this a volume 
of the sample to be tested for protein was added, the volume being 
dependent upon the estimated protein concentration, i.e. small
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volumes (10^1) for high protein concentrations and vice versa.
To an additional 5 tubes, 5>il, lOpl, 2^1, 50pl and 75jil 
of BSA (img/ml) was added, this gives the standard protein curve. 
The negative control was 100pl of buffer. To all tubes 0.2ml of 
reagent D was added. The tubes were mixed thoroughly and left for 
30 mins at room temperature (R.T.). The optical density of the 
suspensions was measured at 700nm. A standard curve was con­
structed from the readings for the known quantities of BSA used in 
the assay. From this curve the protein content of the unknown 
samples were determined.
2.5 Concentration of protein samples.
Sucrose concentration: Protein samples were placed in visking tubing
sacks which had been boiled thrice in deionised water plus 0.001M 
EDTA. These sacks were covered in sucrose and left until the 
required degree of concentration was achieved.
Freeze drying: Protein samples were freeze dried using an Edwards
freeze drier.
Vacuum dialysis: Protein samples were concentrated by vacuum
dialysis using visking tubing, treated as described above.
Ultrafiltration: Samples were concentrated using an Amicon with YM30 or
PM30 membranes, these membranes exclude all molecules smaller 
than 30000 daltons.
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2.6 Preparation of glass plates for methods employing agarose. 
Glass plates were washed and cleaned with ethanol before use. 
Plates were poured on a level table and allowed to cool before 
the wells were punched. The size of plates used varied, 9 -6ml 
of agarose were used for 10 x 10cm glass plates, 3ml of agarose 
for glass slides and 5.3ml of agarose for 50mm plastic petri 
dishes.
2.7 Double immunodiffusion (Ouchterlony technique, Ouchterlony, 1958)
Buffer: 5 litre of deionised water, 9.21 g barbitone, 51-54g
sodium barbitone and 5g sodium azide.
Agarose: 5g of agarose was added to 500ml of hot buffer and
when dissolved, 15g of polyethylene glycol (PEG, molecular 
weight 4000) was added.
This technique was employed to identify antigens or test antiserum 
specificity, using known antiserum or antigens. Two or 5nmi holes 
were punched in agarose gel on microscope slides in a pattern con­
sisting of a central well surrounded by 6 equally spaced peripheral 
wells (as shown below). A distance of 10mm separated the inner
O
o o
o
o O
o
and outer wells. The inner well was filled to the brim with anti­
serum (or antigen) and the outer wells with antigen (or antiserum).
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or doubling dilutions of a given sample. Plates were left over— 
night at R.T. in a humidified chamber to allow the antibody and 
antigen to diffuse towards each other. When the diffusion was com­
plete the presence or absence of precipitation lines (indicating 
the specific interaction of antibody and antigen) was recorded.
For large antigens or antiserum containing IgM the plates were allowed 
to develop for up to 48 hours (hrs).
This technique is sensitive (picking up to l;ig of protein),
however its application is limited to precipitating antibody- 
antigen reactions. In general it was used as a rapid means of
identifying proteins and screening antisera, but not for any
quantitative analysis.
2.8 Radial immunodiffusion (Mancini technique, Mancini,
Carbonara and Heremans,1965)
Buffer (a): As described in 2.7
Agarose(a): As described in 2.7
Agarose(b): 20 ml of 5 x VBS and 10 ml of O.IM EDTA were heated 
together and 1.5g agarose was added, when dissolved the 
final volume was made up to 100ml with water.
This technique was used to quantitate antigen concentrations. 
Agarose(a) was used for non-complement components and agarose(b) 
for complement components. The appropriate agarose contained a 
monospecific antiserum at a dilution suitable for the determination 
of the antigen concentration. The radial immunodiffusion was 
performed in plastic petri dishes (diameter 50mm) covered with
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3.3ml of agarose containing the appropriate antiserum dilution.
Two mm wells were punched and filled to the brim with antigen
or doubling dilutions of the test antigen together with doubling
dilutions of a known standard antigen concentration. The plates
were left at R.T. for 48hrs in a humidified chamber. The
diameter of the precipitin rings were measured and a standard curve
2
was plotted using the diameter squared (D ) of the known standards 
against their, antigen concentration (Fig. 6). From the standard 
curve the concentration of the unknown antigen was determined, 
this technique is reputed to be sensitive to 1-3}ig/ml of antigen 
(or antibody). This, however, may be limited ^  the concentration 
of antibody (or antigen) in the gel.
2.9 Immunoelectrophoresis (TÈP, Graber and Williams 1933)
Buffer (a): As described in 2.7
Agarose (a): As described in 2.7
Buffer (c): 17-Og of barbitone was dissolved in 500ml of water,
23.5 ml of 1M HCl was added to give a pH of 8.4 . Finally 
the volume was made up to 2 litres with water. This was 
used as the 1ER tank buffer.
Agarose (c): 1•5g of agarose was added to 100ml of buffer con­
taining 4.5g sodium barbitone, 11.65ml of 0.086M EDTA, 
pH to 8.4 with approximately 32.5ml of O.IM HCl with the 
remaining volume being made up with water.
1ER combines electrophoretic separation, diffusion and immune 
precipitation of proteins. In most cases it was used to identify 
proteins and their cleavage products. Glass plates were covered with 
agarose (agarose (a)) for electrophoresis of non-complement proteins
FIG. 6 Example of a standard curve 
for a Mancini plate
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and agarose(c) for electrophoresis of complement proteins) and 
a series of wells (2mm) and troughs were cut in the agar using 
a template, The wells were filled to the brim with the test 
antigen and the plate was subjected to electrophoresis for 2 to 
3 hrs at 40mA. The extent of the electrophoresis was monitored 
by the passage of bromophenyl blue across the plate. After 
electrophoresis the appropriate antiserum was placed in the troughs 
and both antigen and antibody were allowed to diffuse at R.T. over­
night in a humidified chamber. The resultant precipitation arcs 
between antigen and antibody were recorded.
2.10 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAG-E) phosphate buffer (tube gels)
Protein samples were electrophoresed in polyacrylamide tube 
gels in the presence of 0.1% SDS according to the method of Weber, 
Pringle and Osborn (1972). Pour and 5% gels were made up from stock 
solutions as follows :
Stock 4% gel 5% gel
30g acrylamide, 0.8g bis- 
acrylamide in 100ml water
10 ml 10 ml
1M phosphate buffer pH 6.5 7.5 ml 6.0 ml
Water 56.7 ml 43.4 ml
10% SDS 0.75ml 0.60ml
TEMED 40pl 30;il
Ammonium persulphate 75mg 60mg
The first four solutions were mixed together then the TEMED and 
ammonium persulphate were added, after the ammonium persulphate had 
dissolved the gels were immediately poured. The gels were cast in
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glass tubes (0.5cm x 10cm), overlaid with water and left over­
night to set. Before use the tube gels were pre-electrophoresed
for 30 mins at 2mA per tube in tank buffer (100ml IM sodium phosphate
buffer pH 6.5 and 10ml 10% SDS made up to 1 litre with water).
Protein samples were run reduced or non-reduced in sample buffer 
(0.5ml 10% SDS, 0.05ml 2-mercaptoethanol, 1.0ml glycerol, 0.05ml 
IM sodium phosphate buffer, pH 6.5, 0.1ml 0.5% bromophenyl blue 
(tracking dye) made up to 5ml with water, for non-reduced sample 
buffer the 2-mercaptoethanol was excluded). Reduced samples 
were boiled for 2 mins prior to electrophoresis. The samples were 
layered onto the tube gel surface and electrophoresed at 6mA per 
tube at a constant current setting, the electrophoresis was stopped 
when the tracking dye (marking the buffer front) was about 1 cm from 
the tube base. The gels were then removed and stained for Ihr 
at 37°C with 0.1% Page blue 090 in methanol/acetic acid/water 5/1/4 
(v/v/v). The gels were then destained with methanol/acetic acid/ 
water 1/1/8 (v/v/v). Together with the protein samples reduced 
Sigma and BDH molecular weight markers (2.1) were run and used to 
form a standard curve from which the molecular weights of the 
protein samples could be determined (Pig. 7). This technique can 
pick up approximately l^g of protein.
2.11 SDS-PAOE in slab gels.
Samples were electrophoresed in 5% polyacrylamide gels 
according to the method of Laemmli (1970). The following stock 
solutions were made up and used in the preparation of both the 
separating and stacking gels as follows:
FIG. 7 Standard curve for Sigma molecular 
weight markers (reduced)
79
Stock solution Separating 
gel 5%
Stacking 
gel 3%
Acrylamide 30%/bis- 
acrylamide both (w/v) 10 ml 1.8 ml
0.75M Tris Hcl pH 6.8 - 3 ml
0.75M Tris Hcl pH 8.8 30 ml -
10% SDS 0. 6ml 0.18ml
Ammonium persulphate 60 mg 18 mg
TEMED 30 pi 9 pi
Water 19.4ml 13 ml
Both gels were prepared by mixing the above ingredients and the gels 
were poured immediately. Slab gels were poured between glass plates 
(20 X 20cm) separated by 1.0mm spacers, the separating gel was over­
laid with water until set, this was removed and the stacking gel 
poured, a comb forming lanes was then inserted and the gel allowed to 
set. The electrophoresis buffer contained 10ml of 10% SDS, 33ml 
of 0.75M Tris and 220ml of 0.86M glycine made up to 1 litre with 
water. Samples were run reduced by boiling in an equal volume of 
reducing sample buffer (30ml of 10% SDS, 8.5ml of 0.75M Tris-Hcl, pH 6.8, 
10ml glycerol and 5ml 2-mercaptoethanol made up to 100ml with water) 
for 2 mins. The samples were carefully layered on top of the gel 
and electrophoresed for approximately 2.5hrs at 33mA, at a constant 
current setting or until the tracking dye had reached the bottom of 
the gel. The gel was stained as described in 10.7. The electro­
phoretic mobilities for each protein were calculated and the system 
was calibrated using reduced Sigma high molecular weight markers 
as described in 2.10. The staining of gels with Page blue G90 
allows 0.2pg of protein to be detected, however if gels are silver 
stained (see below) the sensitivity is increased 10-50 fold.
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2.12 Silver staining.
Slab gels were stained using a silver staining kit. The
following protocol was followed. The slab gel was:
1 ) fixed for 30 mins in 100ml of buffer containing 40% methanol
and 10% glacial acetic acid,
2) fixed for 15 mins in 100ml of buffer containing 10% methanol
and 5% glacial acetic acid,
3) fixed for 15 mins in 100ml of buffer containing 10% ethanol
and 5% glacial acetic acid,
4) 200ml of oxidiser (20ml concentrate plus 180ml water)
was added for 5 mins at R.T.,
5) gel was washed thrice with 400ml of water, 5 mins for each wash,
6) 200ml of silver reagent (20ml concentrate plus 180ml water) 
was added for 20 mins at R.T.,
7) the gel was then washed in 400ml of water for 20 mins.
8) 200ml of developer (1 bottle in 3.6 litres of distilled water) 
was added for 30 seconds, the developer was removed and the cycle 
repeated twice,
9) the reaction was stopped by adding 400mls of 5% glacial acetic 
acid for 5 mins,
10) the gel was finally stored in water.
The protein bands stain dark brown.
2.13 Separation of serum from rabbit blood.
Rabbit blood was collected into glass universal containers, 
heated to 37°C for 30 mins (to allow clot formation) followed by a 
further 30 mins at 4°C (to allow clot retraction). The blood was then 
spun and the serum decanted. The serum was further heat-inactivated
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at 56 C for 30 mins to destroy the complement components.
The serum was aliquot ed and stored at -20°C until required.
2.14 Standardization of erythrocytes (E)
Suspensions of sheep or human E's were standardized using 
the following method. A lOOpl sample of E s was removed from a 
known volume and added to 2.9ml of water. The optical density
of the lysate was measured using a wavelength of 541nm (OD^^^) 
and 414nm An OD reading of 0.370 at corresponds
to an E concentration of 1x10^ cells/ml, likewise 0.185 at OD^^^
8 8 
equals 5x10 cells/ml and 0.327 at OD^^^ equals 1x10 cells/ml.
The volume of the E suspension can be adjusted to the required
cell concentration using the following formula;
OD measured
Volume of E required = Initial volume x X
X  = 0.327 at OD^^^ gives 1x10 cells/ml
X  = 0.185 at OD gives 5x10 cells/ml
541
X  = 0.370 at OD^^^ gives 1x10^ cells/ml
2.15 Radioiodination of proteins
Radiolabelled proteins were used for most of the work des­
cribed in this thesis. The following method was used to label 
proteins with and is a modification of the method described
by McConahey and Dixon (1966).
One ml of protein (Img/ml) in PBS was incubated in a glass 
bijoux bottle with lOpl of freshly made Chloramine T (5mg/ml in
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PBS) and 37 MBq of carrier-free I for 70 seconds at R.T. Then 
30pl of L-tyrosine (0.5mg/ml in 0.01M NaOH) was added to stop the 
reaction. At this stage a 10pl sample was taken enabling the
determination of labelling efficiency and total isotope input.
125
Protein-bound I was separated from free isotope by passage 
over a 0.5cm x 8cm Dowex (100-200 mesh) column equilibrated with 
PBS, collecting 0.5ml fractions. A lOpl sample from each fraction 
was added to 0.99ml of PBS and these were counted in an automatic 
gamma counter (Packard, Model 3000) to determine the distribution 
of radioactivity. The tubes containing the radiation peak were 
pooled. This contains the radiolabelled protein, the free iodine 
remains bound to the column. The quantity of radiolabelled protein 
was determined by precipitation in 10% trichloracetic acid. This 
was performed by adding lOpl of the pooled radiolabelled protein 
to 200pl of BSA (10%) and 1ml of TCA (20%). After mixing the tubes 
were spun at lOOOOg for 5 mins and the counts in the supernatant 
and pellet were measured. The percentage precipitable radio­
labelled protein is equal to the counts per minute (cpm) in the pellet 
divided by the cpm in the pellet and supernatant times 100. The 
protein content of the pool was determined by measuring the absorb- 
ancy at 280nm (2.4).
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C H A P T E R  3
PURIFICATION OF CR1 FROM HUMAN ERYTHROCYTES
AND THE PRODUCTION OF ANTISERUM TO CR1.
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INTRODUCTION
CR1 was originally purified from human erythrocytes 
in 1979 by Fearon, who lysed washed human erythrocytes 
in hypotonic buffer and then solubilized the washed 
membranes with the non-ionic detergent NP-40. Soluble 
CR1 was purified by sequential ion exchange, gel filtration 
and affinity chromatography. Prior to the commencement of 
my project, this purification method had been successfully 
repeated in this laboratory by Dr. W. S. Kilpatrick who 
also raised a rabbit anti-CR1 antiserum. The purification 
procedure was repeated twice unsuccessfully during the course 
of this project; with modifications to the method a third 
attempt was fruitful and this method will be described.
The antiserum used throughout the project was raised by 
Dr. W. S. Kilpatrick. This antiserum was monospecific giving 
a single precipitin line when tested against purified CR1 by 
double immunodiffusion. Its specificity for CR1 was con­
firmed by its ability to inhibit the agglutination of C3b 
coated erythrocytes by CR1, to agglutinate human lymphocytes, 
monocytes and PMNs which bear CR1 and its inability to 
agglutinate trypsin treated human erythrocytes which no 
longer bear CR1.
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METHODS
3.1 Column screening procedure
The presence of CR1 in the starting material and column 
fractions were screened for using the haemagglutination of 
EAC43’b (3.3) Z fractions were screened for protein using 
the Polin assay (2.4), pH (2.3) and conductivity (2.3).
3.2 Preparation of EAG43h (Lachmann & Hobart, 1979)
Treatment of human serum with zymosan: 100mg of zymosan was 
suspended in 10ml of isotonic VBS and boiled for 30 mins.
The suspension was then washed thrice in isotonic VBS and 
finally resuspended in 10ml. One ml of the zymosan suspension 
was then spun down, the supernatant removed and the pellet was 
resuspended in 10ml of normal human serum (NHS). This was
incubated for 1 hr at 37°C in a shaking water bath The
.0
suspension was then centrifuged for 5 mins at 2 C at lOOOg.
The supernatant was decanted, the serum is now depleted of C3
by approximately 50% and this is called R3.
Sheep red blood cells coated with rabbit IgG anti—SRBC 
were kindly given by Mrs. J. Veitch and these were standardized 
to 2xl0^/ml in GVB^^ (2.14), 20ml was put into a round bottomed 
glass flask and warmed to 37°G. To this was added 1ml of warmed 
human R3 followed 75 seconds later by 200;pl of warmed Antrypol 
(100mg/ml). This mixture was incubated for a further 2 mins 
at 37°G in a shaking water bath, then 20ml of ice cold GVB
was added and the cells were washed thrice in ice cold GVB .
PLATE 1. Haemagglutination of EAC43b
by purified CR1 •
Far right hand wells are 
the controls.
I, oc D ri m o  0  0  ©
_ _ *
i. ©  ©  ©  ©  ©  ©  ©  ©
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After the final spin the cell pellet was resuspended in 5ml of 
ice cold 0.01M EDTA in GVB and incubated for 2 hrs at 37°C 
in a shaking water hath to allow the decay of the terminal 
complement components. Finally the cells were washed thrice in 
GVB^^ and standardized to 1x10^/ml (2.14), the cells were 
stored at 4°C until required.
3.3. Haemagglutination of EAC43b.
Fifty y.1 of GVB^^ was put into the wells of a round bottomed 
micro-titre plate, and an additiont^^O^l was put into the first 
well; to this 5^1 of the sample to be tested for CR1 was added. 
This was doubly diluted across 7 wells, then 50pl of EAC43b 
(1x10^/ml) were added to each well and to an additional well 
containing buffer alone which acted as the control. The plate 
was gently shaken and left at R.T. for 2 to 4 hrs or until the 
cells in the control well formed a firm button in the well bottom, 
The degree of agglutination was then determined, expressing the 
haemagglutination titre as the last dilution at which there was 
positive agglutination. The result is expressed as the titre 
or the reciprocal titre (Plate 1).
3.4 Preparation of erythrocyte membranes.
Wash buffer: Isotonic saline 150mM containing lOmM benza-
midine, 0.5mM phenyl methyl sulfonyl fluoride (PMSF) 
in dimethyl sulphoxide, 0.02% (w/v) sodium azide and 
0.5mM isotonic EDTA.
Lysis buffer: 5mM sodium phosphate, 0.5mM isotonic EDTA
pH 7.8 containing ImM benzamidine and 0.5mM PMSF. 
Solubilization buffer: 5mM sodium phosphate, 0.5mM isotonic
EDTA, 150mM NaCl, 1% NP-40, pH 7.5 containing 
lOmM benzamidine, 0.5mM PMSF and 0.02% (w/v) sodium 
azide.
Six packs of fresh blood and 12 packs of expired blood were 
pooled and washed thrice in wash buffer ensuring the complete 
removal of the buffy coat layer. The erythrocyte pellets were 
then resuspended after the final wash in lysis buffer and the 
final volume was made up to 7 litres with lysis buffer. This 
was left overnight at 4°C, the cell membranes were then washed 
with 100 litres of lysis buffer in a Pellicon cassette (Amicon) 
or until the membranes were free of haemoglobin. The Pellicon 
cassette is a positive pressure dialysis unit, and contains a 
membrane which has an exclusion limit of 2000000 daltons, therefore 
molecules larger than 2000000 daltons (i.e. CR1) are retained 
in the system recycled and continually washed free of haemoglobin. 
Once washed the membranes were concentrated using the Pellicon 
cassette, then made up to 1.3 litre with solubilization buffer.
The membranes were solubilized overnight at 4°C with continuous 
stirring. The solubilized membranes were then spun at 48,200g 
for 30 mins. at 4°G in a Beckman ultracentrifuge model L2-65B 
to free the solution of insoluble material. The supernatant 
containing the solubilized GR1 was removed and to this sufficient 
ice-cold water containing lOmM benzamidine, 0.5mM isotonic EDTA, 
0.02% sodium azide(w/v) and 0.5mM PMSF was added to lower the 
conductivity of the solution to the conductivity of the buffer 
used for the Biorex cation exchange column (5 to 6 mS at 0®G).
3•5 Biorex cation exchange column
Biorex 70 is a weakly acidic carboxylic cation exchanger 
binding positively charged ions, the extent of binding being 
dependent upon the degree of charge. The material to be 
applied to the column should be dialysed into the starting 
buffer at a pH above the isoelectric point therefore giving the 
molecules a net positive charge. These will bind to the 
Biorex and can be eluted by increasing the salt concentration 
as the Na^ ions competitively displace the positively charged 
bound proteins.
Buffer: 50mM sodium phosphate, 20mM NaCl, 0.2% NP-40
pH 7.2, containing 10mM benzamidine, 0.5mM isotonic 
EDTA, 0.02% (w/v) sodium azide and 0.5mM PMSF. 
Column: Biorex 70 mesh size 100-200 was extensively equil­
ibrated with buffer until the final pH was 7.2. and
a conductivity of 5 to 6 mS at 0°C, after degassing
the Biorex 70 was poured into a 5x30cm column. Two
column volumes of buffer were run through before
sample application.
The solubilized erythrocyte membranes (1800ml) were applied 
to the column with a flow rate of 80ml per hour, collecting 
20ml fractions. Once the starting material had been washed 
through with buffer until the protein content of the fractions 
was less than 0.01mg/ml, a 5 litre 0.3M linear salt gradient 
was applied to elute the CR1 from the column. The column fract­
ions were screened as described in 3.1. The tubes showing
positive haemagglutination were pooled and concentrated using
ultrafiltration (2.5) with a PM30 membrane. To this concen­
trated pool a four-fold volume of ice cold water containing
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lOmM benzamidine, 0.5mM isotonic EDTA, 0.02% sodium azide (w/v) 
and 0.5mM PMSF was added. This pool was applied to the 
C3-sepharose affinity chromatography column.
3• 6 C3-sepharose affinity chromatography column.
A C3-sepharose affinity chromatography column was used to 
bind and immobilise all C3b-binding material from the Biorex 
70 pool, while the non-C3b-binding material was washed 
straight through the column. C3b-binding material was 
then specifically eluted with NaCl and NP-40. As C3b is the 
natural ligand for CR1, it should bind specifically and be 
eluted with the NaCl and NP-40.
Buffer: lOmM sodium phosphate pH 7.3 containing lOmM benza­
midine, 0.5mM isotonic EDTA, 0.02% sodium azide (w/v) 
and 0.5mM PMSF.
Column: C3-sepharose was prepared as follows:
CNBr-activated Sepharose 4B (2g) was washed 4 times 
in O.OOIM HCl and the pellet was then resuspended in 2ml of 
human C3 at 4mg/ml (purified as described in Chapter 6) in 
O.IM NaHCO plus 0.15M NaCl. This was incubated overnight at 
4°C with continuous mixing. The suspension was then spun for 
5 mins at lOOOg, the supernatant was removed and its protein 
content established by measuring the absorbancy at 280nm (2.4). 
This enabled the calculation of how much C3 had bound to the 
sepharose beads, this was found to be 99%. The sepharose beads 
were then incubated with a 10-fold volume of 1M ethanolamine 
pH 8.0 for 2 hrs at R.T. with mixing, to inactivate any un­
coupled sites. The beads were then washed with 0.1M acetate
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buffer pH 4.0 containing 1.0M NaCl followed by O.IM borate
buffer pH 8.0 containing 1.0M NaCl, this washing cycle was
repeated thrice. The conjugated sepharose beads were then 
resuspended in buffer, and 5ml of the C3-sepharose was poured 
into a 5ml syringe barrel, the end of which had been blocked 
with glass wool.
The diluted pool from the Biorex column (3.5) was applied 
to the C3-sepharose column collecting 15ml fractions. A step­
wise elution scheme was used to elute CR1 . During the wash 
steps 5ml fractions were collected and for the elution steps 
2ml fractions were collected. The flow-rate was variable as 
the column was small and not attached to a pump. The elution
scheme was as follows: 50ml of buffer, 50ml of buffer containing
0.1% NP-40, 50ml of buffer, 50ml of buffer containing 200mM NaCl, 
50ml of buffer and finally 50ml of buffer containing 0.1% NP-40 
and 200mM NaCl. The column fractions were screened as des­
cribed in 3.1, the tubes containing CR1 activity as determined 
by haemagglutination were pooled and dialysed into the starting 
buffer for the lentil lectin-sepharose column.
3.7 Lentil lectin-sepharose affinity chromatography column,
Lentil lectin binds glycoproteins and this material bound to 
sepharose was used to specifically bind proteins containing 
glycoprotein eluted from the C3-sepharose column. CR1 con­
tains glycoprotein and therefore should bind specifically to the 
lentil lectin-sepharose. Bound material was competitively 
eluted using o(-methyl-D-mannoside.
Buffer: 1OmM Tris/HCl, 200mM NaCl, 0.1% NP-40, 0.7mM CaCl^^
0.7mM MgCl , 0.7mM MnClg pH 7.4 containing lOmM
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benzamidine, 0.5mM isotonie EDTA, 0.02% sodium 
azide (w/v) and O.^mM PMSF.
Column: 1ml of lentil lectin-sepharose in a plugged glass
pipette.
The dialysed pool from the C3-sepharose column was applied to 
the lentil lectin-sepharose colur% the column was then washed 
with buffer (20ml) and the CR1 was then eluted using buffer 
containing 200mM X-methyl-D-mannoside. Two ml fractions were 
collected and these were screened as described in 3.1. The 
tubes containing CR1 activity as determined by haemagglutination 
were concentrated by ultrafiltration using a PM-30 membqane (2.5) 
The protein content and the haemagglutination titre of the con­
centrated pool were re-determined. The purity of the CR1 was 
tested using SPS-PAGE in 5% slab gels (2.11) with silver 
staining (2.12).
3.8 Production of anti-CRI antiserum.
Using both pool 1 and pool 2 of purified CR1, 700ul of the 
protein was made up to 2ml with PBS. An equal volume of 
Freund’s complete adjuvant was added and the mixture was emulsi­
fied and injected subcutaneously into rabbits. This was 
repeated a further 3 times at 3 to 4 week intervals, substitut­
ing Freund's incomplete for Freund's complete adjuvant. A 
further 2 boosts were given at 3 weekly intervals intraperitoneally 
The rabbits were then bled during intervals over a week (2 weeks 
after the last boost) and exsanguinated at the end of this 
period.
The antiserum specificity was tested using double immune—
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diffusion (2.7).
3.9 Anti-CR1 antiserum produced by Dr. W.S.Kilpatrick.
The anti-CR1 antiserum used for the experiments documented in 
this thesis was raised prior to the initiation of this project 
by Dr. W. S. Kilpatrick. The following briefly outlines the 
nature of the antigen and the immunization schedule used.
0 .5ml of CR1 purified from human erythrocytes (protein con­
centration unknown) was emulsified with an equal volume of 
Freund's complete adjuvant and injected intramuscularly and 
subcutaneously into stock rabbits. After two boosts at 14 day 
intervals with 0.5ml of CR1 emulsified in an equal volume of 
Freund's incomplete adjuvant, the rabbits were bled at intervals 
during the following 7 days with exsanguination at the end of 
this period.
The specificity of the antiserum was tested using 
double immunodiffusion (2.7), inhibition of lymphocyte and 
neutrophil rosette formation and agglutination of human erythro­
cytes (Fearon, 1979).
For all experiments using anti-CR1 the serum from only
one rabbit was used.
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RESULTS.
A total of 18 packs of blood, 12 expired and 6 fresh, were 
used for the isolation of CR1 from the erythrocyte membranes.
After washing in saline the cells were lysed in 7 litres of 
lysis buffer giving erythrocyte ghost membranes and the 
released cellular contents. The ghost membranes were washed 
free of haemoglobin using positive pressure dialysis in a 
Psllicon cassette. This apparatus allows the continuous and 
rapid washing of the membranes and within 24 hrs using 100 litres 
of lysis buffer the membranes were free of haemoglobin.
Using the Pellicon the membranes were then concentrated and re­
suspended in 1.3 litre of solubilizing buffer. After overnight 
stirring at 4°C the membranes dissociate because of the presence 
of detergent in the solubilization buffer. At this stage 
the membranes had a haemagglutination titre of 1/250. The 
protein content was not tested because of the high density of 
cellular material present which would make an accurate determin­
ation difficult. The insoluble material was removed by ultra­
centrifugation. The supernatant containing the soluble GR1 
had a protein content of 1.55mg/ml (in a volume of 1.3 1) and 
a haemagglutination titre of 1/250*, therefore no GR1 activity 
had been lost with the removal of the insoluble material. By 
adding 500ml of ice cold water the ionic strength of this pool 
was lowered to 5*5^8 (at 0 G), the conductivity of the starting 
buffer for the Biorex column.
The starting material (1800ml) was applied to the Biorex- 
70 cation exchange column (Fig. 8). A large amount of protein 
did not bind to the column and was eluted in the first 200 fractions; 
however, none of these fractions showed positive haemagglutination. 
The column was then washed with 600ml of buffer and the salt
FIG. 8. Elution profile from Biorex-70
100-200 mesh column, showing conduct­
ivity (mS at 0°C -- ), protein (rag/ml
0-0-) and reciprocal haemagglutination 
titre (----- ).
(1) Application of sample,
(2) Application of wash buffer,
(3) Application of 600mM linear salt 
gradient.
95
( ---------- ) ©«iq-xq. L iO T C (.'B U T q .n x S S B iii0 'B q  { s o o j d T o a y
oo Oo oo
CM
Oo o
xm/3m) UTa^ojj
kO CO VO
I
CM
siu) AxATC^onpuoo
c
o
•H
4-)Ü
cd
1:4Cm
II—I
oo
96
gradient was applied. Immediately the gradient was applied 
a small amount of weakly bound protein was eluted (fractions 
240-255), this had no CR1 activity. CR1 was eluted between 
a conductivity of 6 to UmS (at 0°C) from fraction 265 to 310, 
the CR1 containing fractions eluted immediately prior to the 
major protein peak. Fractions 265 to 310 were pooled to 
give a volume of 550ml. This volume was then reduced to 
234ml by ultrafiltration using an Amicon flow cell (2.5) with 
a PM30 membrane. The protein content of the concentrated 
pool was 0 .71mg/ml and the haemagglutination titre was I/64O.
One hundred and thirty four ml of the pool was frozen at -70°C 
for further purification at a later date, the remaining 100ml 
was mixed with 400ml of ice-cold water to lower the conductivity 
to 2.8mS (at 0°C).
This 500ml pool was applied to a 5ml C3-sepharose column.
The column profile (Fig. 9) shows most of the proteins to 
have passed straight through the column or to have been eluted 
with the first wash or the first elution buffer containing 
NP-40 applied at fraction 38 (Fig 9,[3]) after which no detect­
able protein was eluted. CR1 with a haemagglutination 
titre of 1/20 was eluted between fractions 5 to 29 and 51 to 63. 
However the majority of the CR1 was eluted with the column 
buffer containing 0.1% NP-40 and 200mM NaCl (Fig 9, [7]) with 
a peak haemagglutination titre of 1/1280. Fractions 92 to 
104 were pooled (45^1), the pool had a haemagglutination titre 
of 1/320 but had no detectable protein. This pool was dialysed 
into the starting buffer for the lentil lectin Sepharope affinity 
chromatography column.
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FIG. 9 Elution profile of CR1 from
C5-sepharose 4B affinity chromat­
ography column.
[1] Application of sample,
[2] Application of wash buffer,
[3] Application of wash buffer, 
plus 0.1 % NP-40,
[4] Application of wash,
[5] Application of wash buffer 
plus 200mM NaCl,
[6] Application of wash buffer,
[7] Application of wash buffer 
plus 0.1% NP-40 and 200mM 
NaCl
All of the 45ml pool was applied to the 1ml lentil- 
lectin-Sepharose column(Pig. 10). The column was screened for 
protein using the Polin assay but none was detected. CR1 was 
eluted with the elution buffer containing ^-methyl-D-mannoside 
in two distinct peaks, both having a haemagglutination titre 
of 1/1280. Therefore two pools were made, pool 1 consisting 
of fractions 25 to 25 and pool 2 fractions 26 to 31. Pool 1 
had a volume of 4ml and pool 2 was 8ml, these were concentrated 
using ultrafiltration to 2ml and 2.5ml respectively. The protein 
content and the haemagglutination titres of the two pools are 
given below.
Pool 1 Pool 2
Protein ug/ml 48 32
Haemagglutination titre 1/1280 1/1280
The purified protein from pools 1 and 2 were anlysed by SDS- 
PAGE using 5% slab gels (2.11). The purity was tested by 
silver staining the gel (2.12), as this metliod has a high 
sensitivity, detecting very low concentrations of contaminants.
A single protein band was detected (Plate 2), this had a reduced 
molecular weight of 230000 which is consistent with that des­
cribed by Fearon (1979)- A summary of the CR1 purification
is given in Table 11.
Antiserum was successfully raised against the purified 
CR1 and showed positive reactivity against CR1 when tested 
by double immunodiffusion (3-8, Plate 3)*
FIG. 10 Elution profile of CR1 from lentil- 
lectin-Sepharose 4B affinity chroma­
tography column.
(1) Application of sample,
(2) Application of wash buffer,
(3) Application of wash buffer
plus 200mM <3<-methyl-D-mannoside.
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TABLE 11. Summary of CRI purification 
profile
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Protein
content
Haemagglutinat­
ion titre
Volume
Lysed membranes N.T. H.T. 7000 ml
Solubilized membranes N.T. 1/256 1500 ml
Biorex column S.M. 1.55 mg/ml 1/256 1800 ml
C5-Sepharose S.M. 710 ug/ml 1/640 254 mli
Lentil lectin- 
Sepharose S.M.
N.D. 1/520 45 ml
Purified CR1 pool 1 48 ug/ml 1/1280 2 ml
pool 2 52 ug/ml 1/1280 2.5 ml
N.T.
N.D,
8.M.
*
not tested
not detectable
starting material
only 100ml further purified.
PLATE 2 Purified CR1 (track a = pool 1 , 
track b = pool 2) run reduced on 
a 59^  SDS-PAGE Laemmli slab gel, 
silver stained (track c = reduced 
Sigma molecular weight markers)
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PLATE 5 Double immunodiffusion plate showing 
positive reaction between pure CR1 
(centre well) and doubling dilutions 
of rabbit anti-CR1 antiserum 
(a = neat, doubly diluted in a clock­
wise direction)
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DISCUSSION
Prior to this successful purification of CR1, I had made 
two previous unsuccessful attempts following precisely the method 
described by Fearon (1979)* There were 5 main problems with this 
method which probably lead to the loss of CR1 during purification. 
Firstly, we were informed by Dr. R. Sim (personal communication) 
that CR1 is exquisitely sensitive to degradation, however, in 
Fearon's method there was only one enzyme inhibitor used, PMSF 
and only at the stage when the cells were being washed free of 
haemoglobin. Secondly, the column was screened for CR1 using 
an assay which quantified the ability of CR1 to inhibit the
activity of the alternative pathway C5 convertase (C5bBbP). This 
assay was time consuming, and whilst controls gave repeatable 
results the samples did not always do so; hence it was very 
difficult to establish exactly where CR1 was being eluted.
Thirdly, the time scale of the purification was in excess of 4 
weeks, resulting from a) the use of the ultracentrifuge to wash 
the membrances free of haemoglobin which could take up to 10 days, 
and b) the inability to get consistency between the assays used to 
screen for CR1 . Therefore the combination of CRI's sensitivity 
to proteolysis, the variability in screening the column for CR1 
and the time taken for purification probably accounts for the 
lack of success of this method on the two previous attempts.
These difficulties were overcome by introducing the following 
modifications to the method: a) proteolytic inhibitors, e.g.
benzamidine, PMSF, sodium azide and EDTA, were included in all 
the buffers throughout the purification, b) the haemagglutination 
of EAC45b was used to screen for CR1*, this assay was quick, 
sensitive and reproducible, c) membranes were washed rapidly
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by pressure dialysis in a Pellicon cassette. This procedure 
took only 12 hours whereas 10 days were required to wash the 
membranes by ultracentrifugation.
3
Approximately 1x10 washed human erythrocytes were used 
for the purification of CR1, this is equivalent to the amount 
used by Fearon (1979). The cells were then lysed using a hypo­
tonic buffer, washed free of haemoglobin and the cleaned membranes 
were then solubilized using the non-ionic detergent NP-40 
releasing the CR1 into the soluble phase. This solution had a 
haemagglutination titre of 1/256 and this was not reduced when 
the insoluble material was removed by ultracentrifugation. The 
soluble material in the supernatant was applied to the Biorex 
anion exchange column after the conductivity had been reduced to 
5.5 mS (at 0°C) using ice cold water.
A total of 2015mg of protein was applied to the Biorex 
column (in 1800ml) with a haemagglutination titre of 1/256.
CR1 was eluted with the salt gradient between 6 and 14 mS (at 
0°C), this was not mirrored by the protein profile (Fig. 8).
This pool (550ml) was concentrated by ultrafiltration to 234ml 
(haemagglutination titre 1/640) and had a total protein content 
of I66mg (0.71mg/ml), therefore 8% of the applied protein was 
recovered in this pool. Only 100ml of this pool was processed 
further, the remainder being stored at -70 C for use at a later 
date.
In the original paper (Fearon, 1979) the next purification 
step was the passage of the pool over a Bio-G-el A-5M gel filtration 
column. This step was omitted because on the two previous attempts 
it was found that it did not contribute significantly to the 
purification of CR1. Furthermore it brought about significant 
dilution of the CR1 pool.
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The 100ml pool was then applied to a C3-Sepharose followed 
by a lentil-lectin affinity chromatography column, with CR1 
binding to its natural ligand 03b linked to the Sepharose and 
being eluted with NP-40 and a high salt buffer-, and with the 
lentil-lectin Sepharose colum GR1 would bind via its carbo­
hydrate moieties using -methy1-D-mannoside for elution.
The majority of CR1 was eluted from the C3-Sepharose column 
using NP-40 and 200mM NaCl, however this contained no detectable 
protein, with all the protein passing straight through the column 
or being eluted with 0.1% NP-40. Some 03 binding protein was 
eluted using NP-40 alone, this protein agglutinated EAC43b at a 
very low titre. This maybe CR1 or perhaps another protein 
exhibiting C3 binding properties. The fractions containing CR1, 
as determined by haemagglutination were pooled (Pig 9)• This 
pool (45ml) contained no detectable protein and had a haemagglut­
ination titre of 1/320’, this was then applied to the lentil-lectin 
Sepharose column after dialysis into the starting buffer. CR1 
was eluted in two peaks both with a haemagglutination titre of 
1/1280. It was possible that these two peaks represented two 
of the polymorphic variants of CR1, therefore two pools were made. 
As for the C3-Sepharose column, no detectable protein was found 
in the column fractions containing CR1. These fractions were 
concentrated, pool 1 contained 48ug/ml and pool 2 32ug/ml, in total 
176ug. However, if the whole 234ml had been processed the 
recovery would have been approximately 412ug and this represents 
0.02% of the starting material applied to the Biorex column.
Fearon’s (1979) recovery from approximately the same quantity of 
erythrocytes was 150ug of CR1: therefore the modifications to 
this method increased the yield nearly two-fold.
The silver staining of the slab gel shows the CR1 to be
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pure (Plate 2) and a single band of molecular weighty There 
was no obvious molecular difference between the GR1 of pools 
1 and 2 from the lentil-lectin Sepharose column. However, 
minor differences may have existed between the CR1 of those 
two pools, for example, carbohydrate composition. Such minor 
differences may not have been picked up by SDS-PAG-E. Both 
of these pools had a final haemagglutination titre of 1/1280.
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C H A P T E R  4
METHOD FOR QUANTITATING THE NUMBER
OF ANTIGENIC CR1 SITES PER CELL USING
A RADIOIMMUNOASSAY.
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INTRODUCTION
The number of CR1 antigenic sites per erythrocyte have
previously been quantitated by Wilson et al (1982) and lida
et al (1982) using a radioimmunoassay (RIA). The latter group
used a radiolabelled monoclonal antibody directed against the
receptor whilst the former group used a polyclonal antiserum.
As the anti-CRI antiserum used in this project was polyclonal
(3.9) the assay system used was modified from the method described
by Wilson et al (1982). Basically the assay quantitates the amount 
1 25
of I-labelled F(ab')^ anti-CRI bound to the cell surface and 
from this, using Scatchard plot analysis (Scatchard, 1949) the 
number of receptor sites for the F(ab') anti-CRI molecules per 
cell can be calculated. However, as the antiserum is polyclonal 
two controls were introduced into the system. Firstly a batch 
of cells were pre-incubated with an excess of F/ab')^ derived from 
normal rabbit serum IgG (NRS F(ab')g) prior to incubation with 
labelled F/ab')^ anti-CRI. The excess of NRS F/ab')^ blocks 
non-specific binding sites and this allows the total binding of the 
label to the cells to be measured. Secondly a batch of cells were 
Incubated with an excess of unlabelled F(ab')  ^anti-CRI prior 
to the addition of ^^^I-F(ab') anti-CRI. The excess of cold 
F(ab') anti-CRI blocks all specific binding sites and therefore 
any binding of the label to the cells is non-specific. The 
specific binding of the anti-CR1 is equal to the total,
minus the non-specific, and it is this value which is used for
Scatchard plot analysis.
The F(ab') moieties of both the NRS and anti-CRI antiserum
were used to stop the interaction of the Fc portion with Pc Y
receptors of leucocytes.
This assay was initially established on erythrocytes as they
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were easily isolated in a pure form and in large numbers. Using 
erythrocytes the interassay variation was established and the 
effect of storage of blood at 4 C on the CR1 numbers. This was 
necessary as it seemed likely that patient samples taken in after­
noon clinics, would require to be stored for assaying the next day.
Lay and. Nussenzweig (I968) and Huber et al (I968) established 
the trypsin sensitivity of CR1 . We examined the effect trypsin 
had on CR1 levels investigating whether there was a dose dependent 
removal of CR1 by different amounts of trypsin and whether the 
assay could pick this up.
Once the RIA conditions were established using erythrocytes, 
the assay system was then extended to quantitate CR1 levels on all 
the peripheral blood cells. Fearon (1980) did single point deter­
minations of CR1 numbers on erythrocytes, B cells, PMNs and mono­
cytes using a polyclonal F/ab')^ anti-CRI and found that they 
had 950, 21,000, 57,000 and 48,000 sites per cell respectively. 
However the study was not extended to examine a larger sample of 
the population. In 1982 lida et al examined CRI numbers in the 
lysates of peripheral blood erythrocytes, mononuclear cells and 
PMNs using a monoclonal antibody to CR1, and found them to have 
respectively 1,400, 38,000 and 140,000 CR1 per cell. However 
the number of individuals studied was not disclosed.
The aim was thus to investigate this area further by exam­
ining CR1 levels on intact cells which is perhaps more akin to 
the in vivo situation, and to look at the distribution of CR1
levels on the peripheral blood cells.
The protocol used to separate the cell populations from whole 
blood involved several steps. Ube blood was firstly spun over 
a Ficoll-Hypaque gradient, this gave two cellular pools^ pool
containing erythrocytes and PMNs which were separated further
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using dextran sedimentation, and a pool of lymphocytes and 
monocytes. These were separated using tissue culture flasks 
coated with the micro-exudate from baby hamster kidney cells 
(BHK flasks), the monocytes adhere to the micro-exudate within 
a 45 minute period, leaving free in suspension the lymphocytes 
which are decanted. The monocytes are then 'stripped off using 
EDTA. This method of lymphocyte-monocyte separation was used 
in preference to the more conventional technique of allowing 
monocytes to adhere to tissue culture plates, as this procedure 
takes up to two hours, inhibiting the completion of the RIAs 
on the same day as the blood was sampled.
All assays were performed on ice to stop internalization of 
the Ffab')^ fragments by the leucocytes. EDTA was present in 
the media during the RIA to stop cell clumping.
Peripheral blood samples from 10 people were studied, 8 were 
normal and 2 were RA patients (criteria for RA patients is given 
in 7.3).
MATERIALS AND METHODS
4.1 Normal rabbit serum (NRS)
NRS was obtained by bleeding stock rabbits from the 
marginal ear vein as required. The serum was separated 
from the blood as described in 2.13.
4.2. Rabbit anti-human erythrocyte CR1
Anti-CRI was prepared as described in 3.9 and the serum 
was separated from the blood as described in 2.13.
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4.3 Purification of IgG from rabbit serum
Diethylaminoethyl cellulose (DE52) is an anion exchanger 
binding negatively charged ions, the extent of binding being 
dependent upon the degree of charge. The material to be applied 
to the column should be dialysed into the column buffer (pH 7.6, 
0.8 to ImS at 4 0), under these conditions IgG should not bind 
to the column and be washed straight through, with the remaining 
proteins being retained.
Column: 2.7 x 9.0cm column (60ml syringe barrel) containing
DE52 extensively equilibrated with buffer.
Buffer: 0.01M sodium phosphate buffer pH 7.6 (0.8 to ImS
at 4°C).
A 10 to 15ml serum sample dialysed into 0.01M sodium phosphate 
buffer pH 7.6 was applied to the column and washed through with 
buffer.
Five ml fractions were collected, the protein concentration 
of each tube was measured using the absorbancy at 280nm (2.4).
The elution profile from such a column is shown in Fig. 11. The 
tubes containing the protein peak were pooled and concentrated 
using sucrose or freeze drying (2.5). The purity of the IgG 
was tested using immunoelectrophoresis (2.9) with sheep anti­
whole rabbit serum antiserum. A single precipitin arc indicated 
pure IgG. The IgG was also run on 5% SDS-PAGE in phosphate 
buffer (2.10) and presented as a single band with a molecular 
weight of 150,000 daltons. Approximately 50 to 75mg of IgG was 
recovered per 10ml of serum applied.
The IgG was aliquoted and stored at -20°C until required.
01 q and P may be eluted under these conditions, these were 
not detected on the gel and if present would not interfere with 
the RIA.
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4.4- Preparation of F(ab')^fragments from rabbit IgG
IgG was purified from NRS (4.1) and anti-CRI antiserum 
(4.2) according to the method described in 4.3. Aliquots 
of the rabbit IgG were dialysed overnight at 4°C into 5 litres 
of O.IM sodium acetate. After dialysis the pH of the IgG pool 
(approximately 5ml, variable protein concentration) was adjusted 
to 4.5 with O.IM acetic acid, warmed to 37^0 and then incubated 
overnight at 37 C with Img of porcine pepsin. The digest was 
then spun at 4,500g for 10 mins to precipitate any insoluble 
material. The supernatant was decanted and the pH was adjusted 
to 7.4 using solid Tris. The digest was then concentrated 
using sucrose or freeze drying (2.5) prior to gel filtration or 
applied directly to the gel filtration column.
Gel filtration was used to separate F^ab')^, Fc and any 
undigested IgG. A 3 to 5ml sample of digested IgG was applied 
to a 1.5x90cm Sephadex GI50 superfine column equilibrated with 
PBS. The flow rate was 10 to 12ml per hour and 1ml fractions 
were collected. These were screened for protein by measuring 
the absorbancy at 280 nni (2.4). Ihe peaks obf-ained were screened 
IgG, F(ab’)2 and Fc by double immunodiffusion (2.7) and immuno- 
electrophoresis (2.9) using a 1/10 dilution of sheep anti­
rabbit F(ab') specific antiserum to precipitate F(ab')^, and 
also 5% SDS-PAGE tube gels (2.10).
The conversion of IgG to F(ab') was visualized by immuno- 
electrophoresis, with the F/ab')^ fragments being more electro­
negative than intact IgG therefore travelling further towards the 
anode (Plate 4). Double immunodiffusion was used as a first 
line screen of the peaks obtained from the gel filtration column 
to distinguish the pool containing Fc (which showed no reaction 
with sheep anti—rabbit F(ab')g antiserum) and those containing 
F(ab*) or undigested IgG. The latter two pools were distinguished
PLATE 4. Immunoelectrophoresis plate
showing the difference in electro­
phoretic mobility between rabbit IgG 
(well a) rabbit P(ab') (well b). 
Ih^ trough contained a l/lO dilution 
of sheep anti-rabbit P(ab') .
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by Immunoelectrophoresis and by 8D8-PAGE gels, with intact 
IgG having a molecular weight of 150,000 daltons and P(ab') 
fragments 100,000 daltons in a non-reduced form. The elution 
profile for a Sephadex G150 superfine gel filtration column 
is shown in Fig. 12.
The retained pools of NR8 F/ab')^ and Ffab')^ anti-CRI 
were stored in aliquots at -20^C until required.
4•5 Preparation of human erythrocytes
10ml of venous blood was mixed with 20^1 of preservative 
free sodium heparin in a glass universal container. The 
^lood was then washed three times in RPMI I64O containing 1.%
B8A (RPMI-BSA) ensuring the complete removal of the buffy coat 
layer. The erythrocytes were standardized to 2.5xlO®/ml (2.14)
4 .6 Radiolabelling F(ab’)^  anti-CRI
P(ab’)2 anti-CRI was radiolabelled with carrier-free
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I as described in 2.15.
4.7 RIA to determine the number of antigenic sites per
erythrocytes for F(ab')^ anti-CRI 
200^1 of erythrocytes at 2.5xlO^/ml were added to 56 
(12 tubes in triplicate) microcapped centrifuge tubes (MCC tubes)
To tubes 1 to 6, 12.5^g of NRS P(ab')2 was added. To tubes 7 to 12,
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12.5ug of Ffab')^ anti-CRI was added. The tube contents were
mixed thoroughly and then incubated for one hour at 4°C on a
1 28
Matburn mixer. Increasing concentrations of I-Ffab')^ 
anti-CRI were then added to tubes 1 to 6 and 7 to 12 as outlined 
in the table below:-
Tube number 1 & 7 2 & 8 3 & 9 4 & 10 5 & 11 6 & 12
^^^I-F(ab')2
anti-CRI 
added (pg)
0.25 0.5 1 .0 2.0 3.0 4.0
The tubes were inverted by hand and incubated for one hour 
at 4°C on a Matburn mixer, after which the contents were layered 
onto 300jil of separating fluid (6:4 dibutyl phthalate: dinonyl 
phthalate) in MCC tubes and spun at 8,000g for 2 mins. This 
separates the erythrocytes from the fluid in which they were 
suspended. The cells carrying bound ^^^I-F/ab')^ anti-CRI were 
pelleted to the tube bottom and the unbound isotope remained on 
top of the separating fluid. The supernatants were then removed 
from each tube and discarded. The base of the tube containing 
the cell pellet was cut off and placed in a glass test tube.
These tubes were then counted in a Packard gamma-counter for 
one minute to determine the amount of radioactivity bound to the 
cell pellet (counts per minute, cpm). Six empty tubes were in­
cluded in each run to determine the machine background and 2 tubes 
containing 10^1 of ^^^I-F/ab')^ anti-CRI were included to calculate 
the input of isotope into each tube.
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4.8 Numerical calculations
The machine background was subtracted from all cpm values.
The triplicate values attained for bound cpm in tubes 1 to 12
were averaged and the standard errors calculated. If however
any of the triplicate values diverged by greater than 10% from
one another they were not included in the calculation. The
mean bound cpm for tubes 1 to 6 and 7 to 12 were plotted together
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with the standard errors against the input of I-Ffab')^ anti-
CRI expressed as cpm. The line drawn through cpm values
attained from tubes 1 to 6 represented the total binding of the
isotope to the erythrocytes, whilst the line through the cpm values
from tubes 7 to 12 represented the non-specific binding of the
isotope to the cells. From these two curves the specific binding 
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curve for I-F(ab')  ^anti-CRI was obtained by subtracting the 
non-specific binding values from the total binding values over a 
range of input values. Using the specifically bound cpm at 
given input values, a Scatchard plot was drawn, plotting specific­
ally bound cpm versus bound/free cpm. A line was drawn through 
these points using linear regression analysis and the intercept 
of the line with the Y axis was calculated. The value for the 
point of intercept was then multiplied by the correction factor 
(cf). This factor accounts for the decay of radiation, the 
number of cells in the assay tubes and converts the Y intercept 
value obtained in cpm into the number of F(ab')2 unti-CRI molecules 
per cell, utilizing 6.03x10^ , the number of F(ab')g molecules 
in Ipg (derived from Avagadro's number)
cf = (6.03 X 10^^ ______________________ ) /Number of cells
(input cpm for of i^6l-F(ab'jg anti-CR1 ) / per tube
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4.9 Trypsinization of erythrocytes
Erythrocytes were washed, standardized to 2.5xlO^/ml 
(4 .5) and incubated for one hour at 37°C with Img, O.OImg 
and O.OOOImg of trypsin per ml of erythrocytes. After the 
incubation the cells were put directly onto ice and washed 
thrice with ice cold RPMI-BSA. The cells were then re­
standardized to the required cellular concentration.
4.10 Media used for isolation of peripheral blood cells
Hanks buffered salt solution (HBSS); One packet of powdered 
HBSS was dissolved in 80ml of water, 5ml of 7.5% sodium bi­
carbonate was added and made up to a final volume of 100ml 
with water. 50ml of the solution was filtered through a 
sterile Millex-GS 0.22pm filter unit into a sterile bottle 
containing 450ml of sterile water.
RPMI-culture media (RPMI-CM); RPMI I64O was supplemented
with penicillin (10,000 units/ml), streptomycin (10,000 meg), 
fungazone (25 meg) and 2mM L-glutamine.
RPMI-foetal calf serum (RPMI-FCS): As for RPMI-CM but
supplemented with 10% FCS which had been heat-inactivated 
for 2 hours at 56°C.
EDTA-PBS : 25ml of 20 times normal strength PBS was added
to 25ml of water and 65ml of 0.086M isotonic EDTA pH 7.2 
to 7.4. This was filtered as described for HBSS preparation 
and added to 450ml of sterile water.
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Ficoll-Hypaque; 25ml of 33.9% Hypaque and 60ml of 9% Ficoll 
were mixed together to give Ficoll-Hypaque with a specific 
gravity of 1.077-
4.11 Cell Separation
40ml of venous blood was aliquotted into 2 sterile uni- 
versals containing 20^1 of preservative-free sodium heparin.
The 20ml aliquots were then mixed with 15ml of RPMI-CM and 
layered onto 15ml Ficoll-Hypaque in a sterile Falcon tube. The 
tubes were then spun at R.T. for 45 mins at 400g. After centri­
fugation the upper layer containing diluted plasma was decanted 
and retained. The white interfacial band containing the mono­
cytes and lymphocytes was harvested and treated as described in 
4 .13. The remaining Ficoll-Hypaque was discarded and the 
pellet composed of erythrocytes and PMNs was treated as described 
in 4 .12.
4.12 Separation of erythrocytes and PMNs
The pellet from the Ficoll-Hypaque separation was mixed 
with an equal volume of retained plasma. This was cooled for 
30 mins at 4°C and then mixed with 6% dextran (w/v) in PBS 
in a ratio of 400^1 dextran to 1ml of blood. This was placed
in a measuring cylinder and left at 37°C for 30 mins or until 
the erythrocytes had sedimented below 50% of the starting volume. 
The top 50% which contained the PMNs contaminated with erythro­
cytes was removed and placed in sterile universal container.
The contaminating erythrocytes were removed by repeated water 
shocking, returning the solution to isotonicity each time
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by adding an equivalent amount of 2N saline as water. The 
PMNs and erythrocytes were finally washed and resuspended in 
RPMI-BSA plus 0.01M isotonic EDTA pH 7.2 to 7.4 (RPMI-BSA- 
EDTA).
4*13 Separation of monocytes and lymphocytes
Four BHK flasks (flasks in which baby hamster kidney 
cells have been cultured and then removed leaving the flasks 
coated with a micro-exudate to which monocytes preferentially 
adhere leaving the lymphocytes in suspension, kindly given by 
Mrs. L. Jones) were washed twice with HBSS before use. The 
white interfacial layer from the Ficoll-Hypaque separation was 
made up to 48ml with RPMI-FCS and 12ml aliquots were added to 
each BHK flask.
Each flask was gassed with a mixture of 5% CO in air for 
30 seconds and incubated at 37°C for 45 mins. The supernatant 
containing the non-adherent lymphocytes was decanted into a 
sterile universal container and washed in RPMI-BSA-EDTA. The 
flasks containing the adherent monocytes were then washed thrice 
with warmed RPMI with gentle swirling to remove any loosely bound 
cells. The platelets were then removed by adding per flask 
5ml of 1:1 EDTA-PBS to RPMI-FCS for 30 seconds. After decanting 
this mixture, a second aliquot of 5nil was added to the flasks, 
which were then incubated for 15 mins at 37 C, in order to remove 
the monocytes from the micro-exudate. These were then washed in 
RPMI-BSA-EDTA.
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4 • 1 '4 Determination of GR1 sites/cell on human peripheral
blood cells
Erythrocytes were standardized to 2.5xlO®/ml in RPMI-BSA- 
EDTA (2.14)• Leucocytes were counted in an improved Neubauer 
counting chamber (depth = 0.1mm 1/400mm ) and adjusted to the 
following in RPMI-BSA-EDTA; monocytes 1xlO^/ml, lymphocytes 
5xlO^/ml and PMNs 1x10^/ml. The RIA was performed as des­
cribed in 4.7 but with the following modifications; a) all 
stages other than the separation of the cells from fluid were 
performed on ice, b) all points were performed in duplicate 
and c) only 5 input values of F/ab')^ anti-CRI were used 0.25, 
0.5, 1.0, 2.0 and 5.0^g of protein.
RESULTS
Rabbit NRS IgG and rabbit IgG anti-CRI were purified from 
their respective sera using anion exchange chromatography (4-3) 
The IgG was further cleaved using pepsin to obtain P(ab')2 
Fc fragments and occasionally undigested IgG and Fc' fragments. 
These moieties were separated by gel filtration using Sephadex 
GI50 superfine (4.4). The purity of the retained NRS F/ab')^ 
and F(ab') anti-CRI was tested using double immunodiffusion, 
immunoelectrophoresis and SDS-PAGE phosphate buffer tube gels 
(4 .4). Once purified these F(ab') fragments were used to 
develop the RIA for quantitating the number of CR1 sites per 
erythrocyte for the ^^^I-F(ab')2 anti-CRI molecule. The method 
used was based loosely on that described by Wilson et al (1982). 
As an example of how the receptor levels were calculated, the 
results of a RIA performed on the erythrocytes of a 30 year old
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normal male are given. Table 12 shows the raw data in cpms.
Columns a, b and c represent the triplicate determinations for
tubes 1 to 5 (representing total binding of ^^^I-F(ab') anti-
CRI to the erythrocytes) and tubes 7 to 12 (representing
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non-specific binding of ^I-F(ab') anti-CRI to the erythro­
cytes). The mean of these values, the mean minus the machine 
background, standard deviation and standard errors are tabled.
The numbers asterisked were not used in further calculations as 
they deviated from the remaining two numbers by greater than 10%. 
However, this rule was not always possible to follow, for example 
tube 5, the triplicate values were 6746, 8428 and 9729 • These 
clearly differ by greater than 10%, but as no two numbers are 
close in their value, the mean of the three values was taken.
These results were then plotted as a graph (Fig. 13). The Y-axis
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represents the amount of I-F/ab')^ anti-CRI bound to the
erythrocyte pellet and the X-axis the input of radiation expressed 
as cpms and ^ g of protein. The total binding curve (tubes 1 to 
6) is concave to the abscissa indicating that the binding sites 
for the ^^^I-F/ab')^ anti-CRI are saturable. The non-specific 
binding curve (tubes 7 to 12) however is linear indicating non­
saturable binding sites. The specific binding curve attained
by subtracting the non-specific binding values from the total 
binding values is also concave indicating saturable binding sites 
for the radiolabelled ligand.
By using the values for the specifically bound cpm at 
input values of 2000x10^ to 4000x10^ (Table 13), the free cpm 
can be calculated and a Scatchard plot drawn, plotting specifically 
bound cpm versus specifically bound divided by free cpm. The 
Scatchard plot derived from the figures in Table 13 is shown in 
Fig. 14. This graph is not normally drawn, with the intercept
TABLE 12 Raw data from RIA
in cpms
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FIG. 13. Binding curves for I-Ffab')^
anti-CR1 to normal human erythrocytes 
from a 30 year old male
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TABLE 13* Data used to construct a 
Scatchard plot
126
0 O (00 KO 1X0 (000 CM r- 00 CO (00KO CM O
\ O o O O O
CQCO O o O O O
O o O O O0 O o O O 1X00 CM co CM (00 MOIH tr- MO MO 1X0 1X0k (00 KO (00CM CM KO
o o O O O
PQ o o O O 1X0co 00 00 KOCM KO KO 'M-
o o O O O
PQ o LO O O 1X0CO 00 1X0 (00 CMS CM KO KO KO 'd-
o O O O O
PQ o LCO O O OE4 MO LfO KO O MO
CMO
Lf\ MO 10- 00 00
o O O O oo O O O o% o LCO O 1X0 o
1
CM CM KO KO
o
tO
1» §E 1—1 OPl 1—1ü cdü
tO •H rHQ-h r—1
•H CdO ü ü S0 •H P3UA cp ü1—1 CQ •Hcd 1 ü 0-p d 0 0o o Pi Pp> ü ra Ch
FIG. 14 Scatchard plot
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with the Y axis being obtained by linear regression analysis.
In this assay the intercept with the Y-axis is at 9278 and the
cf (4.8) for this assay was 1.06’, therefore there were 9834
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sites per erythrocyte for the I-P(ab') anti-CRI molecule 
(CR1 sites/cell). Assays which gave a Scatchard plot with a 
linear regress coefficient (r) of less than -0.8 were repeated.
The interassay variation was assessed by performing the 
RIA on a single normal blood sample twice on a given day; it 
was found to be approximately 10%.(e.g. 5064 and 5520, 1260 
and 1316). The effects of storage of the erythrocytes at 
4°C in RPMI-BSA was also tested; in a single study it was found 
to have no effect on CR1 numbers within a 24hr storage period
(see below).
GR1 sites/erythrocyte
Pre-storage 9589
Post-storage 9754
The effects of storage periods greater than 24 hrs were 
not tested and this would require further investigation.
The effects of trypsin on GR1 numbers was examined by 
incubating erythrocytes with 3 doses of trypsin (img/ml,
0.01mg/ml and 0.0001mg/ml) for 1 hour at 37°G (4.9)’, the excess 
Ipypsin was removed by repeated washings and the receptor levels 
were qiiantitated pre- and post- incubation (4.7). The effects 
of trypsin on the erythrocytes from 5 normal individuals were 
studied. In all cases, Img/ml of trypsin brought about total 
removal of the receptors (Fig. 15), with the total binding curve
125
and the non-specific binding curve for I-F/ab')^ anti-GRI 
to the trypsinized erythrocytes overlapping, making it impossible
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to derive a specific binding curve. The lowest dose of 
trypsin (0.0001 mg/ml) did not remove all the receptors, as the 
total binding curve and non-specific binding curve for the
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I-FCab')^ anti-CRI no longer overlapped, and therefore a 
specific binding curve could be obtained. However large errors 
did not permit the determination of CR1 levels. This may have 
been caused by the alteration of the cell surface charge by 
trypsin, which may have influenced the binding of the F(ab' 
moieties.
The RIA was adapted to determine the number of CR1 sites/ 
cell on lymphocytes, monocytes and PMNs. The method of cell 
separation employed Ficoll-Hypaque to separate the pool of 
lymphocytes and monocytes from the pool of erythrocytes and PMNs 
(4 .11). The monocytes and lymphocytes were further purified 
using flasks coated with the micro-exudate from baby hamster 
kidney cells (4.13). PMNs and erythrocytes were separated using 
dextran sedimentation (4.12). The combination of these techniques 
enabled the complete separation of lymphocytes, monocytes, PMNs 
and erythrocytes within 3 to 4 hours, and generally yielded 
sufficient cells to use at the stated cellular concentrations (4.14) 
When there were insufficient cells, the cellular concentration was 
decreased and the cf value (4.8) adjusted to accommodate for the 
change.
The RIA was performed on the peripheral blood cells of 10 
individuals (Table 14)» two of whom were RA patients. Out of the 
34 assays performed 24 failed to give a result. In 20/24 assays 
the total binding and non-specific binding curves overlapped 
(LO, Fig. 16), consequently a specific binding curve could not 
be attained. The curves (Fig. 16) were similar to those found
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when erythrocytes were treated with sufficiently high doses of 
trypsin (Img/ml) to remove their receptors (Pig. 15).
In 4 assays the errors between the duplicate determinations 
were greater than 10%, a further 6 samples were not tested.
Some results were obtained from blood samples 2, 3, 4, 5 
and RA patients 1 and 2 (Table 14) • The CR1 sites/erythrocyte 
varied from 494 to 1594 with the lowest values being found in 
the RA patients. The two lymphocyte measurements of CR1 sites 
were very close; 1037 and 1076. There was one monocyte measure­
ment of 889 CR1 sites, and 3 determinations of CR1 sites/PMNs, the 
results being 93,000, 10,000 and 6,327. Unfortunately there 
was no successful measurement of CR1 sites on the lymphocytes, 
monocytes, PMNs and erythrocytes from a single blood sample.
DISCUSSION
The result of a single RIA to determine the number of 
CR1 sites/erythrocyte has been given as an example, the result 
being 9605 CR1 sites/erythrocyte. This can be compared with 
the single determination of 950 CR1 sites/erythrocyte by Fearon 
(1980), the average of 113 normals of 5014_+155 CR1 sites/erythro- 
cyte by Wilson et al (1982) and the average of 52 normals of 
1410+^610 receptors by lida et al (1982). The latter two groups 
looked at a large population sample; I have performed such a study 
the results of which will be discussed in a later chapter.
It must be pointed out that the CR1 numbers per cell deter­
mined by different groups will not correlate. This is a result 
of using a specific antiserum to quantitate the number of receptor 
sites. For example, with a monoclonal anti-CRI antibody only 
one antibody will bind per receptor, whilst with a polyclonal
TABLE 14 CR1 sites/cell on the 
peripheral blood cells 
from 8 normals and 2 RA 
patients
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Cell type 
sample
Erythrocytes Lymphocytes Monocytes PMNs
1 NT LO NT LO
2 1594 1037 NT LO
3 LE LO 889 93000
4- 705 1076 LO 10000
5 LO LO NT 6327
6 LE LO LO LO
7 LE LO LO LO
8 LE LO LO LO
R.A.1 632 LO NT NT
R.A.2 494 LO LO LO
NT = 
LO = 
LE =
not tested 
lines overlapping 
large errors
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FIG. 16 Binding of I-Ffab'jg anti-CRI 
to lymphocytes of a normal 
individuals.
X Total binding curve values
• Non-specific binding curve
values (slightly displaced to 
right where values overlap)
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antiserum more than one antibody molecule may bind to each 
receptor and the number of molecules binding will vary with 
different batches of antiserum.
As a consequence of this it is difficult to establish the 
exact number of CR1/cell. However when one uses the same anti­
serum for a complete study, then comparisons of the levels between 
individuals and groups of individuals are valid.
The interassay variation was found to be approximately 10% 
and 24 hrs storage periods at 4°C in RPMI-BSA had no effect on 
the receptor levels. Longer storage periods were not tested, but 
such a study has been performed by Minota et al (1984). CRI sites/ 
cell were determined using a RIA with a monoclonal anti-CR1 
antibody and the erythrocyte surface area was determined by measur­
ing the level of wheat germ agglutinin (WG-A) binding sites using a 
RIA (WGA binds to glycophorin a major component of erythrocyte 
membranes). This allowed them to standardize the number of CR1 
sites in a given surface area of erythrocyte. They looked at these 
3 parameters in 124 individuals over 8 days (Table 15). They 
found that CR1 levels declined when erythrocytes were stored for 8 
days at 4°C in Alsever's solution. As a result of these findings 
they suggested that erythrocyte CR1 levels should be measured 
within 24 hours of sampling. However, there are several criticisms 
of these experiments: a) there was no mention of the interassay
variation for either assay used, b) the percentage drop in CR1 
sites/cell was the same on day 1 as day 3 (Table 15), c) the 
number of WGA binding sites/cell varied in both upward and downward 
directions over the 8 day storage period. For example, the value 
on day 8 is 10% higher than day 0,* if it were the day 0 value the
4
standardized CR1 sites would be 8.6 rather than the stated 7.8x10 
(Table 15). On the basis of these experiments it was
TABLE 15. Decrease in CR1 during the storage 
of erythrocytes at 4°C 
(Prom Minota et al, 1984)
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Days stored 
at 4°C
CR1 sites/ 
cell
Lectin (WGA) 
binding sites/ 
cells X 105
Standardized 
CR1 sites X 104
0 829 7.7 10.7
1 705 8.1 8.7
2 665 7.8 8.5
3 707 8.2 8.6
4 687 7.7 8.9
5 643 8.4 7.6
6 645 8.1 7.9
7 660 8.5 7.8
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difficult to determine whether CR sites/cell varied with storage.
In addition Minota et al (1984) stored their erythrocytes in 
Alsever's and the storage media used may affect the stability 
of the receptor. In order to minimise the loss of receptors, 
especially from patients whose erythrocytes may already have low 
levels, the erythrocytes were assayed within 24 hours of receiving 
the blood, as this was shown to have no effect on receptor levels 
under the conditions used.
CR1 was sensitive to trypsin and Img/ml removed CR1 from all 5 
samples of erythrocytes tested. This treatment caused the total 
binding and non-specific binding curves to overlap (Fig. 15). There­
fore any samples of erythrocytes tested which gave such a graph 
were said to have no receptors.
For the experiments on the peripheral blood cells only duplicate 
point determinations were made; this was due to a) the large number 
of assays being performed at the same time and b) the demand for anti­
serum making it impossible to perform triplicate determinations. 
Consequently this may have contributed to the large errors found in 
some of the assays, particularly those performed on the erythrocytes 
which had given consistently good results during the development of 
the RIA.
Clearly it was the assays which were performed on the leucocytes 
which gave overlapping lines and prevented the calculation of the 
receptor levels. Erythrocytes treated with high doses of trypsin 
gave similar results. However, it cannot be assumed that leucocytes 
have no CR1, as this phenomenon was associated with the leucocyte 
RIAs it was thought possible that it was perhaps some property of 
the leucocyte which gave rise to the observed results. The following 
factors, therefore may have influenced the outcome of the assay on 
peripheral blood cells:
a) Leucocytes have a more involuted and fluctuating cell surface
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compared with erythrocytes and perhaps the purification and 
assay techniques perturb the cell membrane in such a manner that 
the anti-CR1 antiserum could no longer gain access to the receptor.
By studying fluorescent probes it has been shown that the distri­
bution of CR1 within the membrane of leucocytes is as punctuated 
discrete clusters (Fearon et al, 1981, Abrahamson and Fearon 1983, 
Jack and Fearon, 1984) and that their motion was non-random 
within the plane of the membrane. This is unlike, for example, the 
HLA antigens which move freely and diffusely within the membrane 
(Petty et al, 1980, Haferaan et al, 1982). It is therefore possible 
that membrane folds for example may sterically hinder the access 
of specific antibodies to the clustered receptors. Another poss­
ibility is that the receptors become endocytosed. However this 
seems unlikely as Abrahamson and Fearon (1983) have shown that this 
process does not occur at 0°C to 4°C, the temperature at which these 
assays were performed.
b) The antiserum used in the RIA was raised in rabbits against 
human erythrocyte derived CR1. It is therefore conceivable that 
antigenic differences between CR1 on erythrocytes and leucocytes 
may not enable the antiserum to cross-react. However structural 
studies on CR1 from human erythrocytes and leucocytes by Dykman 
et al (1983b) showed that the CR1 from these two cell types was 
identical although the CR1 from the PMNs was 5000 daltons heavier.
The fact that six assays on leucocytes did work also seems to suggest 
that the antiserum does interact with the leucocyte CR1 and there­
fore is not the causal factor.
c) CR1 is known to be trypsin sensitive (Lay and Nussenzweig 1968, 
Huber et al 1968) and its effects on CR1 numbers on erythrocytes 
has already been discussed. It is thus possible that enzymes 
released from the leucocytes during the purification procedure
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(performed at R.T.) may have cleaved the receptor from the 
cell surface.
Although the former two possibilities discussed should not be 
completely dismissed, it seems more likely that it is the latter 
mechanism which is responsible for the poor RIA results. This 
is further supported by recent work in our laboratory, where CR1 
numbers have been successfully measured on human PMNs*, however 
this was possible only if enzyme inhibitors such as soya bean 
trypsin inhibitor (SBTI), pepstatin A, leupeptin and EDTA were 
present in the media throughout the purification of the cells
and during the RIA.
The results obtained for the CR1 sites/erythrocyte compared 
favourably with those found by Fearon (1980, 950 CR1 sites/erythro­
cyte) and lida et al (1982, 1400 CR1 sites/erythrocyte) and CR1 
levels on erythrocytes will be discussed more fully in Chapter 7.
The results for the leucocytes however compared less favourably.
For example, Fearon (1980) found B lymphocytes to have 21,000 
CR1 sites/cell compared with 1037 and 1076 in this study, monocytes 
to have 48,000 CR1 sites/cell compared to 889 and PMNs to have 57,000 
CR1 sites/cell with 6327, 10,000 and 93,000 being found in this 
study. The differences observed cannot be due to temperature as 
his assays were also performed at 4 0. However as the biggest 
discrepancies are between the lymphocytes and monocytes, this may 
be as a result of the purification procedure. Fearon (1980) used 
the panning technique on plastic petri dishes to separate the 
two cell populations as opposed to the BHK flask method used in
my experiments. My technique may have resulted in the altered
expression of the receptor in the cell membrane. The results also 
greatly differ from those found by lida et al (1982). However, 
they were using cellular lysates and therefore it was probably
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not correct to make a direct comparison as lysis may have 
exposed internal pools of CR1 (Fearon and Collins, 1983,
Kay, Glass and Salter, 1979, Glass and Kay, 1980, Lee, Hakim 
and Fearon, 1984).
Unlike the RIA performed on the leucocytes being 
unsuccessful, the RIA performed on the erythrocytes was 
successful. The assay conditions were successfully determined 
and the ability to reproduce the assay was good. This assay 
was used to examine erythrocyte CR1 levels and these results 
are discussed in Chapter 7*
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C H A P T E R  5
VISUALIZATION OF CR1 ON ERYTHROCYTES
USING INDIRECT IMMUNOFLUORESCENCE.
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INTRODUCTION
Immunofluorescence is a technique which has been widely 
used to visualize the location and distribution of cellular com­
ponents. Several groups (Petty et al 1981, Fearon et al 1981, 
Hafeman et al 1982, Abrahamson and Fearon 1983, Jack and Fearon 
1984) have looked at CR1 on human leucocytes using immunofluorescence, 
but such studies have not been performed on human erythrocytes.
It was decided to examine erythrocyte CR1 using indirect immuno­
fluorescence to investigate the possibility that this procedure 
might be useful in the study of erythrocyte CR1 in immune complex 
diseases.
In addition to performing immunofluorescence on normal human 
erythrocytes, the technique was used to examine normal erythrocytes 
which had been treated with different doses of trypsin (Img/ml, 
0.01mg/ml and 0.0001mg/ml),to enable the visualization of dose 
dependent loss of CR1 brought about by the trypsin (discussed in 
Chapter 4). The effects of trypsin on the pattern and intensity 
of fluorescent staining was compared with the quantitative deter­
mination of CR1 numbers by RIA (4-7) and the semi-quantitative 
determination of CR1 levels by haemagglutination of EAC43h.
MATERIALS AND METHODS
5.1 Polyclonal F(ab')^ anti-CRI
This was obtained as described in Chapter 4'
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5.2 Monoclonal anti-CR1 antibody
The commercial IgG, anti-CRI monoclonal antibody was puri­
fied from the culture fluid in which it was supplied using an 
affinity chromatography column composed of sheep anti-mouse IgG 
antiserum conjugated to CNBr-activated Sepharose 4B. This was 
prepared as follows:
CNBr-activated Sepharose 4B (ig) was washed 4 times in 
0.001M HCl and the pellet was then resuspended in 1ml of sheep 
anti-mouse IgG antiserum (lOmg/ml) in 0.1M NaHCO plus 0.15M 
NaCl. This was incubated overnight at 4^0 with continuous mixing. 
The suspension was then spun for 5 mins at lOOOg, the supernatant 
was removed and its protein content established by measuring the 
absorbancy at 280nm (2.4). This enabled the calculation of how 
much sheep anti-mouse IgG antiserum had bound to the Sepharose 
beads4 this was found to be 90%. The Sepharose beads were then 
incubated with a 10-fold volume of IM ethanolamine pH 8.0 for 2 hrs 
at R.T. with mixing, to inactivate any uncoupled sites. The 
beads were then washed with 0.1M acetate buffer pH 4.0 containing 
1.0M NaCl followed by 0.1M borate buffer pH 8.0 containing l.OM 
NaCll this washing cycle was repeated three times. The conjugated 
Sepharose beads were then stored in VBS plus 0.01M EDTA at 4 C
until required.
A glass pipette plugged with glass wool acted as the column. 
This was filled with 2ml of the conjugated Sepharose 4B and washed 
extensively with PBS. As it was probable that some of the con­
jugated antiserum may bind the substrate irreversibly because of 
high affinity binding reactions, it was decided to saturate these 
with normal mouse IgG prior to the application of the monoclonal 
as the conventional technique of dropping the pH may not dissociate 
high affinity bonds. The column was therefore run collecting
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1ml fractions as follows: lmi of normal mouse IgG
(5mg/ml, kindly given by Miss A. Pyfe) was applied to the column 
and washed through until the absorbancy at 00^^^ dropped to 
0.001, the bound material was then eluted with 0.1M glycine- 
HCl pH 2.5 (tubes containing 0.1M glycine-HCl pH 2.5 were returned 
to pH 7 using solid Tris). The column was then washed with 
PBS then 2ml of the monoclonal antibody (total protein 4mg/ml) 
was applied, washed through with PBS then eluted with 0.1M 
glycine-HCl, pH 2.5. The protein peak was then dialysed into 
PBS, then concentrated by freeze drying (2.5). The protein content 
was then measured using the absorbancy at 280nm (2.4).
5.3 Absorption of second and third layer antiserum with 
human erythrocytes 
Fresh human erythrocytes were washed with PBS containing 
1% BSA (PBS-BSA) and standardized to 1xlO^/ml (2.14). To 1ml 
of packed erythrocytes, 1ml of antiserum was added, the erythro­
cytes were resuspended and left at R.T. for 1 hr with occasional 
mixing. Finally the cells were spun down and the absorbed anti­
serum (supernatant) was removed and stored at -20°C until required.
5.4 Immunofluorescence using polyclonal F(ab')^ anti-CRI
Normal erythrocytes were washed in PBS-BSA and standardized 
to 2xlO^/ml (2.14). 50yl was added to LP2 tubes and to this 50^1 
of the polyclonal F(ab') anti-CRI (Img/ml) was added. After 
mixing, the tubes were incubated at R.T. for 30 mins. The cells 
were then washed three times with PBS-BSA and then 50yul of 1/10 dilution
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of goat anti-rabbit IgG was added, and incubated in 
the dark for 30 min at R.T. The cells were then washed 
three times in PBS-BSA, then 50jil of 1/10 dilution of FITC 
conjugated swine anti-goat IgG was added and incubated in the 
dark for 30 mins at R.T. After a final wash in PBS-BSA the 
cells were resuspended in 100yl of PBS-BSA. For the control 
NRS F/ab')^ was used instead of F(ab') anti-CRI.
5 • 5 Immunofluorescence using monoclonal antibody to CR1
The method used was similar to that described in 5»4 with 
the following modifications:
0
a) erythrocytes were standardized to 1x10 /ml,
b) 20^1 was added at all stages rather than 30jil,
c) second layer antiserum was absorbed sheep anti-mouse IgG,
d) third layer antiserum was FITC conjugated absorbed 
rabbit anti-sheep IgG.
For the control normal mouse IgG was used instead of the 
monoclonal antibody.
5.6 Microscopy and photography
The microscope used was a Leitz Orthoplan with a high 
pressure mercury lamp, HBO 220, light source and a Ploem 
illuminator. This system is designed to allow only light 
below a wavelength of 490nm to reach the mounted cells and 
only light above 520nm to reach the eye piece, since the peak 
of FITC absorption is at 490nm and the peak emission at 520nm. 
The cells were viewed in an improved Neubauer counting chamber 
(depth = 0.1mm l/^OOmm^) with an 30K) objective. Photographs
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were taken using Kodacolor VR 1000 ASA colour print film 
with a 90 second exposure time.
5-7 Trypsinization of erythrocytes
Normal human erythrocytes were trypsinized as 
described in 4 .9 .
5.8 Preparation of EAC43h
EAC43b were prepared as described in 3*5
5.9 Haemagglutination of EAC43h
Into the wells of a round bottomed microtitre plate was placed 
50ul of GVB^^. Test human erythrocytes (50]il, IxlO^/ml) were 
added to the first well and doubly diluted across 7 wells. Then, 
to each well, 50yil of EAC43b (ixlO^/ml) in GVB^^ were added.
The plate was gently shaken and left for 2 to 4 hrs at R.T.
Two controls were included in the plate, one containing 50^1 of 
GVB^^ and 50pl of EAC43b (1xlO^/ml) and one containing O^jxl of 
GVB^^ and 50^1 of test human erythrocytes (IxlO^/ml). These 
control wells should show no agglutination, if they did the test 
was repeated.
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RESULTS
The immunofluorescence technique was performed using 
rabbit polyclonal F(ab') anti-CR1 or a commercially available 
monoclonal antibody to CR1 as the first layer antiserum. In 
total 3 layers of antiserum were used to increase the sensitivity 
of the assay. Both the second and third layer antisera were 
commercially supplied, and were pre-absorbed with human erythrocytes 
prior to use, to prevent any non-specific interaction with the 
erythrocytes. The third layer antiserum was conjugated to 
fluorescein isothiocyanate (FITC).
The monoclonal anti-CR1 antibody was purified using affinity 
chromatography (Fig. 17). A total of 0.711mg of the normal 
mouse IgG applied did not bind to the column and was washed through 
with PBS, 0.226mg was eluted with 0.1M glycine-HCl (pH 2.5). 
Therefore 2mg of the 3mg of mouse IgG applied remained irreversibly 
bound to the column, blocking all the high affinity binding sites 
on the Sepharose 4B conjugated sheep anti-mouse IgG. The mono­
clonal antibody was then applied, the culture fluid in which it 
was supplied passed straight through the column and had a total 
protein content of 3.728mg. The peak eluted with 0.1M glycine- 
HCl (pH 2.5, fractions 48 to 52) was pooled, dialysed into PBS 
and concentrated, the recovery was 26pg/ml. The company who 
supplied the monoclonal antibody estimated the presence of 
28ug/ml of specific antibody therefore 26p.g/ml represented a 
93% recovery.
Indirect immunofluorescence on human erythrocytes using the 
monoclonal antibody to CR1 as the first layer was unsuccessful 
since it was below the level of detection. This was probably a 
consequence of using a monoclonal antibody, as one would expect only 
one antibody molecule to bind per receptor and therefore the amount
PIG. 17. Elution profile for purification of 
monoclonal anti-CR1 antibody using 
a sheep anti-mouse IgG affinity chrom- 
otography column.
1 ) Application of normal mouse IgG and
elution with PBS,
2) Application of 0.1M Glycine-HCl pH 2.5,
3) Application of PBS,
4) Application of monoclonal antibody
and elution with PBS,
5) Application of 0.1M glycine-HCl pH 2.5
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of FITC-conjugated antibody binding would be reduced. This is 
in comparison to using a polyclonal antiserum as the first 
layer, this would have multiple binding sites on a single 
receptor and consequently the amount of FITC-conjugated anti­
serum binding would be greatly enhanced and detectable.
Results were 'detained using the F(ab' ) fragment of the poly­
clonal rabbit anti-CRI as the first layer. However, the success 
of this technique was spasmodic with no consistency in the 
assay repeatability. For example, a blood sample from a
given normal individual might have given positive fluorescence 
whereas a second sample from the same individual might not 
have done so. The most probable reason for this is that the 
number of CR1 on the erythrocytes is so low that often they are 
below the limit of sensitivity of the indirect immunofluorescence 
technique. The ability to detect CR1 in a few cases suggested 
that these individuals had high CR1 numbers. The failure to 
detect CR1 by immunofluorescence on the erythrocytes of some 
of these individuals, on repeated testing, could suggest that 
CR1 numbers in normal people vary from time to time. However, 
the lack of consistency could simply indicate the lack of 
reproducibility of the immunofluorescence technique when it is 
used in situations where the antigen density is very low.
The results of an indirect immunofluorescence assay performed 
on the erythrocytes of a normal individual are shown in Plates 
5, 6 and 7. Control erythrocytes (Plate 5) were incubated 
with NRS F(ab') as the first layer antibody rather than Ffab')^ 
anti-GR1 (5.4). There was no non-specific binding of this frag­
ment to the erythrocytes as indicated by the lack of fluorescence. 
In contrast cells incubated with F(ab') anti-CR1 showed positive 
fluorescence (Plates 6 and 1), these cells did exhibit a fluo-
PLATE 5 Indirect immunofluorescence on
human erythrocytes using NRS 
Ffab')^ as the first layer anti­
serum (control).
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PLATES 6 and 7 Indirect immunofluorescence 
on human erythrocytes using F(ab') 
anti-CR1 as the first layer antiserum. 
There are foci of fluorescence on the 
cell surface
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rescent haze over the cell surface. However there were 
discrete fluorescent bright spots and by adjusting the focus 
of the microscope and therefore the plane of vision, these 
were seen on all the cells.
Trypsin treatment of the cells resulted in a faint back­
ground staining in the negative controls when high doses were 
used (Plate 8). The trypsin has probably altered the cell 
surface in such a manner as to increase the non-specific binding 
of the first or second layer antiserum or the PlTC-conjugated 
antiserum. Erythrocytes which had been incubated with 
Img/ml trypsin (5.7) no longer had any fluorescent bright spots 
on their surface but rather a faint halo (Plate 9). With 
0.0Img/ml trypsin bright fluorescent specks were present on some 
of the cells (Plate 10). Plate 11 is the control. With the 
lowest dose of trypsin (0.0001mg/ml) there was a normal pattern 
of fluorescence (Plate 12). Plate 13 is the control. There­
fore, trypsin removes CR1 from the erythrocyte surface in a 
dose-dependent fashion. This dose-dependent removal of CR1 
was also visualized and semi-quantitated using haemagglutination 
(5.9). Untreated cells agglutinated to a titre of 1/64, those 
treated with Img/ml trypsin demonstrated no agglutination, with 
0.01mg/ml trypsin there was partial agglutination and with 
0.0001mg/ml trypsin their agglutination titre was 1/32 (Plate 14), 
a dilution one-fold less than that for untreated erythrocytes. 
Therefore, although the immunofluorescence technique failed to 
show reduced CR1 levels when the lowest concentration of trypsin 
was used, the haemagglutination assay results indicated that even 
with this low dose 0.0001mg/ml trypsin, some reduction in CR1 had 
been achieved. A difference in titre of one dilution (1/64 to 
1/32) may represent a genuine difference in CR1 levels between the 
trypsinized erythrocytes and the untreated erythrocytes. However^
PLATE 8 Indirect fluorescence on human
erythrocytes treated with Img/ml 
trypsin and using NRS Ffab')^ 
as the first layer antiserum 
(control)
PLATE 9 Indirect immunofluorescence on human 
erythrocytes treated with Img/ml 
trypsin and using F'ab')^ anti-CR1 
as the first layer antiserum
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PLATE 10 Indirect immunofluorescence on 
human erythrocytes treated with 
0.01mg/ml trypsin and using 
Ffab')^ anti-CRI as the first 
layer antiserum
PLATE 11 Indirect immunofluorescence on 
human erythrocytes treated with 
0.01mg/ml trypsin and using NRS 
Ffab')^ as the first layer anti­
serum (control)
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PLATE 12 Indirect immunofluorescence on 
human erythrocytes treated with 
0.0001mg/ml of trypsin and using 
F(ab') anti-CRI as the first 
layer antiserum
PLATE 13 Indirect immunofluorescence on 
human erythrocytes treated with 
0.0001mg/ml of trypsin and using 
NRS FCab')^ as the first layer 
antiserum (control)
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PLATE 14 Haemagglutination of EAC43b by 
human erythrocytes and erythro­
cytes treated with Img/ml, 
0.01mg/ml and 0.0001mg/ml 
trypsin (lane b, lane a = control)
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the error limit for a haemagglutination ass^y is considered 
to be ^1 dilution, which could account for the discrepancy 
seen between the haemagglutination and immunofluorescence 
results.
In addition, when trypsinized erythrocytes were stored 
overnight at 37 C their haemagglutination titre remained unchanged, 
The number of CR1 sites/erythrocyte as determined using the 
RIA (4 .7) was not measured on the cells used in the experiments 
described. However, the number of CR1 sites/erythrocyte was 
determined on the same individual at a later date. The untreated 
cells had I488 CR1 sites/erythrocyte, cells treated with Img/ml 
trypsin had no receptors (with the total and non-specific binding 
curves overlapping as described in Chapter 4) and those treated 
iwith 0.01mg/ml trypsin had 482 CR1 sites/erythrocyte. The lowest 
dilution was not tested.
DISCUSSION
CR1 within the membrane of human erythrocytes has been shown 
to be distributed in punctuate discrete clusters, as demonstrated 
by indirect immunofluorescence. This distribution pattern has 
been reported for CR1 on human leucocytes (Petty et al 1981, 
Fearon et al 1981, Abrahamson and Fearon 1983, Jack and Fearon, 
1984). CR1 on leucocytes has been extensively investigated 
using immunofluorescence techniques; however to date no such 
work has been reported for erythrocytes.
Indirect immunofluorescence was performed bn normal human 
erythrocytes using either polyclonal rabbit F/ab')^ anti-CRI 
or a commercially available monoclonal antibody to the receptor
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as the first layer antiserum. The assay system using the
monoclonal antibody was not sufficiently sensitive to detect 
the receptor by immunofluorescence. Using the polyclonal anti­
body to the receptor, positive immunofluorescence was obtained 
on several occasions. However, this assay system had obvious 
limitations. Firstly, a certain density of receptors seemed 
to be required to give positive immunofluorescence despite 
using 3 layers of antiserum which should have increased the 
assay sensitivity (compared to direct immunofluorescence). This 
necessity for a certain receptor density probably accounts for 
the failure to visualize CR1 on some of the erythrocyte samples 
tested. Due to this limitation further experiments using the 
immunofluorescence technique became impossible. For example, 
it would have been interesting to examine the distribution pattern 
of CR1 on erythrocytes of different ages, the effects of storage 
at 4°C and 37°C on the CR1 distribution pattern, and, whether 
CR1 was re-expressed on trypsinized erythrocytes.
Stored (overnight at 37°C) trypsinized erythrocytes did not 
recover their receptors as assessed by haemagglutination. This 
result can be interpreted in 3 ways: a) CR1 had been re-expressed
but the assay system was not sufficiently sensitive to detect 
them, b) there is no internal pool of CR1 in erythrocytes or 
c) there is an internal pool but it is not being expressed.
Thus immunofluorescence, haemagglutination and RIA showed 
the dose-dependent removal of CR1 from the erythrocyte cell surface 
by trypsin. The immunofluorescence technique was used to show 
foci of fluorescence suggesting that CR1 was present as clusters 
within the cell membrane and not diffusely distributed.
Several groups have examined CR1 on leucocytes using 
immunofluorescence. Petty et al (1981) using immunofluorescence
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and photobleaching recovery experiments showed the lack of 
lateral diffusion of the CR1 clusters in the cell membrane, 
whilst HLA antigens and lipid probes were randomly distributed 
and moved freely within the membrane plane. Thus they inter­
preted this to mean that the CR1 clusters represented a special- 
ization of the cell surface and that the distribution was 
physiologically relevant, based on the observation that Uyb 
deposited on particulate surfaces tended to be as clusters and 
hence would easily interact with the pre-clustered CR1.
Fearon et al (1981) investigated this further and looked 
at the ability of GR1 to mediate adsorptive pinocytosis, based 
on the knowledge that other membrane receptors distributed in 
such a manner, e.g. low density lipoprotein receptors on fibro­
blasts, could mediate this function. Like Petty et al (1981), 
they demonstrated the punctuate distribution of CR1 on leucocytes 
and excluded the possibility that this distribution was a mani­
festation of the sampling procedure or due to prior binding of 
C3b to the receptor. They demonstrated the ability of these 
receptors to become internalized at 37°C if cross-linked with 
F(ab') anti-CRI. This process was not dependent upon micro­
filaments as cytochalasin B did not inhibit the internalization 
and this distinguishes adsorptive endocytosis from phagocytosis 
which is dependent upon the cell's cytoskeleton. As a result 
of their experiments, they suggested that the receptors may be 
associated with another cytoplasmic structural protein called 
clathrin and that CR1 were clustered within clathrin coated 
pits and it was by this mechanism that soluble immune complex 
endocytosis was mediated.
This was confirmed by Abrahamson and Fearon (1983) who looked 
at the binding and the fate of internalized material. This was
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studied using fluorescent and electron microscopic examination 
of cells which had been labelled with monospecific PCab')^ 
anti-CRI anb anti-Ffab')^ conjugated with rhodamine or ferritin. 
They examined PMNs and mixed leucocyte populations from various 
normal donors and found that at 37 C the antibody cross-linked 
receptors became internalized, the Ibalf t:uM being 5 mins and 
there after the ferritin conjugated antibody was delivered to the 
lysosomes within 20 mins. Using electron microscopy the exact 
fate of the ferritin granules could be followed. On the cell 
surface most of the ferritin was within endocytic invaginations 
having cytoplasmic bristle coats (coated pits), they were not 
found associated with uncoated invaginations or large phagocytic 
processes. Intracellularly, ferritin was primarily present 
within lOOnm coated vesicles which were 0.3pm beneath the cell 
surface with eventual delivery to the lysosomes.
Thus, there seems to be agreement, that CR1 is clustered 
within clathrin-coated pits on the membranes of human leucocytes, 
and that the cross-linking of these receptors by the appropriate 
ligand results in their internalization. These are by no means 
the only receptors to be clustered within clathrin-coated pits, 
und this clustering probably represents an important process for 
communicating between the intracellular and extracellular compart- 
ments. For example, cultured human fibroblasts have been shown 
to take up low density lipoprotein, epidermal growth factor, 
-macroglobulin and insulin by this mechanism (Pearse and 
Bretscher, 1981). The function of the coated vesicle seems to 
vary with cell type, with the most frequent role being absorption 
and secretion (Pearse 1976). The low density lipoprotein 
receptor on human fibroblasts has become the prototype model for 
studying receptor mediated endocytosis via coated pits. From
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this model several properties of coated pits have been 
established:
1) the structures are transient, continually being formed and 
pinched off,
2) life span is less than 3 mins ,
3) coated pits m^y contain several receptor types (nui
4) the major component of the pits is clathrin (Brown and
Goldstein 1979).
However, certain pertinent points remain unanswered, for 
example, how does the receptor escape degradation In the lyso-
soraes and how does the clathrin coated pit become coupled to the 
receptor, is it constitutive or is it a result of the ligand 
binding? (Pearse and Bretscher 1981). Abrahamson and Fearon 
(1983) demonstrated the lack of clathrin coated pits beneath areas 
where ferritin granules were bound, at temperatures lower than
37°C, nor was monovalent Fab' ahtî-CRI sufficient to induce 
endocytosis (Fearon et al, 1981), indicating that for coupling 
of CR1 with clathrin coated pits receptor perturbation is required 
(i.e. cross-linking) and perhaps there is a critical cytomechanical 
event required for endocytosis.
Therefore the clustered CR1 receptors on leucocytes may 
provide a mechanism for the elimination of soluble C3b-bearing 
complexes from the extracellular milieu. This however does not 
answer why CR1 on erythrocytes appeared clustered, as visualized 
using indirect immunofluorescence. This possibly arose as a result 
of the assay procedure or is this a natural state, having some 
physiological relevance. This would require further investigation.
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C H A P T E R  6
PURIFICATION OF HUMAN G3, AND 
DEVELOPMENT OF AN RIA TO QUANTI­
TATE THE NUMBER OF FUNCTIONAL 
CR1 SITES PER CELL.
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INTRODUCTION
Human 03 was purified from fresh human plasma to enable 
the development of an RIA which would measure the number of 
functional binding sites on CR1 bearing cells for the natural 
ligand C3b.
C3 was purified using a modification of the method described 
by Tack and Prahl (1976) and consisted of fractionating human 
plasma with polyethylene glycol (PEG) followed by chromatographic 
separation using an anion exchange column and a hydroxylapatite 
column. This procedure yields in addition to C3, P, B, I, H,
C2, C4 and C3.
Prior to the commencement of this project, the CR1 levels on 
human erythrocytes had been measured serai-quantitatively using 
lAHA (Miyakawa et al, 1981, Inada et al 1982) or quantitatively 
using radiolabelled CR1 specific antiserum (Wilson et al 1982, 
lida et al 1982). These RIAs measured the number of antigenic 
sites per cell for the CR1 specific antibody (CR1 sites/cell) and 
the development of such an RIA was discussed in Chapter 4* How­
ever, in addition to this type of RIA, Wilson et al (1982) developed 
an RIA to quantitate the number of functional sites per cell using 
radiolabelled dimeric C3b. This functional RIA described by 
Wilson et al (1982) was used as the basis for the development of an 
RIA to measure the number of functional CR1 sites per cell. In 
addition this assay would enable the distinction between receptors 
which may be antigenically detectable but perhaps blocked and 
therefore functionally inactive.
For the development of this assay dimeric human C3b was chosen 
to be the radiolabelled ligand, based on the observations of 
Arnaout et al (1981) that dimeric C3b binds to CR1 with a greater 
affinity than monomeric C3b. Two methods were used to chemically
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cross-link C3b, firstly using dithiobissuccinyl propionate 
(DTBSP) which yields polymers which can be reduced into their 
natural monomeric state or secondly dimethyl suberimidate which 
produces polymers which are stable and non-reducible.
The G3b dimers were then separated from the remaining 
monomeric C3b and polymeric G3b using sucrose gradient fraction- 
ation or gel filtration, for use in the RIA.
MATERIALS AND METHODS
6.1 Preparation and fractionation of plasma with PEG
Unless otherwise stated all purification steps were performed 
at 4°G. Two litres of fresh human plasma was collected from the 
Blood Transfusion Service, this was immediately put on ice and the 
following protease inhibitors were added: 0,02% sodium azide
(w/v), lOmM benzamidine, 0.3mM PMSF (In dimethyl formamide) 
and ImM EDTA (from a 0.086M isotonic EDTA stock solution). With 
continuous stirring 15% (w/v) PEG (mol.wt. 4000) in lOOmM sodium 
phosphate buffer pH 7*4* containing 150mM NaGl, 15mM EDTA and 
0.3mM PMSF was added, to give a final concentration of 5% PEG, 
and stirred for a further 30 mins on ice. This was then spun 
at 3000g for 13 mins, the supernatant was retained and the pellet 
discarded. To 3 litres of the supernatant 1 litre of 28% (w/v)
PEG (in the aforementioned buffer for 13% PEG) was added to give 
a final PEG concentration of 12% (w/v). This was allowed to stand 
for 30 mins on ice and then was centrifuged at 7000g for 20 mins.
The supernatant was retained and frozen at -70 G, from this 02 and 
B can be further purified. The pellet was then resuspended in a
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minimum volume of starting buffer for the first column (6.2).
6 • 2 Piethylaminoethyl (DEAE) Sephacel anion exchange column
Column: 3 x 90cm column containing 1766cm^ of degassed DEAE
Sephacel equilibrated with starting buffer.
Starting buffer: lOmM Tris/HCl pH 7.8, conductivity 2mS at 4°C
plus 30mM ^  -amino-n-caproic acid (EACA), 3mM EDTA 
and lOmM benzamidine.
The protein sample in starting buffer was applied to the 
column and washed through with 2 column volumes of starting buffer, 
until the elution fractions had a protein content of less than 
0.Img/ml. A 5 litre 0.3M NaCl linear salt gradient in starting 
buffer was then used to elute P, I, H, 03, 03 and 04. The
flow rate of the column was between 100 and 150ml per hour and 
23ml fractions were collected. The pH and conductivity of every 
5th. fraction was measured as was the protein concentration using 
the absorbancy at 280ntti. The column was screened for P, I, H,
05, 03 and 04 using radial immunodiffusion plates containing the 
appropriate antiserum to detect these components (6.4). The 
tubes containing P, I,U, 05 and 04 were pooled and stored at 
-70°0 with lOmM benzamidine and 0.5mM PMSF. The partially puri­
fied 03 was further cleaned up by passage over a hydroxylapatite 
column.
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6 .3 Hydroxylapatite anion exchange column
Column. 3 x 60cm column containing 1177cm^ of hydroxylapatite 
equilibrated in starting buffer.
Starting buffer: 23mM potassium phosphate buffer pH 7 .4,
lOOmM KOI and 50mM EACA
The partially purified C3 pool from the DEAE Sephacel column 
was concentrated to 300ml by ultrafiltration using a YM 10 membrane
(2.3) and applied to the column and the following stepwise elution 
scheme was used: 2 litres starting buffer, 2 litres
23mM potassium phosphate buffer, pH 7.4 plus 2M KOI and 30mM 
EACA, 2 litres starting buffer, 2 litres 0.123 potassium phosphate 
buffer pH 7*4 plus lOOmM KOI and 50mM EACA, 2 litres O.4M potassium 
phosphate buffer pH 7-4, plus lOOmM KCl and 50mM EACA. A flow 
rate of 120ml per hour was used and 15ml fractions were collected 
into tubes containing 1ml of lOOmM EDTA pH 7-4- The pH, conduct­
ivity and protein content of every 5th. tube was monitored. The 
presence of 03 and C5 was established using radial immunodiffusion 
with anti-C3 and anti-C5 antiserum (6.4). Tubes containing C3 
were pooled and concentrated by ultrafiltration using a YM 10 
membrane (2.5)* The 05 pool was stored at -70 C with lOmM 
benzamidine and 0.5mM PMSF.
The 03 purity was tested reduced and non-reduced on 4%
SDS-PAGE phosphate tube gels (2.10). The protein concentration 
was determined using Folin assay (2.4), radial immunodiffusion
(6.4) and nephelometry (nephelometry was kindly performed by 
Mrs. J. Veitch). The haemolytic activity of 03 was determined 
using a 03 haemolytic titration (6.5).
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6.4' Detection and quantitation of complement components 
using radial immunodiffusion 
The DEAE Sephacel column was screened for P, H, C5, 03 
and 04 using radial immunodiffusion. As this purification pro­
cedure is well documented the whole column was not screened for 
all 6 components. The areas screened for each component were 
determined using the conductivity at which they were expected to 
he eluted from the column after application of the salt gradient.
Complement component Area screened
p Exclusion peak
I 1.3 to 3.5mS
H 4 to 7mS
05 5 to 8mS
03 6 to lOmS
04 8 to 12mS
Radial immunodiffusion plates were set up as described in (2.8), 
using the following dilutions of monospecific antisera in agarose 
type (b).
Anti-P antiserum 1/1000 dilution
Anti-I " 1/50
Anti-H " 1/25
Anti-05 " 1/30
Anti-03 " 1/25
Anti-04 " 1/35
A standard curye for 03 was obtained by using doubling dilutions
of normal human serum (NHS) containing a known concentration of 03
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6.5. Haemolytic titration of human C3
This assay was used to determine the haemolytic activity 
of the purified 03. The method used EAs (antibody coated
SRBOs) sensitised with 01, 04 and oxidised 02 (°*^02). Oxidised 
02 was used to give a more stable and haemolytically active 
classical pathway 03 convertase. Oell lysis was brought about 
by adding the terminal components in the form of 05 and guinea- 
pig serum depleted in components 3, 4 and 5 (GPR345, guinea-pig 
serum treated with potassium thiocyanate and hydrazine). The 
test sample of 03 was titrated into the system and the number 
of haemolytic units of 03 per ml could be calculated from the 
degree of lysis it caused.
Reconstitution of EA04s: Frozen EA04s (antibody coated SRBOs
sensitized with human 04) were kindly donated by Mrs. L. Jones 
and were reconstituted according to the following protocol. The 
cells were quickly thawed in a 37°0 water bath and the following 
were added:
0.23ml of D50S incubated for 5 mins at 37°C
1.00ml of Mannitol GVB++ incubated for 2 mins at
2.00ml of I I I I I I
8.00ml of I I I II 5 mins "
5.00ml of DGVB^^ I I 2 mins "
10.00ml of I I I 2 mins "
10.00ml of I I I 2 mins "
10.00ml of I I " 10 mins "
The EA04 suspension was then spun for 4 mins at lOOOg at R.T 
The supernatant was discarded and the cell pellet was washed 
thrice in DGVB^^ or until the cells stopped lysing. The cells 
were then standardized to 1x10 /ml (2.14) in DGVB
Preparation of EA0Ï48: All the following steps except where
otherwise stated were performed on ice with ice cold reagents
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and buffers. Purified human Cl was diluted to l/lOOO in 
heated to 37°C and added to an equal volume of EAC4s at 37°C,
These were mixed and incubated for I5 mins at 37°C in a shaking 
water bath. The cells were then spun at lOOOg at R.T. for 5 mins 
The supernatant was removed and the cells were resuspended to 
their original volume in DG-VB^^.
Preparation of EAC14°^^2: Purified human 02 was oxidised by
adding 100^1 of 02 to lOOpl of oxidising mixture (lOpl KI/I plus 
2ml O.IM KPO^ pH 6.0) and incubated at R.T. for 5 mins. The 
volume was made up to 5ml and added to an equal volume of EACt4s. 
The cells were incubated for a further 10 mins at 30^0 then spun 
at lOOOg for 5 mins at R.T, the supernatant was discarded and the 
cell pellet resuspended to the original volume in DGVB . To
test the activity of the EAC14°^^2, 300^1 of 1/15 dilution of
++
normal rat serum (0 rat) in O.O4M EDTA/GVB was added to 100^1 of
EAG14°^^2 and incubated at 37°C. If the cells are correctly 
sensitised this should result in lysis within 5 mins. These 
cells can now be used in the 03 haemolytic assay.
Assay for haemolytic 03 : A l/lOO dilution of GPR345 was made
in DGVB’^’^ and to this human 05 was added to give a final dilution 
of 1/200. This was used as the buffer in which 03 was doubly
diluted starting at 1/1000. To lOOpl of the diluted 03 lOOpl of 
EA014°^^2 was added and the tubes were incubated in a shaking water 
bath at 37°0 for 1 hr. Two ml of saline was added to the tubes 
and these were then spun at lOOOg for 5 mins. The OD of the 
supernatants at 414 nm were measured. The controls were as follows
Reagent blank (RB) = EAOI4 ^2 + GPR345 + buffer + saline
100% lysis (100%) = " + " + " + water
Complement colour (00)= GPR345 + " + saline
Cell blank (OB) = E A C 1 4 ° ^  + buffer + buffer + saline
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The percentage lysis of the EAC14“ ^2 in the presence of CJ
was determined using the following formula:
°°414 ^^""ple - RB
* lysis = ^ ------------- — 55--------  X 100 = Y
414 100% - 414 RB
Z value = (1 - Y)
By calculating the Z value for each dilution of 03 and plotting 
the Z value against the 03 dilution a straight line graph is 
obtained from which the number of haemolytic units of 03 per ml 
can be calculated.
6.6 Formation of 03b
Purified human 03 was converted to 03b by trypsinization.
The method was based upon those used by Arnaout et al (1981) 
and Nilsson, Handle:& McOonnell-Mapes (1975)
0.6% w/w trypsin to 03 was incubated at 37°0 for 3 mins.
Then a 2-fold weight excess of soya bean trypsin inhibitor 
(SBTI) to trypsin was added and incubated for a further 2 mins 
at 37°0 to stop further cleavage. The conversion of 03 to 03b and 
the presence of any further breakdown fragments was analysed 
using lEP (2.9) with a 1/10 dilution of rabbit anti-human 03c 
antiserum in the troughs to precipitate the 03 fragments. 03b 
is more negatively charged than 03 so it migrates further towards 
the anode; the presence of 03b was also confirmed using 4% SDS- 
PAGE tube gels (2.10).
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6.7 0313 polymerization using DTBSP
One ml of C3b at 5mg/ml in 0.05M sodium phosphate buffer 
pH 7*5 was added to 25p.l of DTBSP at 3*7mg/ml. After thorough 
mixing the solution was incubated at R.T. for 2 hrs. Then 3pl 
of 1M Tris/HCl pH 7.3 was added to prevent polymerization and 
then the polymerized C3b was dialysed against 0.05M sodium 
phosphate buffer pH 7-5 to remove any remaining DTBSP. A sample 
was then run on 4% SDS-PAGE phosphate tube gels (2.10) to check 
whether the polymerization had been successful.
The method was repeated using 'ôyl, lOjil, 15^1 or 20jXL of 
DTBSP at 3-7mg/ml.
6.8 G3b polymerization using dimethyl suberimidate
A 50mM stock solution of dimethyl suberimidate was 
made up in a buffer composed of equal volumes of 200mM NaOH 
and BOOmM triethanolamine pH to 8 with concentrated HCl.
The C3b and dimethyl suberimidate stock solution were 
mixed to give a final protein concentration of Img/ml and lOmM 
dimethyl suberimidate. After mixing the solution was left at 
R.T. for 1 hr. A sample was then run on 4% SDS-PAGE phosphate 
tube gels (2.10) to check whether the polymerization had been 
successful.
The method was repeated using dimethyl suberimidate at 
a final concentration of lOmM, 20mM or 40mM or using a 0.2M 
Tris/HCl buffer pH 8 (Wilson et al, 1982) as opposed to the 
NaOH-triethanolamine buffer.
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6.9 Sucrose gradients
Sucrose solutions were made up in PBS. Gradients composed 
of 1ml of 10%, 20%, 30% and 40% or 1ml of 7 .5%, 15%, 22.5% and 
30% were formed on ice in 13 x 51mm polyallomer centrifuge tubes. 
500^1 of the sample to be fractionated was carefully layered onto 
the top of the gradient and spun at 4°C for 16 hrs at 105,000g on 
a Beckman model L2-65B ultracentrifuge. 200^1 fractions were 
then collected from the tube base using a sucrose gradient 
fractionator. The protein content of each fraction was analysed 
using Folin assay (2.4) and the polymer content analysed on 4% 
SDS-PAGE phosphate tube gels (2.10).
6.10 Separation of G3b polymers by gel filtration
Two types of gel filtration columns were used, both were 
equilibrated in 0.05M sodium acetate pH 5-6 plus 1M NaCl and 
1ml fractions were collected.
a) 1.5 X 86cm Sephadex GI50 superfine column
b) 2.6 X 90cm Sephadex S200 column
The protein and polymer content of each fraction was
analysed as described for sucrose gradients (6.9)
RESULTS
The method used to separate 03 from human plasma employs 
the linear polymer PEG as an agent for fractionating the plasma 
proteins followed by chromotography. The 5% (w/v) PEG removes 
the bulk of the plasma fibrinogen, and the 12% (w/v) PEG
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precipitates C4, C3 and C5 leaving in solution albumin and
transferrin. A brief resume of the protocol used to purify C3
is given in Fig. 18. The elution profiles for the DEAF
Sephacel and hydroxylapatite columns are shown in Fig. 19 and
Fig. 20 respectively.
The DEAE Sephacel column yielded: P, I, H, 05, 03 and 04.
The column was screened using radial immunodiffusion with mono-
specific antiserum against the aforementioned complement components
2
The results of these plates are expressed as D (mm) in Fig. 19.
P was eluted between fractions 35 and 70; however this is not 
marked in Fig. 19 as the rings were very faint and despite counter- 
staining for 24 hrs with a second layer antibody (1/10 dilution 
of sheep anti-rabbit antiserum) the rings could not be accurately 
measured. Pools were made of the fractions containing P, I, H 
and 04 and these were stored at -70°C. Tubes 340 to 360 were 
pooled, to give a 03 fraction slightly contaminated with 05, 
after concentration this was applied to the hydroxylapatite 
column.
03 and 05 were resolved on the hydroxylapatite column by using
a stepwise elution scheme (Fig. 20). Only the high molarity
phosphate buffer (0.4M potassium phosphate buffer) applied at
fraction 360 eluted any protein from the column. This contained
03 as determined by radial immunodiffusion with no contaminating
05. The 03 was eluted between tubes 375 and 450 in two peaks,
three pools were made, pools 1 and 2 consisting of peaks
1 and 2 respectively and pool 3 the residual tubes.
Oolumn fractions Volume
Pool 1 385 - 420 600ml
2 421 - 430 200ml
3 375-384, 430-450 500ml
PIG. 18 Protocol used for human 
03 purification
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Fresh human plasma
DISCARD
y
)% PEG cut ---- > supernatant + precipitate
Source of C2 and B
y
12% PEG- cut > • precipitate + supernatant
Redissolve apply to DEAE Sephacel column
P, H. I, 03, 03 and 04
Hydroxylapatite column
4/
Pure human 03
PIG. 19 Elution profile from DEAE Sephacel
column showing conductivity (mS at
0°G ---), protein (OD nm
^oU
and complement component levels as 
measured by radial immunodiffusion 
(D^mm ---- )
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FIG 20. Elution profile from hydroxylapatite
column showing conductivity (mS at
Q ° C  ), protein (OD )
280nm
and 03 level as measured by radial 
2
immunodiffusion (D mm ---- )
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PLATE 15 Purified C3 (reduced and
non-reduced) run on 4% SDS- 
PAGE phosphate gels.
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These pools were concentrated by ultrafiltration, then 
the protein content was measured using Folin assay, nephelo- 
metry and radial immunodiffusion. The results of these assays 
are summarized in Table 16 together with the profile of 
protein recovery for the whole purification procedure. It is 
clear that the protein concentrations as quantified by these 
three methods in some instances give conflicting results. For 
example, the protein content of pools 2 and 3 as determined by 
Folin assay do not correspond with those determined by radial 
immunodiffusion. This is probably due to the high concentrations 
of PMSF and benzamidine in these pools interfering with the Folin 
assay and it is for this reason that protein measurements could 
not be made using OD^gQum. There was also some difference in 
the level of 03 in pools 1 and 2 as determined by nephelometry and 
radial immunodiffusion. The reason for the lower values of 03 
as determined using nephelometry is that this technique requires 
the presence of carrier proteins for an accurate determination of 
the 03 concentration.
The purity of 03 was tested using SDS-PAGE phosphate 
gels (Plate 15). Pools 1 and 2 were tested’, non-reduced the 
molecular weight was 170,000 daltons and reduced the chain was 
120,000 and the ^  chain 80,000 daltons.
The recovery of 03 in mg was 30% (using 03 protein concen­
tration determined by radial immunodiffusion) based on an 
estimated value of Img/ml of 03 iu the starting material. The 
haemolytic titration of pools 1 and 2 (Fig. 21a and 21b) showed 
pool 1 (Fig.21 a) to have 310,000 haemolytic units/ml and pool 2 
(Fig. 21b) to have 8,333 haemolytic units/ml.
TABLE 16. Profile of protein recovery 
during C3 purification
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purified human CJ>
(a) Pool 1
(b) Pool 2
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C3 was successfully cleaved to C3b using trypsin (6.6) 
and this was confirmed by lEP, with C3b being more electro­
negative than 03 thus travelling further towards the anode.
This, together with the use of SDS-PAGE tube gels, showed 
that there were no further 03 breakdown products. The 03b 
produced by this method was used for polymerization. DTBSP 
and dimethyl suberimidate were used to chemically cross-link 
03h. The results of these two methods will be discussed 
separately.
DTBSP was initially used to polymerize 03b and the 
polymerized molecules were then separated according to size 
using sucrose gradients (20% / 30% / 40% / 50%, 6.9). By 
using a sucrose gradient fractionator, fractions could be collected 
from the base of the tube’, 200pl fractions were collected and this 
gave 11 fractions per gradient, with fraction 1 containing the 
highest molecular weight oligomers. The fractions were then 
screened for protein by Folin assay (2.4) and the polymer content 
was analysed on 4% SDS-PAGE phosphate tube gels (2.10). This 
method of polymerization produced very little dimeric C3b. In 
an attempt to optimize the dimeric C3b yield the amount of DTBSP 
in the reaction mixture was titrated. Five yl, 10jul and 15/il of 
DTBSP were used instead of 25;il and this did reduce the extent of 
G3b polymerization. After fractionation on 20% / 30% / 40% / 50% 
sucrose gradients the protein profile for the gradients (Fig 22) 
showed a peak in fractions 7 and 8 for all three concentrations 
of DTBSP used. However, the gels did not show an increase in 
dimer formation, but of trimer and monomer. As the yield of 
dimer was poor despite adapting the method it was decided to try 
another means of cross-linking 03 (dimethyl suberimidate) and use 
7.5% / 15% / 22.5% / 30% sucrose gradients to try and give a better
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separation of monomeric, dimeric and trimeric C5b.
The use of dimethyl suberimidate to polymerize C3b did 
yield fewer high molecular weight oligomers, as demonstrated 
by the small amount of protein in the lowest fractions of the 
gradient (Pig. 23), however it also produced a lot of monomeric 
C3b in which the and ^  chains had become cross-linked.
Gradient fractions 2, 3 and 4 did contain dimer contaminated with 
monomer. It was decided to adapt the method by increasing the 
amount of dimethyl suberimidate used, to try and increase the 
degree of polymerization. In addition, the polymerization was 
performed in a 0.2M Tris/HCl - pH 8.0 buffer according to the 
method described by Wilson et al (1982).
Increasing the concentration of dimethyl suberimidate 
from lOmM to 20 or 40 mM did not alter the degree of C3b poly­
merization. The method described by Wilson et al (1982) 
gave a low yield of dimer and a high percentage of monomeric C3b.
By using lOmM dimethyl suberimidate it was possible to get 
a pool containing dimer and monomer C3b (50:50 as determined by 
the visualization of band densities on the 4% SDS-PAGE phosphate 
tube gels). These could not be resolved further despite using 
gel filtration (6.10).
It was evident that dimer contaminated with monomer would 
have to be used in the RIA and that using lOmM dimethyl suberimidate 
was the best means for producing dimer. However, on a second 
attempt of this method C3b did not become polymerized and we 
were informed by the company supplying this chemical that it had 
a very short shelf life and probably had decomposed rendering it 
non-functional.
PIG. 22 Effects of a) b) ICÿil and
c) Vÿyl of DTBSP on the profile 
of 03b from 20% / 30% / 40% / 50% 
sucrose gradients.
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PIG. 23 Profile of protein recovery of
dimethyl suberimidate treated C3b 
from 7 .5% / 15% / 22.5% / 30% sucrose 
gradient.
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The method using DTBSP and 7.596 / 1596 / 22.596 / 5096 sucrose 
gradients was then repeated. This cross-linked C3b up to 
a pentameric form (Plate 16), with fractions 1 and 2 con-
taining high molecular weight oligomers (Plate 17), fractions 
3 and 4 containing dimeric, trimeric, tetrameric and pentameric 
C3b (Plate 18), fractions 5 and 6 monomeric, dimeric and 
trimeric C3b (Plate 19), fractions 7 and 8 monomeric and dimeric 
C3b (Plate 20) and finally, fractions 9, 10, 11 and 12 having 
monomeric C3b with breakdown fragments in fractions 11 and 12.
The fractions (7 and 8) containing dimer contaminated with mono­
mer were pooled and concentrated, and from a starting concentration 
of 3mg/ml, 0.8mg/ml was recovered in the form of dimer contaminated 
with monomer.
DISCUSSION
03 was purified successfully from fresh human plasma and 
converted to G3b using trypsin; however as is clear from the 
results section pure C3b dimer was not attained despite trying 
two methods of chemical cross-linking (DTBSP and dimethyl sub­
erimidate) and fractionation (sucrose gradients and gel filtration) 
The use of dimethyl suberimidate as a cross-linking agent was 
abandoned because of the spontaneous decomposition of this linking 
agent. DTBSP gave dimeric C3b; however the protein recovery 
was low; another problem with this method of cross-linking was 
that the links spontaneously broke down after long periods of 
storage, as the links formed by DTBSP are reducible unlike those 
formed by dimethyl suberimidate. Due to these difficulties and the 
low yield of dimeric C3b it was decided to abandon the development 
of the functional RIA.
PLATE 16 DTBSP polymerized C3b (a=reduced, 
b= non-reduced) on 4% SDS-PAGE 
phosphate gels
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PLATE 17. High molecular weight oligomers 
of DTB8P polymerized C^b,
(a) fraction Ï and
(b) fraction 2
from the sucrose gradient (run
non-reduced on 4% 8DS-PAGE
phosphate gels)
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PLATE 18 Dimeric, trimeric, tetrameric
and pentameric DTB8P polymerized 
C3b,
(a) fraction 3 and
(b) fraction 4
from the sucrose gradient (run 
non-reduced on 4% 8D8-PAGE 
phosphate gels)
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PLATE 19 Monomeric, dimeric and trimeric 
DTB8P polymerized C3b,
(a) fraction 5 and
(b) fraction 6
from the sucrose gradient (run
non-reduced on 4% 8D8-PAGE
phosphate gels)
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PLATE 20 Monomeric and dimeric DTB8P 
polymerized C3b,
(a) fraction 7 and
(b) fraction 8
from the sucrose gradient (run
non-reduced on 4% 8D8-PAGE
phosphate gels)
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C H A P T E R  7
GR1 LEVELS ON THE ERYTHROCYTES OF NORMAL
INDIVIDUALS, SLE AND RA PATIENTS.
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INTRODUCTION
Before this project was started four studies had been 
done on the erythrocyte CR1 levels in normals, SLE and RA 
patients. The results of these studies are discussed 
extensively in chapter 1. However to briefly summarize;
four groups found the SLE patients to have lower CR1 
levels on their erythrocytes compared to the normal controls. 
The causative factor, however was an area of dispute.
Wilson et al (1982) and Miyakawa et al (1981) present data 
to support the view that CR1 numbers are inherited, whilst 
lida et al (1982) and Inada et al (1982) believe that low 
CR1 levels could be a secondary manifestation of the disease 
process. Thus the aim was firstly, to compare CR1 levels 
on the erythrocytes from normals, SLE and RA patients.
Secondly, to see whether CR1 levels in these groups varied 
with time and thirdly to examine CR1 levels in normal and SLE 
families. Thus it was hoped to determine whether CR1 levels 
are inherited or not. In addition extensive serological 
studies were performed on the RA and SLE patients to see if 
any of the results of routine serological tests correlated 
with erythrocyte CR1 levels.
MATERIALS AND METHODS
7.1 Normal controls
A total of 70 blood samples from 44 normal individuals 
were studied. The age range was from 18 to 65 and consisted 
mainly of laboratory personnel and members of the normal
families.
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7•2 SLE patients
A total of 41 blood samples from 53 SLE patients were 
studied (Tan et al,1982). Immediately prior to venous 
blood sampling the SLE patients were examined for evidence 
of disease activity. The criteria used for the assessment 
of the SLE patients fulfilled the ARA classification scheme 
which is as follows: Active disease, continuing clinical
activity of involved organ system(s) e.g. polyarthritis, 
vasculitis, lupus pernio rash, proven presence of pleurisy 
or pericarditis, continuing active urinary sediment with cells 
and casts alone or in addition to proteinuria when present. 
Inactive disease was diagnosed when none of the above were 
present. Serology was not used to define disease activity. 
The blood samples were kindly supplied by Dr. Asad Zoma and 
Prof. K. Whaley. The disease activity of the patients was
not disclosed until after the GR1 determinations had been 
completed.
7.5 RA patients: A total of 25 blood samples from
20 RA patients were studied (Ropes et al 1959)• Immediately 
prior to venous blood sampling the RA patients were examined 
for evidence of disease activity.
7.4 Quantitation of CR1 sites/erythrocyte
The RIA to quantitate the number of 0R1 sites/erythrooyte 
was performed as described in 4*7-
193
Serological studies: Ten ml of blood was collected
and allowed to clot in a plain glass tube, the serum was 
removed and stored at -70 C until required. Serum samples 
from SLE and RA patients were examined for total haemolytic 
complement (CH50), 04, 03, B and CÎ-INH levels (Whaley 1985).
In addition samples from RA patients were examined for 
rheumatoid factor levels using latex and RIA, and SLE patients 
were examined for antinuclear antibody and DMA binding 
capacity (Webb and Whaley 1974)• Some SLE samples were also 
examined using the Crithidia test for double stranded DMA 
and for immune complex levels. All the serological tests 
were performed very kindly by the staff of the immune-pathology 
laboratory, except the determination of immune complex levels 
by PEG precipitation and conglutinin binding; these were 
kindly performed by Dr. S. Cobb. In the latter assay 
fixed bovine serum conglutinin binds immune complexes con­
taining iC3b. In the former assay circulating immune complexes 
are precipitated with PEG and their IgG content measured 
by radial immunodiffusion.
7.5 Serial studies: These were performed on 9 normal
individuals, 8 SLE patients and 4 RA patients. The time 
periods between individual determinations were variable.
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Rg-piily studies; In total six families were 
studied, two normal families and 4 families where 1 or 2 
members had SLE. The families were chosen on the basis 
that a) all immediate family members were alive, b) the 
family was willing to take part in the study and c)j^ geo- 
graphically accessible. The CR1 sites/erythrocyte in an 
individual family were all performed at the same time.
7*8 Statistical analysis; Where applicable the data 
were analysed using the Mann-Whitney U-test for non- 
parametric data.
RESULTS
Erythrocyte CR1 levels in patients and normal individuals
The CR1 sites/erythrocyte were studied in three groups; 
a group of normal controls randomly picked and the SLE and 
RA patient groups, comprising of patients picked at random 
by the clinicians supplying the blood samples. The distri­
bution of CR1 sites/erythrocyte in these three groups is given 
in Fig. 24.
The distribution of CR1 numbers in the controls (n=70) 
was unimodal, the mean level was 3320 CR1 sites/erythrocyte 
with a range from 0 to 21692 CR1 sites/erythrocyte. The mean 
level of CR1 sites/erythrocyte in the SLE group (n = 4I ) was 
1541 and like the normal group the range was wide, from 0 to 
15766 CR1 sites/erythrocyte, however this can be attributed
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FIG. 24 Distribution of CR1 sites/erythrocyte 
in normal individuals and patients 
with SLE and RA. The horizontal 
lines represent the mean values and 
the arrows the median values.
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to one outlying point (15766 CR1 sites/erythrocyte) with 
the remaining being clustered between 0 and 5500 CR1 sites/ 
erythrocyte. In the SLE patient group 11 of the blood 
samples studied had no receptors, in comparison to one in 
the normal group. The mean for the SLE patients was sig­
nificantly lower than for the normal controls (p <0.001).
The mean for the RA group (n= 25) studied was 14IO CR1 sites 
/erythrocyte, which is significantly less than the normal 
mean (p <0.05). The range of CR1 sites/erythrocyte
(350 to 4259) was narrower than the normal controls and the 
SLE patients. However, unlike the SLE patients there were 
no RA patients who had zero receptors on their erythrocytes.
The mean CR1 sites/erythrocyte for the SLE and RA patients 
differed significantly (p <0.05).
These results were replotted as cumulative frequency curves 
which gave a clearer indication of the differences and simi­
larities between the normal, SLE and RA groups studied (Fig.25). 
The cumulative frequency curve for the normals is sigmoidal 
with only minor irregularities in this shape between 50 and 
77%. Eighty per cent of the normal population studied had 
4000 CR1 sites/erythrocyte or less. The remaining 20% con­
stituted the large range from 4000 to 21692 CR1 sites/erythrocyte 
The curve for the RA patients was also sigmoidal paralleling 
the normal curve to the 50% point after which it deviated 
towards the SLE curve. This observation indicated that the 
RA group studied did not have many patients with very high or 
very low CR1 numbers. Although the cumulative frequency 
curve for the SLE group was also sigmoidal, 27% of the patients 
had no receptors at the time of study. The curve is displaced 
towards the origin in comparison to the curve for the normals,
FIG. 25 Cumulative frequency curves of
CR1 numbers in normal individuals
(---- ), patients with SLE (---- )
and RA
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clearly indicating that this group have fewer CR1 sites/ 
erythrocyte than normals but that they also exhibit a wide 
receptor range.
Relationship between CR1 levels and other laboratory tests 
The relationship between CR1 numbers and the results 
of the other laboratory tests were investigated in the 
SLE and RA patients (Tables 17 and 18). Complement levels 
and rheumatoid factor levels (7.5) were assessed in the 
RA patients. Complement levels, the levels of antinuclear 
antibodies (ANF) and DNA binding antibodies (7.5) were 
assessed in the SLE patients. Unfortunately these were 
not performed on every blood sample tested for CR1 levels.
Most of the complement levels in the SLE patients (Table 17) 
and RA patients (Table 18) were normal, with no correlation 
between CR1 sites/erythrocyte and the parameters measured 
(see table below, the normal ranges for these assays are given 
in Table 19).
C5 C4 B C1-INH CH50 RF RIA
RA patients 0.4 0.11 0.57 0.25 0.21 -0.2
SLE patients -0.08 0.06 -0.22 -0.20 -0.25 -
Clearly CR1 levels do not correlate with the serum levels of 
complement components in the SLE or RA patients, nor do they 
correlate with circulating rheumatoid factor (RE) levels in 
the RA patients. The ANF and DNA binding values were assessed 
in the SLE patients.
TABLE 17 Results of CR1 sites/erythrocyte, 
C3 (pg/ml), C4 (pg/ml) B (jag/ml) 
cT“INH (pg/ml) and CH50 (units/ml) 
in 34 samples from SLE patients
199
Patient Disease
activity
CRI 03 04 B CI-INH CH30
8.C. Active 0 694 174 146 306 83
D.D. Inactive 0 943 306 138 317 191
H.McG Active 0 903 230 186 410 273
C.McG. Active 0 1243 199 223 224 308
J.M. Active 0 1020 299 230 270 201
E.McH. Active 0 1700 302 240 368 234
A.C. Active 0 1476 486 238 273 203
J.M. Active 0 1134 620 238 382 199
E.McH. Active 0 1387 294 270 474 269
J.McD. Active 0 1313 414 204 417 -
R.H. Active 240 767 136 208 234 -
C.F. Inactive 377 938 134 178 198 179
C.F. Inactive 463 1030 347 202 203 160
M.S. Inactive 476 1337 426 173 332 244
J.G. Inactive 376 1379 339 207 310 226
S.S. Inactive 637 1370 377 281 287 139
M.G. Active 643 1411 337 242 330 180
M.G. Active 634 1296 216 286 290 -
B.D. Active 680 890 213 198 478 184
M.McD. Inactive 772 1129 243 187 322 267
K.E. Inactive 886 963 238 143 232 276
M.B. Inactive 898 932 270 137 268 218
I.T. Inactive 936 904 404 212 390 242
J.M. Inactive 1062 1331 333 173 327 249
M.G. Active 1126 1334 222 289 220 133
B.D. Active 1160 839 179 389 374 176
I.M. Inactive 1361 874 189 227 268 203
C.B. Inactive 1611 968 164 196 231 148
J.G. Inactive 1977 1427 326 283 234 239
L.B. Inactive 4333 931 336 127 241 139
S.S. Inactive 4934 1233 284 241 291 229
M.G. Inactive 3197 1330 400 292 330 128
B.D. Inactive 3306 1132 190 160 196 176
M.G. Inactive 13766 976 339 134 273 173
TABLE 18 Results of CR1 sites/erythrocyte, 
03 (pg/ml), 04 (jag/ml), B (jig/ml) 
cT-INH (jag/ml), CH50 (units/ml) 
determinations and rheumatoid 
factor (RF) levels (RF latex and 
RF RIA) in 23 RA patients.
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Patient CR1 03 C4 B CI-INH CH50 RF
latex
RF
RIA
A. J. 334 1887 894 378 414 173 ( + )ve 30400
K.C. 530 1164 472 243 370 198 ( + )ve 9000
M.M. 532 1242 515 185 360 259 ( + )ve 1067
J.D. 606 1314 542 231 528 357 (-)ve -
R.H. 629 860 179 226 296 131 ( + )ve 19652
M.H. 846 1583 457 301 402 343 (-)ve <800
E.F. 925 1328 300 257 300 238 ( + )ve 5550
A.R. 1056 1553 286 287 374 235 ( + )ve 7000
C.D. 1221 959 288 186 244 210 ( + )ve 9000
M.R. 1231 1720 451 358 484 198 ( + )ve 11750
M.B. 1238 1709 212 304 234 184 ( + )ve 10000
M.G. 1250 1850 509 394 354 266 ( + )ve 10500
J.S. 1350 1831 368 242 238 305 ( + )ve 10568
R.H. 1556 931 235 182 272 140 ( + )ve 5533
B.F. 1582 2528 629 364 485 250 ( + )ve 2850
K.C. 1598 2046 652 372 506 324 ( + )ve 40000
M.C. 1712 1887 454 325 312 313 ( + )ve 15363
M.C. 1742 2208 628 346 234 270 ( + )ve 12121
CMcN. 2275 1830 361 274 412 262 - -
P.B. 2525 1882 382 328 442 316 ( + )ve 7350
M.B. 2731 2336 956 412 432 246 ( + )ve 13200
M.S. 3038 - - - - - - <800
H.M. 4259 1762 488 372 463 278 ( + )ve
4700
TABLE 19 Ranges for laboratory 
serological tests
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03
04 
B
CI-INH
CH50
Normal range 
720-1800 pg/ml 
199-574 pg/ml
149-421 }ig/ml 
160-370 pg/ml
150-250 units/ml
RF latex 
RF RIA
(-)
Less than 800 units/ml
DNA binding assay 0 — > 27% Normal
27 — > 33% Borderline (B)
33% — > Raised (R)
Antinuclear factor assay 
(ANF)
Homogeneous staining pattern (H) 
Speckled " " (S)
Nucleolar " " (N)
Crithidia Negative 
Weakly positive 
Strongly positive
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In the 31 blood samples studied there was no correlation 
between CR1 sites/erythrocyte and antinuclear factor or 
anti-DNA antibody levels; however all the SLE patients did 
have antinuclear factor antibodies and 44% had anti-DNA 
antibodies (Table 20).
Relationship between CR1 levels and disease activity
The SLE patient group was further sub-divided into 
those who had active disease and those in whom the disease 
was in remission at the time of study. This division was 
based on the clinical assessment as described in 7.2 and thè 
information was only made available following the completion 
of all the CR1 assays.
The distribution of CR1 sites/erythrocytes in SLE 
patients with active and inactive disease is shown in Pig. 26. 
The mean for the patients with active disease (n=17) was 356 
CR1 sites/erythrocyte, whilst for inactive disease (n:= 24) 
the mean was 2428, these two groups differ significantly 
(p<0.001). Other distinguishing features illustrated by this 
graph are: a) the very high percentage (53%) of patients
with no detectable receptors on their erythrocytes when studied 
during an active disease phase and b) the difference in the 
range of CR1 numbers between active and inactive disease states, 
with the range for the active groups being much '  ^narrower
(0 to 1160 CR1 sites/erythrocyte) than the inactive group 
(0 to 15977 CR1 sites/erythrocyte). The range of the latter
TABLE 20 Results of CR1 sites/erythrocyte, 
ANF (titre and staining pattern) 
and DNA binding (%) in 31 SLE 
patients with varying disease 
activity (ACTIVE, INACTIVE).
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Patient Disease
activity
CR1 ANF DNA
E.McH Active 0 1/1000 H + S 98.1% R
A.G. Active 0 1/256 H Normal
8.C. Active 0 - 96% R
C.McG Active 0 1/64 H -
H.McG Active 0 1/64 H + 8 -
J.M. Active 0 1/1000 s + H Normal
E.McH Active 0 1/1000 H 93.3% R
J.McD Active 0 1/1000 H -
D.D. Inactive 0 - Normal
G.F. Inactive 377 1/1000 H Normal
G.F. Inactive 463 1/256 H Normal
M.S. Inactive 476 1/1000 8 Normal
J.O. Inactive 376 1/64 H Normal
8.8. Inactive 637 1/64 H + N 69.4% R
M.G. Active 643 - 36.7% R
M.G. Active 634 1/1000 H + s -
B.D. Active 680 1/256 H 34.7% R
M.McD Inactive 772 1/1000 H Normal
K.E. Inactive 886 - Normal
I.T. Inactive 936 1/1000 H + s Normal
J.M. Inactive 1062 1/1000 8 Normal
M.G. Inactive 1126 1/1000 8 + H 43.9% B
B.D. Active 1160 1/256 H 30.7% B
I.M. Inactive 1361 1/1000 H Normal
G.B. Inactive 1611 1/256 H 30.8% B
J.G. Inactive 1977 1/256 H Normal
L.B. Inactive 4333 W (+)ve Normal
8.8. Inactive 4934 1/256 H 68.7% R
M.G. Inactive 3197 1/1000 8 61.2% R
B.D. Inactive 5306 1/256 H + S Normal
M.G. Inactive 15766 1/256 H 33.4% R
PIG. 26 Distribution of CR1 sites/erythrocyte 
in SLE patients with active and 
inactive disease. The horizontal 
lines represent the means and the 
arrows the median values.
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TABLE 21 Results of CRI sites/erythrocyte,
ANE (titre and staining pattern), 
Crithidia test for dsDNA and DNA 
binding (%) in 8 active SLE patients 
and 16 inactive SLE patients.
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Patient Disease
activity
CR1 ANF Crithidia DNA
E.McH Active 0 1/1000 H+S St(+)ve 98.1% R
A.G. Active G 1/256 H (-)ve Normal
8.0. Active G - St(+)ve 96% R
C.McG Active G 1/64 H ( + )ve 44.3% R
R.H. Active 240 - St(+)ve 95.1% R
M.G. Active 645 - ( + )ve 36.7% R
B.D + Active 680 1/256 H (-)ve 54.7% R-
B.D. Active 1160 1/256 H ( + )ve 30.7% R
D.D. Inactive G - (-)ve Normal
O.P. Inactive 377 1/1000 H (-)ve Normal
C.P.+ Inactive 465 1/256 H (-)ve Normal
J.G. Inactive 576 1/64 H W(+)ve Normal
8.8. Inactive 637 1/64 H+N ( + )ve 69.4% R
M.McD Inactive 772 1/1000 N (-)— >( + )ve Normal
K.E. Inactive 886 - (-)ve Normal
M.B. Inactive 898 - (-)ve -
I.T. Inactive 936 1/1000 H+S (-)ve Normal
J.M. Inactive 1062 1/1000 S (-)ve Normal
M.G. Inactive 1126 1/1000 S^- H W(+)ve 43.9% B
I.M. Inactive 1561 1/1000 H W(+)ve Normal
C.B. Inactive 1611 1/256 H (-)ve 30.8% B
J.G. Inactive 1977 1/256 H W(+)ve Normal
L.B. Inactive 4553 W(+)ve (-)ve Normal
M.G. Inactive 5197 1/1000 s St(+)ve 61.2% R
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group resembles more the range of CR1 sites/erythrocyte 
found in the normal group (0 to 21692), however, both
groups of SLE patients still differ significantly (p<0.001) 
from the normal group. Clearly SLE patients have reduced 
CR1 numbers and this reduction is more marked when the disease 
is undergoing an exacerbation.
The possible relationship between CR1 levels and serological 
parameters was further studied in the active and inactive SLE 
patients in the hope that the division of the SLE group may 
highlight any correlations present which may have been masked 
when studying the SLE group as a whole. However, there was 
no correlation between CR1 numbers, complement levels and disease 
activity. All the patients studied, both active and inactive 
had antibodies to nuclear factors (Table 21), however in the 
active group 88% had a positive DNA binding test compared to 
27% in the inactive group, 75% of the active group had a 
positive Crithidia test compared to 38% in the inactive group.
In neither the inactive or active SLE patient groups did CR1 
levels correlate with ANF titre or DNA binding levels. There­
fore although there was clearly an increase in autoantibodies 
to dsDNA in active disease states (as determined by DNA binding 
assay and Crithidia test) this does not have any direct correl­
ation with the CR1 levels.
As SLE is considered to be the prototype human immune 
complex disease sera from 4 patients with active SLE and 8 with 
inactive disease were examined for immune complexes (Table 22) . 
There was no correlation between CR1 and immune complex levels 
detected by either the conglutinin binding assay or PEG IgG 
in patients with inactive disease. In patients with active
TABLE 22 Results of CR1 sites/erythrocyte,
conglutinin binding assay (^g equivalent/ 
ml) and PEG IgG (mg/%) in 12 SLE patients, 
4 in an active disease state and 8 in 
an inactive state.
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Patient Disease
activity
CR1 Conglutinin
binding
assay
PEG IgG
8.C. Active 0 54 5.6
C.McG Active 0 22.2 5.85
M.G. Active 645 61.5 18.2
B.D Active 680 78 4.1
D.D. Inactive 0 58.5 7.1
M.S. Inactive 476 34.5 4.45
M.M. Inactive 772 201 4.35
K.E. Inactive 886 18 2.7
M.B. Inactive 898 45 2.35
J.M. Inactive 1062 17.4 4.9
C.B. Inactive 1611 3.75 10.9
L.B. Inactive 4553 34.5 2.22
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disease there was a correlation (r=0.79) between immune 
complex levels (as detected by the conglutinin binding assay) 
and CR1 levels, but this was not found using the PEG- IgG 
method of immune complex quantitation.
Serial measurements of GR1
Serial studies were performed on 9 normal individuals,
4 RA patients and 8 SLE patients. These were performed to 
determine whether CR1 levels varied with time. The time 
periods between individual determinations were variable.
The 9 normal individuals studied were all laboratory personnel 
who were healthy when the blood samples were taken. The 
results (Table 23) were variable and therefore: each
individual will be discussed separately.
E.H. Over 52 weeks this individual shows very little change 
in receptor numbers, the receptors being present at low levels.
I.N. This individual exhibits widely fluctuating receptor 
levels over a 71 week time period, with the receptor levels 
changing even in a one week period, i.e. week 30, 3118 
CR1 sites/erythrocyte, week 31, 4557 CR1 sites/erythrocyte and 
again that week, a blood sample taken 2 days later showed the 
erythrocytes to have 2827 CR1 sites/erythrocyte.
A.F. Within an 8 week period this individual has constant 
GR1 levels, however 40 weeks later the CR1 numbers had increased
nearly six fold.
TABLE 23 Serial studies of CR1 sites/erythrocyte 
in 9 normal individuals, examined at 
variable time intervals, and expressed 
as weeks (wk) from -the first deter­
mination.
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R.S. This individual has relatively constant CR1 levels 
over a 23 week period.
L.J. This individual exhibits widely fluctuating CR1 levels.
K.W. The 0 week and 93 week CR1 levels and the 52 and 56 
week CR1 levels are very similar in this individual.
A.M. The two CR1 determinations made on the erythrocytes 
of this individual are vastly different.
L.M. Despite the long interval between these two blood 
samples the CR1 levels are remarkably close.
K.G. These two determinations of CR1 levels in this individual 
with a 26 week gap do not differ to the extent seen in, for example, 
L.J. but are not as close as seen in, for example, L.M.
Clearly there is a considerable degree of change in CR1 levels
injnormal individuals, with no pattern to the variations.
The serial studies on the RA patients are shown in Table 
24 and the complement and RP factors in Table 23. Individual 
M.C. has fairly constant CR1 levels, however R.H., M.B. and K.C. 
do show some degree of change in their receptor levels. 
Unfortunately the serial studies on the RA patients was limited, 
making it difficult to make any associations between CR1 changes,
complement and RF levels.
Serial studies of CR1 numbers were performed on 8 SLE patients 
(Table 26) together with their complement levels, ANFs and DWAs 
(Table 27) . Three patients serially studied remained inactive 
throughout, one of these patients (C.F) had stable low receptor
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levels, the remaining two (S.S. and J.G.) showed an increase 
in their receptor levels within 3 weeks. Two patients remained 
active whilst being serially studied, patient E.McH had no 
receptors on 3 successive determinations of receptor levels and 
the second patient's (C.McG) receptor levels increased despite 
remaining active. Three patients had changes in their disease 
status whilst being serially studied, and the relationship 
between disease activity and CR1 levels in these three patients 
is illustrated in Fig. 27. In all three patients (M.G.,
J.M. and B.D.) receptor levels increased during periods of 
disease remission and decreased during phases of exacerbation. 
Patient M.G. (Fig. 27a) shows an increase in receptor levels 
despite remaining active and likewise patient J.M. (Fig. 27b) 
shows an increase in receptor levels despite remaining inactive. 
However in patient M.G. the next serial study (Fig 27(a)3) showed 
another increase in the receptor levels and also that the patient 
had entered into a phase of disease remission. There was no 
obvious correlation between CR1 levels and complement, ANF and 
DNA binding levels in the 3 patients extensively serially studied, 
however in 2 out of these three patients there were incomplete 
serological data.
Family studies
CR1 sites/erythrocyte were measured in the families of 
two normal individuals and five patients with SLE, the criteria 
used for the choice of these families is described in 7-7-
TABLE 24 Serial studies of CR1 sites/ 
erythrocyte in 4 RA patients, 
examined at variable time intervals, 
expressed as weeks from the first 
determination.
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TABLE 25 Complement and RE levels 
in the 4 RA patients 
studied serially
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TABLE 26 Serial studies of CR1 sites/
erythrocyte in 8 SLE patients, 
examined at variable time inter­
vals, expressed as weeks from the 
first determination. Disease 
activity is stated as (A) for active 
and (lA) for inactive.
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TABLE 27 Complement levels, AfTF (titre 
and staining pattern) and 
DMA binding (%) in the 7 SLE 
patients study (A=active disease, 
IA=inactive disease)
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FIG. 27 Graphic representation of serial 
studies on 3 SLE patients 
(a) M.G, (b) J.M. and (c) B.D, 
showing changes in the number of 
CR1 sites/erythrocyte with disease 
activity.
•1, #2 etc. represent serial
samples
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For ease of presentation of these data, individuals have been 
divided into one of three groups, based on their CR1 numbers.
The 3 groups were made arbitarily, low (,< 1000 CR1 sites/ 
erythrocyte), medium (1001 to 3999 CR1 sites/erythrocyte) and 
high 4000 CR1 sites/erythrocyte). In the normal control 
group studied 20% had low receptors, 60% medium and 20% high 
(taken from cumulative frequency curve Pig. 25).
Normal family (a) (Fig. 28) had four members, the father 
had medium receptor levels, whilst the mother and two daughters 
had low receptor levels (there were no serological data on this 
family). The second normal family (Fig. 28 (b)) consisted 
of 5 members. The father had medium receptor levels and the 
mother low receptor levels, likewise one daughter, however 
her two sisters had medium receptor levels. None of the 
members of these families had antinuclear or anti-DNA antibodies 
in their sera and CH50, C4, 03, B and CÏ-1NH levels were normal.
At the time family (a) (Fig. 29) was studied the family 
member with SLE had medium receptor levels (1062 GR1 sites/ 
erythrocyte), as did his mother, father and brother. His 
paternal aunt had high receptor levels. However, this patient 
had been studied 2 months previously when his disease status 
was active and he had undetectable receptors.
The patient in the second family (Fig. 29 (b)) had low 
receptor levels, her mother, father and sister had medium 
receptor levels whilst her brother had high receptor levels.
The remaining 2 families studied each contained a set 
of identical twins. Both twins of family (a) (Fig. 30) had 
clinical SLE. However, only one twin of family (b) (Fig. 30)
PIG. 28 CR1 sites/erythrocyte in two 
normal families
Normal family (a)
219
950
874 449
L = low 
M = Medium 
H = High
Normal family (b)
1282
10841568
M M
FIG. 29 CR1 sites/erythrocyte in two 
families where one member is 
an SLE patient
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had clinical SLE; her twin sister only had serological 
evidence of SLE. Monozygosity was established on the 
basis of physical appearance, HLA tissue typing and analysis 
of the blood groups ABO, Rh, Kell, Lewis, Duff and Kidd.
In the first family (Pig 50 (a)) one twin had medium 
(1977) and the other had high (4954) receptor numbers (both 
were inactive at the time of study). The brother had medium 
receptor levels whilst the mother had high receptor levels. 
Unfortunately the father refused to give a blood sample.
In the second family (Fig 50 (b)), the twin with serological 
evidence of SLE (*®) had medium receptor levels (1047) whilst 
her twin (inactive at the time of study) had low levels (577)* 
Both parents had medium receptor levels and their sister had 
low levels.
Except for the patients with SLE none of the SLE family 
members had clinical or serological evidence of SLE.
DISCUSSION
Many studies have now been performed in which the levels 
of OKI on the erythrocytes from normal individuals and patients 
with immune complex diseases have been investigated. In 
particular patients with SLE have been studied with a view to 
a possible understanding of the role of CR1 in determining the 
possible fate of circulating immune complexes which are prevalent 
and possibly phlogistic in SLE. :Li occasional studies RA patients 
have also been studied as th^r ^Lso biave phlogistic circulating 
immune complexes.
PIGr. 30 CR1 sites/erythrocyte in two
■families where there are twins 
with SLE
(# individual with SLE,
*# individual with serological 
SLE only).
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CR1 levels have been determined by two methods, 
firstly by IAEA or modifications of this method or using an 
RIA with either monoclonal or polyclonal CR1 specific anti­
serum. In this project erythrocyte CR1 levels were studied 
in a group of normal individuals, SLE and RA patients and the 
receptor levels were quantitated using an RIA utilizing radio­
labelled polyclonal rabbit F(ab') anti-CR1.
Due to different methods used to quantitate receptor 
levels, it is difficult to make direct comparisons between the 
data obtained by different laboratories. Therefore the results 
obtained in this project will be discussed together with the 
general trends found by other workers.
Erythrocyte CR1 levels in patients and normal individuals 
The range and mean erythrocyte CR1 levels in normal 
individuals obtained by other workers quantitating receptor 
levels using RIA are given below.
Mean CR1 
levels
5014+155
1410+625
707+202
CR1 range 
100 to 8500
145 to 1214 
168 to 1877 
300 to 1400
No. of samples 
tested
113 Wilson et al 1982
52 lida et al 1982
86 Walport et al 1985
124 Minota et al 1984
77 Ross et al 1985
The mean found in this study was 3320 with a range of 
0 to 21692 CR1 sites/erythrocytes. This range is much wider
than those found by other workers, and the mean value is the 
second highest. However, the use of a monoclonal antibody to 
determine the number of receptors by lida et al 1982, Minota 
et al 1984, Walport et al 1985 and Ross et al 1985 would account
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for their lower ranges and mean values. In fact the afore­
mentioned workers have found very similar CR1 levels on the 
erythrocytes of their normal individuals. This is probably 
a result of using a monoclonal anti-CR1 antibody to determine 
the number of receptors. Wilson et al (1982) used a poly­
clonal anti-CRI antiserum, their determined mean value of 
5014jf155 CR1 sites/erythrocyte is closer to the values attained 
in this project, however their range (100 to 8500 CR1 sites/ 
erythrocyte) is much narrower.
Another problem concerning the interpretation of published 
data by other groups is the manner in which the RIA was executed. 
The assay technique used throughout this thesis for the deter­
mination of CR1 sites/erythrocytes was based on the method 
described by Wilson et al (1982) and involves incubating incre-
1 pc
mental amounts of I-F/ab')^ anti-CRI with standardized 
quantities of erythrocytes. With the quantitation of specifically 
bound cpms at a range of input cpm values a Scatchard plot can 
be constructed and therefore the number of CR1 receptor sites 
determined. However the groups analysing receptor levels with 
a monoclonal antibody only incubate erythrocytes with a single 
saturating dose of radiolabelled monoclonal anti-CRI antibody.
lida et al (1982) however created a standard curve using 
purified CR1 from which they could calculate the number of 
P0Q0p-j^ QPg for the level of monoclonal binding observed. Yet, 
for Walport et al (1985) the saturating dose was determined using 
approximately 10 erythrocyte specimens. If this sample of the 
normal population did not contain individuals with very high 
receptor levels they may not pick up such people in future assays.
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and this may lead to artificially narrow ranges of CR1 
numbers.
Wilson et al (1982), Minota et al (1984), Walport et al (1985) 
and Ross et al (1985) further analysed their normal groups by 
constructing histograms of the number of individuals against 
CR1 levels. Walport et al (1985) make no comment about their 
histogram although it does show some degree of clustering of 
receptor sites. Ross et al (1985) believed their histogram 
showed a bimodal distribution of receptor numbers; however 
extensive statistical analysis confirmed that it was unimodal. 
Wilson et al (1982) visualized a bimodal distribution (Pig. 5) 
and further subdivided one group to give a trimodal distribution 
of CR1 sites/erythrocyte in his normal control group. They used 
this as the basis for the proposal that CR1 levels were inherited 
by two autosomal codominant alleles H and L, HH coding for 
high, HL for medium and LL for low receptor levels. The fact 
that the expected phenotype frequencies predicted by the Hardy- 
Weinberg equilibrium did not differ significantly from the 
observed frequencies further supported their argument. How­
ever their histogram distribution pattern was not analysed 
statistically and although there is clearly a bimodal distribution 
pattern it is difficult to support their decision to arbitrarily 
subdivide one cluster to give 3 groups where the phenotype 
frequency coincides with the expected Hardy-Weinberg equilibrium 
for 2 codominant alleles.
The histogram drawn from the data of Minota et al (1985) 
shows 3 distinct clusters of CR1 sites in the normal controls, 
and the observed phenotype frequencies do not differ significantly 
from those found by Wilson et al (1982). However, this group
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stated that if the alleles were codominant, the expected 
frequencies would be LL 25%, HL 50%, HH 25% and not, as 
observed by themselves (and Wilson et al 1982) LL 11% (12%),
HL 53% (54%) and HH 56% (34%), with their results showing a 
strong deviation in favour of the HH phenotype. They there­
fore state that their data do not support a codominant allele 
control of receptor levels but favour a multigene control of 
CR1 expression.
The CR1 levels on normal erythrocytes found in this project 
(Fig. 24) appeared unimodal in their distribution. On the 
advice of the statistician. Dr. P. Boyle, these results were 
replotted as a cumulative frequency curve (Fig. 25), as if any 
genetic subgroups of receptor numbers were present in the normal 
population studied there would be indentations in the cumulative 
frequency curve. As can be seen in Fig. 25 the curve is 
smooth and sigmoidal apart from a few minor irregularities 
between 50 and 77% and this may be due to sampling error or may 
reflect on the size of the population used. However, the data 
does not support the presence of 5 groups within our normal 
population bearing low, medium and high CR1 receptor phenotypes 
on their erythrocytes.
The results attained by lAHA or modifications of this method 
are difficult to compare with those determined using the RIA. 
Several studies have been performed using lAHA, however there 
are considerable problems with this method which is only semi- 
quantitative. These have been highlighted by Minota et al 
(1984) and Uko et al (1985). Both these groups studied the 
ability of serial dilutions of aggregated human IgG (AHG) coated 
with complement (guinea pig) to agglutinate human erythrocytes^ 
Ihe results being expressed as the highest dilution of AHG to 
show positive agglutination.
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Both Uko et al (1985) and Minota et al (1984) found that 
patients and normal erythrocytes demonstrated extreme himodality 
in their haemagglutination patterns, with a group expressing 
no receptors, as indicated by no haemagglutination and a group 
with very high receptor levels with haemagglutination titres 
of approximately 2 , Therefore using this technique there was 
a clear cut discrimination between individuals with no receptors 
and those with very high receptor levels, with no intermediate 
values. Minota et al (1984) further showed that lAHA negative 
erythrocytes very often had intermediate levels of receptors , 
determined using the RIA^ thus suggesting that a critical 
number of CR1 sites/erythrocyte are required for positive IAEA 
in the presence of AHG bearing limited amounts of C3b. This 
would account for the bimodality seen in IAEA titres and con­
sequently makes IAEA data difficult to interprète , and this 
must: always be borne in mind.
There seems to be no correlation between CR1 levels with 
either the sex, blood group (ABO) or age of an individual 
(lida et al 1982).
To date all workers studying erythrocyte CR1 levels in SLE 
patients have found them to be significantly reduced compared 
to normals; this is in concordance with the results found in 
this project. There have been only two studies which have 
determined CR1 levels in RA patients. In this study RA patients 
had significantly fewer receptors (p<0.05) than normals; this 
confirms the result of lida et al who also found their RA 
patients to have significantly fewer receptors (p<0.02) than 
the normals. Ross et al (1985) however found their RA patients 
to have only slightly but significantly lower CR1 levels (p<0.01)
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than the normals. In both of these studies the 8LE patients 
had much reduced CR1 levels in comparison to the RA patients.
The cumulative frequency curves for the SLE and RA 
patients (Pig. 25) like the normal curve are sigmoidal with 
few irregularities in shape indicating no presence of genetic 
sub-groups within these two patient groups. It also clearly 
shows that SLE patients have fewer receptors than normals with 
a large percentage (27%) having no receptors and that the RA 
patients had no patients with 0 receptors and none with very 
high receptor levels.
Relationship between CR1 levels and other laboratory tests 
The possibility that there was a link between low CR1 
levels in SLE and RA with clinical serological parameters was 
investigated. In the RA patients there was no correlation 
between CR1 levels and C3, C4, B, CÏ-INH and CH50 levels, nor 
with RF levels as determined by RIA. In the SLE patients, 
likewise, there was no correlation between CR1 levels and G3,
04, B, CÏ-INH and CH50 levels. In the SLE patients the levels 
of antinuclear factor antibodies (ANF) and autoantibodies specific 
for double stranded (ds) DNA were assessed. There was no correl­
ation between CR1 levels in the SLE patients and the levels of
ANF or anti-DNA antibodies.
No other workers in this field have examined the correlation 
between CR1 levels, RF, ANF and anti-dsDNA antibody levels.
lida et al (1982) correlated haemolytic 04 levels with GR1 
levels', the correlation coefficient was low. Wilson et al (1982) 
examined CH50, C4 and 03 levels in 22 SLE patients and found no 
correlation with CR1 levels. This is in agreement with the 
results found in this thesis.
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Relationship between CR1 levels and disease activity
The division of the SLE patients into those who were 
active at the time of study and those who were inactive (Fig.26) 
shows clearly that receptor numbers are related to disease 
activity. The mean for the active SLE patients was 356 
CR1 sites/erythrocyte as opposed to 2428 CR1 sites/erythrocyte 
for the inactive SLE patients. These two patient groups 
differed significantly (p<0.001). It is also clear that the 
high percentage of individuals with zero receptors were found 
amongst those patients with active disease.
The relationship between CR1 levels and serological para­
meters was studied in the active and inactive SLE patients.
There was no correlation found between CR1 levels, complement 
levels, ANF titres and autoantibodies to dsDNA (as detected by 
the DNA binding assay or Crithidia test). However, there was
a much higher percentage of positive DNA binding assays (88%) 
in active disease as opposed to inactive disease (27%). This was 
further supported by the Crithidia test (75% positive in active 
disease,38% in inactive disease). This confirms the relation­
ship between the presence of anti-dsDNA antibodies and active SLE.
A limited number of sera from SLE patients (4 active and 
8 inactive) were examined for circulating immune complexes 
(conglutinin binding assay and PEG precipitation of IgG containing 
complexes. Table 22). A positive correlation was only found 
between CR1 levels and conglutinin binding complexes (r-0.79) 
in the serum from the active SLE patients.
Several groups have also examined the relationship between 
circulating immune complexes and CR1 levels. However, the variety 
of techniques used to detect and quantitate circulating immune 
complexes make it difficult to compare data, as certain immune
230
complexes may be detected by one method and not another or vice 
versa.
lida et al (1982) studied the presence of circulating 
immune complexes in 20 serum samples from SLE patients using the 
Raji cell and solid-phase C1q-binding assays. Although they 
found CR1 levels to correlate negatively with the results of the 
C1q-binding assay (r=0.49, p<0.05) and not the Raji cell assay 
(r=0.32, p>0.2), the former correlation coefficient is of only 
borderline significance while the latter is not statistically 
significant. Wilson et al (1982) found only 2 out of 22 SLE 
patients to have raised levels of circulating immune complexes. 
Inada et al (1982) examined 103 serum samples from 82 SLE patients 
for circulating immune complexes by measuring the ability of the 
patient's sera (heat-inactivated) to agglutinate standardized 
human erythrocytes in the presence of a complement source., 
(guinea-pig serum) ; the control was the same assay performed with 
a known quantity of AHG. They observed that 55 serum speci­
mens had circulating immune complexes ranging from Ap.g/ml to 
512^g/ml, of these patients 95% had defective CR1 levels as 
measured by a modified lAHA. In a later paper Inada et al (1983) 
showed that 110 out of 184 serum samples from SLE patients had 
circulating immune complexes. Of these 106 (96%) had reduced 
CR1 levels, however, 54 out of 74 samples (72%) had low CR1 but
no circulating immune complexes.
All these results tend to support the view that CR1 levels 
do not correlate exactly with the levels of circulating immune 
complexes. However, an association cannot be ruled out as the 
assay systems used to detect circulating immune complexes may not 
pick up those which may be related to GR1 levels.
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Serial measurements of CR1
Serial studies were performed on erythrocyte specimens 
from 9 normal individuals, 4 RA and 8 SLE patients to examine 
whether there were temporal changes in CR1 receptor levels. 
Unfortunately, the time intervals between the CR1 determinations 
on a single individual were variable. However, the message is 
clear that CR1 levels do vary with time, both in normal individuals 
and patients. Limited serial studies on RA patients show that 
some exhibit larger variations than others (Table 24); because 
of the numbers involved in this study no correlations could be 
made between changes in CR1 levels and changes in complement or 
RE levels. The most significant observation was the changes 
in CR1 levels with disease activity in the SLE patients.
Three patients had changes in their disease activity whilst being 
serially studied (Pig. 27); clearly receptor levels decrease 
during periods of disease exacerbation and increase during phases 
of remission. Despite incomplete serological data on these 
patients there were no apparent correlations between changes in 
CR1 levels with complement, ANF or DNA binding levels. A 
large, carefully designed prospective study would be required
to examine this problem.
To date 6 groups have studied CR1 levels serially in SLE 
patients. There have only been 3 studies on the longitudinal 
variation in CR1 numbers in normal individuals. In all cases 
the studies have been small in numbers, the erythrocyte speci­
mens have been examined irregularly and not all studies have 
examined serological parameters. The results of these studies 
are conflicting. Miyakawa et al (1981) examined CR1 levels 
using lAHA. Serial erythrocyte samples from 50 SLE patients 
showed no variation in their IAHA activity despite being tested
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two or more times. However, the majority of these patients 
were in remission at the time of study and consequently may 
not have expressed great variations in their CR1 levels.
Three of their patients were followed from active disease into 
remission and their IAEA activity still remained low. These 
results must be interpreted with caution as the IAEA technique 
used is relatively insensitive and unsuitable for the detection 
of intermediate receptor levels (as discussed earlier). There­
fore, Miyakawa et al (1981) stated that there were no changes 
in receptor levels with time and this led them to the conclusion 
that the defect was persistent and therefore inherited. Xt is 
possible however, that any change in receptor levels would not 
have been detected by this screening method.
Wilson et al (1982) performed serial studies on 24 normal 
individuals and 10 SLE patients over a one to four month period. 
However they only present the mean variation in receptor levels 
(436+71 CR1 sites/erythrocyte for normals, 361+^ 87 CR1 sites/ 
erythrocyte for SLE patients) and not the variation in receptor 
levels of given individuals. Furthermore the SLE patients were 
not studied during different disease status*, however they do 
state that most of their patients were in remission at the time 
of study. The results of Wilson et al (1982) could indicate 
that individuals do exhibit fluctuations in their receptor numbers, 
however they do not make any comments about the results from
the serial studies.
lida et al (1982) followed four SLE patients through inactive
and active disease phases, and showed that 2 of these patients 
retained low receptor levels (as determined by RIA) when their 
disease status became inactive, whilst two patients showed large 
increases (80% and 176%). Similar studies in normal volunteers
233
showed that their CR1 levels were remarkably stable.
Like I,Ida et al (1982), Inada et al (1982) performed 
serial studies on patients during different disease activities 
(using IAHA) and likewise they found an increase in receptor 
levels during disease remission. This was coupled with a 
drop in circulating immune complex levels but no significant 
change in CH50 or 03 levels.
A single serial study by Nojima et al (1985) using radio­
labelled AHG as the ligand to detect CR1, showed no change in 
receptor levels despite changes in clinical activity, but once 
again this assay technique may pose the same problems as IAHA.
Longitudinal studies by Walport et al (1985) were performed 
extensively on two individuals ; they showed little change; how­
ever it is possible that like 3 of the normals studies in this 
thesis (E.H., R.S. and L.M.) these two people do not exhibit 
large variations in their CR1 levels, or possibly as their assay 
system only uses one point determinations of receptor levels, 
wide fluctuations may be outwith the limits of the assay and 
therefore not detected. They also looked at CR1 levels on the 
erythrocytes of 15 SLE patients and 13 normals on two successive 
occasions and showed that there was no change. However there 
was no mention of the time interval between the two samples.
Finally, Uko et al (1985) followed serially 7 normals 
and there was minimal variation in their CR1 levels as determined 
by IAHA, but SLE patients showed considerable changes and in 3 
cases there were extreme changes. Some individuals showed 
persistently low levels. In six patients extensively serially 
studied there was generally an inverse relationship between CR1 
levels and C3 activation or autoantibodies to dsDHA and therefore
clinical activity.
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The conclusions drawn from the serial studies performed 
in this project are a) given normal individuals can have 
relatively stable receptor levels, moderately or highly variable 
receptor levels, b) a similar situation is found in the RA 
patients and c) a similar situation is found in SLE patients 
but in addition there is an association between disease activity 
and receptor status. This last statement strongly supports 
the view that reduced CR1 levels in SLE are acquired. Similar 
serial studies on SLE patients by lida et al (1982), Inada et al 
(1982) and Uko et al (1985) support this view. However, 
Miyakawa et al (1981) and Nojima et al (1985) find the defect to 
be persistent and postulate that low levels are inherited.
The serial studies performed on normals by other workers (lida 
et al, 1982, Walport et al 1985, Uko et al 1985) partially support 
the findings of this thesis; in all the aforementioned studies 
normal individuals exhibit minimal variation in their CR1 levels. 
Such a situation was found in 3 individuals studied in this 
project, however 5 individuals demonstrated changeable receptor 
levels. The possible causative factors will be discussed in 
the next chapter.
Family studies
Throughout this chapter data from other laboratories 
and results found during this project have been discussed and 
clearly there are two not necessarily incompatible views on the 
causation of low erythrocyte CR1 levels in SLE. Firstly, that 
they are inherited or secondly, that they are acquired as a 
secondary manifestation of the disease process. The data 
presented so far from this thesis supports the view that low 
CH1 levels in SLE are acquired. However, establishing the
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validity of either of these hypotheses is crucial because if 
the abnormality is inherited then clearly it is a factor 
which predisposes to SLE. Alternatively if low CR1 numbers 
are acquired then an understanding of how the abnormality occurs 
light on the pathogenesis of the condition and might 
even suggest new therapeutic approaches.
To determine whether receptor levels are inherited or 
not, extensive family studies have been performed by all workers 
in this field. In this project, two normal families and 
four SLE families were studied, with two of the SLE families 
luckily containing one set of identical twins. For ease of 
presentation 3 groups of receptors were assigned, those with 
low 1000 GR1 sites/erythrocyte), medium (1001 to 3999 CR1 
sites/erythrocyte) and high (>^ 4-000 CR1 sites/erythrocyte) 
receptor levels. It must be stressed that this division is 
arbitrary, uch arbitrary divisions have also been made by 
Walport et al (1985) for the examination of CR1 levels in their 
families? however Wilson et al (1982) and Nojima et al (1985) 
based their divisions on their observed trimodal distribution 
of CR1 levels seen in their normal population. The division 
by the latter two groups resulted in the percentage frequency 
of low, medium and high CR1 phenotypes not differing significantly 
from the Hardy—Weinberg equilibrium for two autosomal codominant 
alleles (discussed previously). The conclusions which can be 
drawn from the family studies performed in this project are.
a) There is clustering of a given CR1 phenotype within an 
individual family, for example, in normal family (a) (Fig. 28) 
there is a clustering of low receptors and in normal family (b) 
(Pig. 28) there is a clustering of low phenotypes around the low 
to medium borderline. Likewise excluding the 8LE patient, a
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similar situation is seen in the SLE families. Both SLE 
families (a) and (b) (Pig. 29) and twins SLE family (a) (Pig.30) 
have medium to high receptor levels, with the remaining twins 
SLE family (b) (Pig. 30) having medium to low receptor levels.
b) The phenotype of the patient's family could not account 
for the CR1 levels found in the patients. This is particularly 
so in SLE families (a) and (b) (Pig. 29). In family (a) the 
affected male started with 0 receptors (during active disease 
state) however as he went into remission his receptor levels 
resemble those of his family. The patient in family (b) was
in an active disease state and unlike the rest of her family 
had low receptor levels.
c) Identical twins do not have the same receptor levels.
The results of these family studies do tend to contradict
each other. On the one hand there seems to be clustering of
CR1 phenotypes in an individual family tending to favour the
inheritance of receptor; however the active SLE patients (SLE
families (a) and (b) (Fig. 29)) do not have CR1 phenotypes akin
to their immediate families and identical twins with SLE do not
have the same CR1 levels (Fig. 30). These latter two findings
favour the acquisition of low GR1 levels in SLE.
The findings of Walport et al (1985) support the above
findings. As previously mentioned they could not assign HH and
LL phenotypes to GR1 levels based on their population data.
There 3 normal families illustrated clustering of receptors,
however in the four SLE families the patients have much lower
GR1 values than the remaining members of the families.
Nojima et al (1985) studied GR1 levels in 3 SLE families (by
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measuring the binding of complement coated I-AHG). All 
3 SLE patients were inactive and had low receptors, 10 out of 11
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family members had intermediate receptor levels and 1 low.
They also state that the mean levels for the patient's relatives 
were lower than the normals but not significantly. Based on 
these findings and the persistent defect in one patient despite 
changes in disease activity they considered the defect to be 
genetic. Obviously one serial study is not sufficient to make 
any claims about CR1 persistence with disease activity. It 
must be pointed out that the SLE families studied by Nojima 
et al (1985) may just be members of the population who have low 
CR1 levels, like the two normal families studies in this project* 
they also make no mention about the disease activities of these 
three patients.
Miyakawa et al (1981) made the original claim that low CR1 
levels are inherited (as determined by IAHA), based on the 
persistence of low CR1 levels with disease activity and this was 
further supported by the high frequency (6 out of 24, 25%) of 
the defect found in the relatives of patients with erythrocyte 
CR1 levels. However, closer inspection of the data presented 
by this group indicates that only 24 family members of 15 SLE 
patients were tested, therefore it would seem impossible to draw 
any conclusive statement about CR1 inheritance when they could 
have only been testing approximately 2 or less family members 
per SLE patient. The results of their serial studies have been
discussed earlier.
Minota et al (1985) performed serial studies on 3 normal 
families and 5 SLE families, however they make no comment on their
results.
Wilson et al (1982) present the strongest data from family 
studies supporting the inheritance of CR1 levels, by two codominant 
alleles. In seven normal families there was appropriate segregation
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of the LL, LH and HH phenotypes and in nine SLE families the 
healthy relatives had fewer receptors than normal subjects.
In addition the pedigree analysis of these 9 families 
supported the diallelic model.
The results of this study supports the view that defective 
CR1 levels in SLE patients may be acquired. This is based on 
the findings that; a) active SLE patients have fewer receptors 
than inactive SLE patients, b) in individual patientsCR1 
levels change with disease activity, c) identical twins with 
SLE do not have the same CR1 numbers, and d) SLE patients with 
low CR1 phenotypes can belong to genotypically high CR1 families. 
The data from the normal population studies does not support 
the inheritance of CR1 levels’, however, the numbers in this 
study (n = 70) are not large enough to make a firm conclusion.
The family studies data does tend to support the inheritance of 
CR1 levels within an individual family or at least a heritable 
component in the expression of erythrocyte CR1 numbers. These 
views are compatible with those cited by Walport et al (1985) and
Uko et al (1985).
In conclusion, CR1 levels can be genetically determined 
(clustering of CR1 phenotypes in families) and a recent abstract 
by Wilson et al (1985) presents data demonstrating an element 
linked to the CR1 gene which controlled the quantitative expression 
of CR1 (but was not related to the structural polymorphism).
Equally though CR1 phenotypes can be acquired particularly in 
active SLE. Therefore low CR1 levels in SLE may be genetically 
determined or a secondary manifestation of the disease process per
se.
The possible causal factors for acquired low CR1 levels will
be discussed in the next chapter.
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C H A P T E R  8
/
INVESTIGATION INTO THE MEANS OF ACQUIRED 
CR1 REDUCTIONS IN SLE PATIENTS
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INTRODUCTION
As a result of the work described in Chapter 7, the 
following conclusions were reached regarding erythrocyte CR1 
levels in normal individuals, SLE and RA patients ;
a) Genetic factors probably play a role in controlling the 
erythrocyte CR1 phenotypic expression, the supportive evidence 
being the clustering of either high, medium or low CR1 levels 
in the six families studied, b) In a number of SLE patients 
reduced erythrocyte CR1 levels seem to be acquired. Several 
pieces of evidence support this view; the variability of given 
SLE patients' CR1 levels with disease activity, the predominance 
of low CR1 levels during active disease phases, the finding that 
identical twins with SLE do not have the same CR1 levels and 
SLE patients with low CR1 phenotypes can belong to families with 
medium to high CR1 phenotypic expression. These latter findings 
suggest that CR1 levels in some SLE patients may be affected 
by environmental factors.
An explanation for the acquisition of low CR1 levels during 
periods of disease activity in SLE is as yet unknown. In this 
chapter preliminary investigations were undertaken to try and 
elucidate this area. A number of distinct possibilities exist 
which may explain the reduction and these fall broadly into two 
categories; a) removal of the receptors and b) blockade of the 
P0Q0p-(^ ors. The former possibility was not studied but could be
envisaged to occur during the circulation of the erythrocyte 
where the receptors may be removed by plasma or cellular enzymes. 
Alternatively the binding of immune complexes to the erythrocyte 
CR1 could be followed by release of the complexes together with 
the receptor. In this chapter 1 have investigated the 
possibility that reduced CR1 levels could be due to receptor
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blockade. This could arise as a consequence of immune complexes 
binding to the erythrocytes, or the binding of anti-erythrocyte 
antibodies, or anti-CRI antibodies all leading to the blockade 
of the receptor making it inaccessible to the radiolabelled 
Ffab')^ anti-CRI probe.
In this chapter the in vitro effect of opsonized immune 
complexes on erythrocyte CR1 levels was examined. In addition, 
erythrocytes from patients were examined for membrane-bound 
immune complexes.
MATERIALS AND METHODS
8.1 Immune complexes
a) BSA anti-BSA immune complexes^ the quantitative precipitin 
curve and equivalence point f.or these complexes were determined 
by Dr. J. K. Naama who kindly donated the antiserum. The 
complexes formed at equivalence, consisted of 5Oui of BSA 
(0.35mg/ml) and iOOpl of a 1 in 2 dilution of rabbit anti-BSA 
antiserum.
b) Thyroglobulin anti-thyroglobulin immune complexesj anti- 
thyroglobulin antiserum was prepared by immunizing two rabbits 
with 2ml of bovine thyroglobulin (0.5mg/ml) emulsified with an 
equal volume of Freund's complete adjuvant. The rabbits were 
given two booster injections at 21 day intervals, using the previous 
protocol, but replacing Freund's incomplete for complete adjuvant. 
Seven days after the last injection the rabbits were exsanguinated 
and the serum was recovered from the blood using the method des­
cribed in 2.13. The IgG fraction of the antiserum was purified
as described in 4-5, and standardized to a concentration of 1.2 
mg/ml. Bovine thyroglobulin was used at Img/ml in PBS.
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The following concentrations of antigen were added to nine 
tubes: 0, 10, 20, 50, 100, 150, 200, 250, 350 and 450ug.
The volume in each tube was adjusted to 550;il by the addition 
of PBS and 100)il of IgG anti-bovine thyroglobulin. The tubes 
were incubated for 1 hour at 37°C and overnight at 4°C and then 
centrifuged at 1500g for 5 mins at 4°C. The supernatants were 
removed and thn pellets consisting of insoluble antigen- 
antibody complexes were washed twice in ice cold PBS. Finally 
the pellets were dissolved in 1ml of 0.1M NaOH. The protein 
content of the tubes was determined by measuring the absorbancy 
at 280nm (2.4), the OD^g^ was plotted against the antigen input 
y-^  (I^ ig* 31), and the equivalence point determined. The 
equivalence complexes consisted of 30pl of thyroglobulin (img/ml) 
and 100^1 of rabbit IgG anti-thyroglobulin (1.2mg/ml).
c) DNA anti-DNA immune complexes: The serum from an SLE patient
with a high DNA binding capacity (96%) was used as the anti-DNA 
antibody source. The serum was heat-inactivated for 1 hour at 
56°C and then diluted 1 in 10 before use. A quantitative pre­
cipitin curve was performed as described for the thyroglobulin 
anti-thyroglobulin immune complexes. However, despite repeated 
testing an equivalence point was not convincingly demonstrated, 
so immune complexes consisting of 5(Mg or 20CMg of DNA (calf thymus) 
and lOOÿul of a 1/10 dilution of the SLE serum were used for the 
experiments.
8.2 Opsonization of immune complexes and incubation with 
normal erythrocytes.
Blood group 0 Rhesus positive erythrocytes were used for 
these experiments and autologous serum was used for opsonization
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of the immune complexes. The erythrocytes and serum were 
prepared as described in 4.5 and 7 .5. For experiments employing 
BSA anti-BSA immune complexes the erythrocytes were suspended in 
RPMI plus 0.1% (w/v) gelatin as opposed to 1% BSA.
The respective antigen and antibody were warmed for 5 mins 
at 37 0 and the desired quantities were mixed to form immune 
complexes at equivalence (8.1). To this 500ul of warmed (37°C) 
fresh autologous normal serum was added and the antigen, antibody, 
serum mixture was incubated for a further 7 mins at 37°C with 
occasional shaking. The opsonized immune complexes were then 
added to pre-warmed 0 Rh positive erythrocytes at 2.5xlO^/ml. 
Quantities of 5 to lOO^ il of immune complexes were added per 
200pl of cells at 2.5x10 /ml and after a 7 mins incubation at 
37°C the cells were either put directly onto ice or washed thrice 
in ice cold buffer and re-standardized to 2.5xlO^/ml.
8.3. Determination of erythrocyte CR1 levels using polyclonal 
anti-CRI pre- and post-incubation with immune complexes 
The number of CR1 sites/erythrocyte pre- and post-incubation 
with 50^1 of immune complexes per 200pl of erythrocytes 
(2.5xlO^/ml) was performed as described in Section 4.7.
8.4 . Determination of erythrocyte CR1 levels using monoclonal 
anti-CRI pre- and post-incubation with immune complexes. 
Mouse ascites fluid containing the monoclonal antibody to 
CR1 Ell was kindly given by Dr. N. Hogg. The antibody was puri-
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fied from the fluid using the following method; to 1ml of the 
ascites fluid enough 0.1M acetic acid was added to drop the pH 
to 4.5' This was monitored using pH paper, then caprylic acid 
was added to give a final suspension of 5%. The tube was 
vigorously shaken by hand then centrifuged at 10000g for 7 mins.
The supernatant was removed and retained, the pellet was dis­
carded. To the supernatant an equal volume of saturated ammonium 
sulphate (SAS) was added dropwise, the mixture was left to stir 
at R.T. for 2 hours, after which the suspension was centrifuged 
at lOOOOg for 7 mins. The supernatant was discarded, the pellet 
was resuspended in PBS and dialysed overnight at 4°C into PBS 
to remove any traces of SAS. This pool contained the mouse 
monoclonal antibody El 1. Its presence was confirmed using double 
immunodiffusion in agarose (2.7), where it gave a positive reaction 
against sheep anti-mouse IgG antiserum.
The RIA using Ell to determine the number of CR1 sites/ 
erythrocyte was performed as follows: Ell was labelled as des­
cribed in 2.15, erythrocytes were washed and standardized to
Q
2.5x10 /ml (4.5) and 200ul aliquots were put into a series of
microcap centrifuge tubes. Ten micrograms (lOpg) of unlabelled
Ell was added to the first 5 tubes which were then incubated for
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30 mins at 4°C with continuous mixing, after which Ipg of I- 
E11 was added to all 6 tubes. The tubes were incubated for a 
further hour at 4 0 with continuous mixing and then the cells were 
separated from the supernatant by centrifugation over 300^1 of 
separating fluid (4.7) at 8500g for 5 mins. The supernatants were 
discarded and the cpm in the pellets measured in a /-counter.
The number of CR1 sites was obtained by subtracting the mean cpm 
value for the tubes pre-incubated with cold Ell from the mean cpm
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value for the tubes incubated with labelled E11 alone. This 
value was converted into the number of molecules of IgG anti-
CRI bound per erythrocyte by multiplying by the correction 
factor (cf).
n-P _ 4*03 X 10^^ / 7
Cf -   /  5X10 '
I-El 1 input in cpm y
Although this means of CR1 determination was extensively 
criticised in Chapters 4 and 7, this one point determination 
assay was employed to give a quick overall picture of receptor 
levels, as the number of tubes in each experiment was too great 
to perform the full titration procedure from which Scatchard 
plots and therefore exact CR1 levels could be derived.
8.5 Kinetics of binding of immune complexes to erythrocytes.
These experiments were performed using thyroglobulin 
^^^I-anti-thyroglobulin immune complexes at equivalence (8.1), 
the immune complexes were opsonized as described in 8.2. To 
a given volume of pre-warmed erythrocytes at 37°C the opsonized 
immune complexes were added (50ul of immune complexes per 200jil 
of erythrocytes at 2.5x10 /ml). The suspension was kept at 37 C 
and at given time intervals duplicate 200jul samples were removed 
and placed on ice. At the end of the experiment, the 200^1 
samples were centrifuged over 300pl of separating fluid at 8500g 
for 5 mins, to separate the cell pellets from the supernatants. 
The supernatants were removed and the cpm in the pellets measured 
in a y -counter. The control for this experiment was the use 
of radiolabelled immune complexes which had not been opsonized.
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^ ^ response binding of immune complexes to erythrocytes.
These experiments were performed using thyroglobulin anti- 
thyroglobulin immune complexes (8.1^ depending upon the experi­
ment these were used labelled or unlabelled. The immune com­
plexes were opsonized as described in 8.2. To given volumes 
of pre-warmed erythrocytes at 37^0 increasing amounts of immune 
complexes were added, from 5ju.l to 10C^l of opsonized immune 
complexes per 200jil of erythrocytes at 2.5xlO®/ml. The cells 
and immune complexes were incubated at 37°C for 7 mins, followed 
by immersion in an icebath. Duplicate samples (containing
7
5x10 cells) were removed from the tubes and centrifuged over 
separating fluid as described in 8.5; the supernatant was removed 
and the cpm in the pellets counted in a / -counter. Variations 
on this experiment were: a) incubating erythrocytes and immune
complexes at 4°C as opposed to 37°C, b) treating the serum with 
1GmM isotonic EDTA or 20mM MgEGTA and c) using unopsonized immune 
complexes.
8.7 Probing of erythrocytes for surface bound components.
Normal erythrocytes and patients's erythrocytes were probed 
for surface bound IgG or 03 fragments,and normal erythrocytes 
treated in vitro with immune complexes were examined to confirm 
the binding of the immune complexes to the cell surface. The 
following antisera were used for these experiments; rabbit anti­
human C3c, donkey IgG anti-rabbit IgG, sheep anti-human IgG, 
rabbit anti-BSA, rabbit IgG anti-thyroglobulin and human IgG 
anti-DNA. The antisera were labelled using the procedure des- 
cribed in 2.15, and were then tested by double immunodiffusion in
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agarose (2.7) against the antigen specific for the antiserum 
to ensure that the antiserum had not been denatured during the 
radiolabelling. For all the assays the same protocol was 
followed. Duplicate 200^1 samples of the erythrocytes 
(2.5x10 /ml) to be tested were placed in microcapped centrifuged 
tubes and to this 10pl of the radiolabelled antiserum was added. 
The tubes were incubated for 1 hour at 4°C with continuous mixing, 
after which the cells were separated from the supernatant by 
centrifugation over 500^1 of separating fluid (4.7) at 8500g 
for 2 mins. The supernatant was removed and discarded and the 
cpm in the pellet was measured in a -counter. The cpm input 
into the system was determined by counting alone 10^1 of the 
radiolabelled anti serum. The binding of the antiserum to the 
cells was expressed as counts per minute, or the number of 
antibody molecules bound per cell.
RESULTS
The in vitro effect of opsonized immune complexes on erythrocyte 
CR1 levels.
Artificial immune complexes (BSA anti-BSA, thyroglobulin 
anti-thyroglobulin and DNA anti—DNA) were opsonized by incubating 
with fresh human serum for 7 mins at 57 8 (Horgan and Taylor 1984). 
The serum used was derived from the same individual as the erythro- 
cytes used for the experiment. The opsonized immune complexes 
were then incubated with the standardized normal erythrocytes 
(50pl of immune complexes per 200pl of erythrocytes at 2.5xloG/ml) 
for 7 mins at 37°C. After washing with ice-cold RPMI-BSA (or in 
the case of the BSA anti-BSA immune complexes RPMI plus 0.1% gelatin)
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to remove excess immune complexes, the number of CR1 sites/ 
erythrocyte were determined (8.5). The number of CR1 sites/ 
erythrocyte prior to the incubation with the immune complexes 
was ascertained by handling a second batch of cells in a similar 
manner omitting the addition of the immune complexes.
In the two assays performed with opsonized BSA anti-BSA 
immune complexes at equivalence the number of erythrocyte CR1 
remained unchanged (Table 28.'). Three assays were performed 
using opsonized thyroglobulin anti-thyroglobulin immune complexes 
at equivalence. These immune complexes brought about partial 
or total blockade of the erythrocyte CR1 (Table 28). An 
equivalence point could not be obtained for the DNA anti-DNA 
immune complexes; two concentrations of calf thymus DNA were 
used to form the immune complexes. In an initial test when 
50^g of DNA was used to form the immune complex, this reduced 
the receptor levels by 64%, whilst the use of 200jig of DNA 
reduced receptor levels by 80% (Table 28). On the basis of 
these observations in all future experiments, opsonized DNA 
anti-DNA immune complexes were formed using 200pg of DNA. In 
two further experiments the opsonized DNA anti-DNA immune complex 
completely blocked the accessibility of the receptor to the
^^^I-F(ab')2 anti-CR1 probe.
To confirm that the immune complexes had bound to the cell 
surface, the cell surfaces were probed for bound C5 fragments 
and/or the antigen used to form the immune complex. Bound C5 
fragments (C5b, iC5b and C5c) were probed for using  ^ ^I-rabbit 
anti-human C3c and anti-BSA, ^^h-r^bbit IgG anti-
thyroglobulin and ^^h-human IgG anti-DNA were used to probe for 
BSA, thyroglobulin and DNA respectively (8.7). Unfortunately, 
both cell bound 03 fragments and antigen were not examined in all
TABLE 28. CR1 levels on normal erythrocytes 
pre- and post-incubation with 
opsonized immune complexes (BSA anti- 
BSA, thyroglobulin anti-thyroglobulin 
and DNA anti-DNA).
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Opsonized immune 
complexes
CR1 sites/erythrocyte 
Pre-incubation Post-incubation
BSA anti-BSA
5713 5678
7019 7572
5265 0
Thyroglobulin 15116 7844
anti-thyroglobul in
26155 0
20921 7575 (50)ig DNA) 
4197 (200pg DNA)
DNA anti-DNA 18800 0
2550 0
251
the experiments, nor in these experiments was any attempt 
made to correlate the level of probe binding with the degree 
of receptor blockade. The results are shown in Tables 29, 
30 and 3i*, in all cases there was an increase in the level 
of probe binding after the cells had been incubated with the 
immune complexes indicating that the immune complexes had 
bound to the erythrocyte cell surface.
Kinetics of binding of immune complexes to erythrocytes
The binding of thyroglobulin immune complexes at equivalence 
opsonized with fresh human serum was studied in four individuals 
(8.5). It was found that the immune complexes in the absence 
of serum had the ability to bind to the cell surface; these 
non-specifically bound cpm were subtracted from the total bound 
cpm (immune complexes bound in the presence of serum) to give 
the specifically bound cpm. Samples were taken at various 
time intervals during a 60 mins period and a representative 
example of a kinetic binding curve is given in Fig. 32.
Similar shaped binding curves were found in two individuals; 
in the fourth individual there was no binding above the non­
specific cpm value; however this individual was known to have 
consistently low CR1 levels and at the time of this study only 
had 140 CR1 sites/erythrocyte as determined using the monoclonal 
antibody Ell (8.4). The 3 individuals who did bind the immune 
complexes were known to have high CR1 levels and the individual's 
erythrocytes used for the experiment shown in Fig 32, had 630 
CR1 sites/erythrocyte at the time of study (8.4). In these 
3 individuals peak binding was always at 15 mins.
TABLE 29 Levels of radiolabelled anti-BSA
(results expressed as cpm, mean of 
two determinations) bound to normal 
erythrocytes pre- and post-incubation 
with opsonized BSA anti-BSA immune 
complexes, together with CR1 levels
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Pre-incubation Post-Incubation Change in GR1 sites
800 11392 3713 -4> 3678
599 12085 7019 7572
TABLE 30. Levels of radiolabelled anti-human 
C3c and anti-thyroglobulin (results 
expressed as cpm, mean of two det­
erminations) bound to normal 
erythrocytes pre- and post-incubation 
with opsonized thyroglobulin anti- 
thyroglobulin immune complexes 
together with CR1 levels.
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125
^I-anti-C3c
binding 
Pre Post
125
I-anti-thyro- 
globulin binding
Pre Post
Change in CR1 sites
NT NT 877 3030 13116-^7844
552 2941 NT NT 3265-^0
419 866 3364 20854 26135— > 0
NT = not tested
TABLE 31 Levels of radiolabelled anti­
human C3c and anti-DNA (results 
expressed as cpm, mean of two 
determinations) bound to normal 
erythrocytes pre- and post-incubation 
with opsonized DNA anti-DNA immune 
complexes together with CR1 levels.
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125j_
Pre
-anti-C3c
Post
125;
Pre
-anti-DNA
Post
Change in CR1 sites
565 111 NT NT 20921-^ 7575
565 936 NT NT 20921-->4197
382 2700 280 2220 18848— >0
1482 1598 12512 17821 2550-->0
NT = not tested
FIG 32. Kinetics of binding of thyroglobulin 
anti-thyroglobulin immune complexes 
to normal erythrocytes.
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Dgse response binding of immune complexes to erythrocytes.
Using radiolabelled thyroglobulin immune complexes 
at equivalence 5 to 100pl of immune complexes were incubated 
td/üi 200yl of erythrocytes (2.5xloG/ml) for 7 mins and then the 
amount of immune complex bound to the cell surface was 
evaluated (8.6). This experiment was performed on erythrocytes 
from 5 people and a typical result is shown in Pig. 33. At 
37 C there was a dose-dependent binding of the immune complexes 
to the erythrocytes; the binding at 4°C was reduced in com­
parison to the binding at 37°C. Higher doses of immune complexes 
were not tested* However, with the doses used there was no 
plateau in the immune complex binding. Unfortunately, CR1 
levels were not quantitated in these experiments.
Further experiments of this type were performed to evaluate 
the complement requirements of this binding reaction. The
experiments were performed as described in 8.6 and the dose- 
dependent binding of the immune complexes to the erythrocytes 
was analysed in; a) buffer alone, b) serum, c) serum treated 
with 20mM MgEUTA and d) serum treated with lOmM EDTA. A
representative result is shown in Fig. 34* Clearly the radio­
labelled thyroglobulin anti-thyroglobulin immune complexes 
are binding in the absence of serum and this was consistently 
found. In Fig. 34 the binding of the immune complexes in the 
presence of serum was enhanced,* however neither 20mM Mg EGTA 
or 10mM EDTA had any effect on the binding of the immune complexes 
to the cell. To evaluate whether the immune complexes affected 
the receptor levels a preliminary experiment was performed where 
50pl of cold immune complexes were incubated with 200jil of 
erythrocytes (2. 5xlO*^/ml), in the presence of buffer alone, serum 
or serum treated with 10mM EDTA; the receptor levels were then
FIG. 34 Dose-dependent binding of thyroglobulin 
anti-thyroglobulin immune complexes to 
normal erythrocytes in the presence 
of a) buffer alone (o), b) serum (■* ),
c) 10mM EDTA treated serum ) and
d) 20mM Mg EGTA treated serum (x)
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quantitated using the monoclonal antibody E11 (8.4). The 
results are tabled below.
Assay conditions___________________CR1 sites/erythrocyte
Buffer alone ^221
Immune complexes + buffer -io82
Immune complexes + serum 266
Immune complexes + serum + q02
10mM EDTA
Although the immune complexes had bound to the erythrocytes 
only immune complexes incubated with normal serum reduced 
the receptor levels significantly.
A further study investigated whether increasing doses of 
cold opsonized thyroglobulin immune complexes brought about a 
reduction in receptor levels as measured by the monoclonal E11 
(8 .4). The presence of immune complexes bound to the
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erythrocyte cell surface was confirmed using I-rabbit IgG 
anti-C3c, ^^^I-donkey IgG- anti-rabbit IgG and ^^^I-rabbit IgG 
anti-thyroglobulin (8.7). The level of binding of the probes 
being expressed as the number of IgG molecules bound per 
erythrocyte. The results are shown in Figs. 55, 36 and 57* 
Clearly as the input of immune complexes increased, the binding 
of the radiolabelled probes increased (Pig 55j Fig 36 and Fig 57) 
and there was a concominant decline in the receptor levels
(Fig. 55).
RTaminatinn of levels Of erythrocyte boimd IgG and 03 fragments  ^
The presence of erythrocyte bound IgG and/or 03 fragments 
were probed for using radiolabelled rabbit anti-human C3c and
PIG. 55 Changes in levels of CR1 (measured
125
by Ell) and binding of I-IgG
anti-rabbit IgG to normal erythro­
cytes incubated with increasing 
amounts of opsonized thyroglobulin 
immune complexes.
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TABLE 32. Binding of "’^ ^l-rabbit anti-
125
human C3c and I-sheep anti­
human IgG to the erythrocytes 
from 2 normal individuals and 
4 SLE patients.
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cpm of ^^^I-anti- 
C3c bound
125
cpm of -anti- 
IgG bound
Normal (1) 1098 NT
Normal (2) 779 6014
SLE (1) 1702 6260
SLE (2) 868 6347
SLE (3) 838 5555
SLE (4) 1648 6351
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sheep anti-human IgG (8.7). The erythrocytes from two 
normal individuals and 4 SLE patients were examined to try 
and establish whether these molecules bound to the erythrocyte 
cell surface could directly or indirectly block CR1, rendering
it inaccessible to I-F(ab') anti-CR1. The results are2
shown in Table 3 2 and are expressed as the mean cpm bound 
to the erythrocyte pellet (mean of 2 determinations). There 
is very little variation in the level of ^^^I-sheep anti-human 
IgG bound to the 5 erythrocyte samples tested. There was 
slightly more variation however, in the levels of ^^^I- 
rabbit anti-human C3c bound.
DISCUSSION
Nelson’s paper of 1955 has the title "The immune- 
adherence phenomenon: An immunologically specific reaction
between micro-organisms and erythrocytes leading to enhanced 
phagocytosis", and in this paper Nelson demonstrated the binding 
of antibody sensitised Treponema pallidum in the presence of 
complement to normal human erythrocytes. The time reaction 
for maximal binding was approximately 5 minutes, and similar 
results were found using the bacterium Diplococcus pneumoniae. 
From his results Nelson proposed that red blood cells prefer­
entially bound sensitised opsonized micro-organisms and presented 
them to the leucocytes therefore enhancing phagocytosis.
In 1981 Siegel et al (1981) put forward the view that 
erythrocytes are an essential component of the immune system, 
and they were the first to propose that erythrocytes have a 
primary role in the removal of circulating opsonized immune
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complexes from the fluid phase of the circulation hy virtue 
of the erythrocyte's CR1, to bind 03 containing complexes.
They stressed that the erythrocytes would be the main carrier 
system as they possess 95% of vascular CR1 on their surfaces 
(based on the numerical data of Fearon 1980) and because of 
the red blood cell to white blood cell ratio a circulating 
immune complex would be 500 to 1000 times more likely to inter­
act with an erythrocyte as opposed to a white blood cell. They 
emphasised that this system would be physiologically advantageous, 
preventing the deposition of harmful immune complexes and 
allowing the leucocytes to function normally without being over­
whelmed by circulating immune complexes.
This view is supported by Cornacoff, Zeger and Herbert (1981),
125who demonstrated the avid binding of soluble I-BSA anti-BSA 
immune complexes to human erythrocytes,* the reaction was com­
plement dependent and larger immune complexes bound more effectively. 
Again this may be of physiological advantage selectively removing 
larger circulating immune complexes. Aikawa et al (1979) also 
demonstrated the IC size dependent binding effect using immune 
complexes derived from the serum of SLE patients.
Medof and Oger (1982) investigated the in vitro binding 
of immune complexes to erythrocytes in detail. Using radio­
labelled BSA anti-BSA immune complexes they first examined the 
effects of the antibody : antigen ratio and the ratio of serum 
to immune complexes on their binding to the erythrocytes. Using 
conditions where the immune complexes were opsonized for 30 mins 
and then incubated with the erythrocytes for a further 45 minutes, 
they demonstrated optimal binding of immune complexes (65%) 
formed in 4 times antibody excess with a serum:immune complex 
ratio of 1:16. The high antibody ratio may be necessary for
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effective complement fixation. critical serum dilution
probably represents a compromise, i.e. ^  lower dilutions 
although C3b may be produced the levels of I may be sufficiently 
high to break it down into non-CR1 binding forms and at 
serum dilutions insufficient 03 may be turned over to allow 
immune complex binding to the erythrocyte. However, using 
these conditions, Medof and Oger (1982) showed that the immune 
complexes bound preferentially to the erythrocytes, although 
less bound per cell compared to the binding to the leucocytes, 
thus confirming the hypothesis of Siegel et al (1981) that 
immune complexes would bind preferentially to erythrocytes by 
virtue of their total higher CR1 concentration.
Kinetic studies by Medof and Oger (1982, using undiluted 
serum) showed a bell shaped binding curve, with maximum binding 
of the immune complexes occurring in 4 mins and dramatically 
dropping off by 8 to 10 mins. The kinetics of binding was 
tested in four people and although the bell shaped curve was 
the same for all four individuals, the levels of peak immune 
complex binding varied from 30 to 65%; this probably reflects 
the different erythrocyte CR1 densities. They found that binding 
release could be delayed using diluted or hypocomplementemic 
serum and Medof and Oger (1982) suggest that sustained immune 
complex binding may possibly have clinical implications in diseases 
with prevalent hypocomplementemia and high immune complex load.
For example a) the equilibrium of free to bound immune complexes 
could be dramatically altered by the availability of complement 
components and regulators, and b) sustained binding of the immune 
complexes to the erythrocytes could paralyse the system's ability 
to bind large immune complex loads', this may allow the immune
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complexes to interact with leucocyte CR1 hearing populations and 
may cause aberrent immune responses.
Similar work, investigating the immune complex binding 
properties of erythrocytes have been performed by Cornacoff 
et al (1983) using an in vivo model. They studied the fate
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of large preformed I-BSA anti-BSA immune complexes (10,000 
to 288000 S) infused into primates, as a means of testing whether 
erythrocyte CR1 acted as a removal mechanism for circulating 
immune complexes in vitro. After infusion immune complexes were 
shown to have bound to the erythrocytes within 30 seconds, the 
great majority bound to the erythrocytes and were cleared after 
passage through the liver, spleen and gut. Lower levels bound 
to the leucocytes, but were cleared more slowly by the liver, 
spleen and gut. The immune complexes which bound to the erythro­
cytes induced no haemolysis and they speculated this was due to 
CRI's inhibitory effects on the complement system.
The size of the immune complexes used in these experiments 
was large, although optimal for binding in their system. This 
however raises questions about the biological significance of 
these results particularly as the infusion of antigen and anti­
body alone did not result in the immune complexes binding to the 
erythrocytes. This may be a reflection on the immune complex 
size perhaps being of insufficient size for binding, or that 
the complexes were cleared too quickly to be detected by the
experimental system.
The experimental data discussed do provide strong experimental 
evidence to support the hypothesis presented by Siegel et al (1981) 
that erythrocyte CR1 acts as an immune complex carrier system.
Thus defects in this system could reduce the ability of affected 
individuals to handle an immune complex load.
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Reduced erythrocyte CR1 levels do exist, particularly in 8LE
patients, and the aim of the work performed in this thesis was 
to examine this defect and to try to establish whether it was 
acquired or inherited; the results are extensively discussed in 
Chapter 7, as are those of other workers in this field. As a 
result of the studies it became clear that low GR1 levels in some 
SLE patients were acquired, with the GR1 levels varying with 
disease activity, strikingly lower in active disease as opposed 
to inactive disease, and the finding that identical twins with 
SLE do not have the same GR1 levels supports this view.
There are two possible explanations for low erythrocyte GR1 
levels; a) receptor blockade and b) receptor removal. The 
latter was not investigated in this thesis; however the following 
means of receptor removal can be considered; a) cleavage of 
the receptor by plasma enzymes or b) removal of the receptor by 
the immune complex during passage through the circulation. The 
first possibility seems an unlikely explanation as normal erythro­
cytes incubated with physiological levels of the following enzymes; 
thrombin, cathepsin G and D, kallikrein and plasmin showed no 
change in their GR1 levels. Elastase was used at two concentrations
0.1% and 1%; only the higher dose reduced the receptor levels.
This enzyme is an intracellular constituent of phagocytic cells 
and it seems unlikely that concentrations of elastase required to 
reduce receptor levels would be found in the circulation (personal 
communication Miss A. W. Fyfe). The second candidate for receptor 
removal "stripping" as a result of the interaction of the immune 
complex bearing erythrocyte with the cells of the fixed mononuclear 
phagocytic system during circulation through the liver and spleen is 
supported by Ross et al (1985). However the in vivo work performed 
by Cornacoff et al (1983), where they infused radiolabelled BSA
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immune complexes into primates showed that erythrocytes cleared 
of immune complexes still possessed the ability to bind more 
immune complexes. Thus the erythrocytes had not been damaged 
after passage through the liver or spleen, similar work performed 
in vitro by Medof, Prince and Oger (1982) produced similar 
results. However, it must be stressed that the fixed mononuclear 
phagocytic systems of patients with immune complex diseases may not 
function normally and may indeed bring about receptor removal.
In support of this argument recent work by Walport et al (1985b) 
demonstrated the loss of CR1 from normal erythrocytes after trans­
fusion into SLE patients (e.g. 493 to 202 GR1 per erythrocyte in 
112 hours). The finding of a soluble form of GR1 by Yoon and
Fearon (1985) which they believed to be derived from the erythro­
cytes (the plasma CR1 being identical in molecular structure to 
the erythrocyte GR1), raises the possibility that GR1 may be lost 
from erythrocytes. They investigated this by incubating normal 
erythrocytes for up to 4 hours at 4°G to see whether receptor 
loss occurred. No reduction was seen. Similarly, this was found
in the storage experiments performed in Chapter 4. Yet at 4 G
all cell processes would be minimal and if energy was required 
for receptor loss the process may not have occurred. More 
relevant information would have been obtained by performing the 
experiments at a higher temperature. It is however possible that 
P0Q0p-|^ or loss does occur, despite the mechanism being unknown.
The second means of reducing receptor levels, receptor 
blockade, was the subject of the investigations performed in this 
chapter. As discussed at the beginning of this section evidence 
has accumulated to support a role for erythrocyte CR1 as an 
immune complex carrier. With this view in mind the possibility
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that immune complexes bound to the erythrocyte cell surface 
could block CR1 was investigated. Three types of immune 
complexes were opsonized and incubated in vitro with normal 
erythrocytes and their effects on CR1 levels determined.
The three types of antigen used for these studies were 
BSA (60000 daltons), thyroglobulin (660000 daltons) and calf 
thymus DNA (molecular weight not determined)*, these antigens 
vary markedly in size and consequently would yield immune 
complexes of vastly different sizes. ' The BSA and thyroglobulin 
containing immune complexes were used at equivalence. Despite 
using serum from an SLE patient with a high anti-DNA antibody 
titre (96% DNA binding capacity) a quantitative precipitin curve 
with DNA failed to yield an equivalence point. This could be 
due to the nature of the DNA antigen which is highly soluble in 
aqueous solutions. In addition, anti-DNA antibodies tend to bind 
to the DNA monogamously, rather than forming cross links between 
individual DNA molecules, consequently the DNA immune complex 
would be more soluble (Lennek et al 1981). The doses of DNA 
used were therefore chosen arbitrarily.
Investigations on the binding of three types of opsonized 
immune complexes to normal erythrocytes showed that although the 
smallest of the three types of complexes (BSA anti-BSA) became 
bound, CR1 levels were unaffected (Table 29). In contrast the 
larger complexes formed with thyroglobulin or DNA brought about 
papbial or complete receptor blockade (Tables 30 and 31)• It 
is thus evident that the degree of CR1 blockade may be related 
to the size of the antigen. It is probable that BSA anti-BSA 
complexes which have reacted with complement are considerably 
smaller than similar complexes formed with thyroglobulin or DNA.
It is also probable that the number of G3b molecules bound per
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complex IS also greater in these two latter types of complex.
Thus the greater quantities of C3b would increase the binding 
affinity of the complex to CR1.(îhis has been demonstrated 
in vitro by Arnaout et al (1983b), they showed that polymerized 
C3b bound with greater affinity than monomeric C3b to erythro­
cyte CR1 ) and they may therefore not be displaced by F^ab')^ 
anti-CRI . The larger size of the complexes would also mean 
that many CR1 sites were inaccessible to the anti-CRI probes.
A point to be noted from these experiments is that the degree 
of receptor blockade is not related to the number of CR1 sites,
i.e. an individual with high CR1 levels may be blocked totally 
by immune complexes, whilst erythrocytes with a low CR1 level 
may only be partially blocked.
In these experiments the presence of the immune complexes 
on the erythrocyte cell surface was confirmed by the binding of 
radiolabelled probes for 03 fragments and the appropriate antigen 
under study (8.7). The levels of probe binding are expressed as 
cpm (Tables 29, 30 and 31) and in all cases there was an increase 
in probe binding to cells after they had been incubated with the 
immune complexes. The variable levels of binding could reflect 
the amount or accessibility of the antigens within the complex.
With the demonstration that in vitro immune complexes could 
bind and block erythrocyte CR1 it was decided to investigate the 
binding reactions further. Thyroglobulin anti-thyroglobulin 
immune complexes were chosen for these preliminary experiments as; 
a) they were known to bind and block receptors and b) large supplies 
of thyroglobulin and antiserum were available.
The first study examined the kinetics of immune complex 
binding to normal erythrocytes from four individuals; in one
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individual (with known low receptor levels) there was no 
binding above background. In the remaining 3 individuals 
(representative result from one individual is shown in Fig. 32), 
there were different phases of immune complex binding and release, 
with maximum binding occurring at 15 mins and with complete 
release by 60 mins.
Kinetic binding curves for BSA immune complexes performed 
by Medof and Oger (1982) were bell shaped with the complex dissoc­
iation being mediated by I (Medof and Prince 1983a) but further 
more in depth studies showed sequential rebinding and immune 
complex release. They proposed that the first phase of dissoc­
iation mediated by I, left sufficient bound C3b to form an alternate 
pathway 03 convertase and this brought about rebinding (Medof and 
Prince 1983a). Together with this, the longer the immune 
complexes had been incubated with the erythrocytes, the less well 
they bound to fresh erythrocytes, PMNs or monocytes', and by analys­
ing the immune complexes on sucrose gradients, they showed demon­
strable reductions in the complex size (Medof and Prince 1983b)y 
ïhus indicating the immune complex handling by the erythrocytes 
had altered their physical and binding properties.
3
Horgan et al (1984) studied the kinetics of binding of H-DM 
anti-DNA immune complexes to erythrocytes and their subsequent 
release. The binding was rapid (less than 5 mins) with a slow 
release; however the rate of release was affected by both the 
antibody:antigen ratio and the molecular weight of the DNA used.
For example, using high molecular weight DNA (6 x 10 daltons) 
the t i for release was 60 mins and with lower molecular weight DNA 
(2 to 6 X 10^ daltons) the t i was 20 mins, and rebinding did not 
occur. Using small complexes (less than 2.5 x 10 daltons)
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there was minimal binding. Analysis of released immune
complexes showed no size chaise 1%^ em increase in 03 breakdown
products. Alack of size cha%^ iMy be unexpected due to the
nature of the DNA molecule but clearly there had been modifications 
of the C3b.
The effects of size on binding and release may reflect the 
amount of antibody bound and therefore complement fixation, with 
large complexes fixing more complement therefore binding with 
higher affinity and for longer to erythrocytes and vice versa.
Clearly the kinetics of binding and release are influenced 
by antigen and antigen size, resulting in different binding and 
processing by the erythrocytes. The different phases of binding 
and release from the erythrocytes seen with the thyroglobulin 
immune complexes (Fig. 32) was a constant finding and could represent 
handling of the immune complexes by the erythrocyte GR1 and the 
complement system, as described by Medof and Prince (1983 a and b); 
however this was not investigated further.
The next line of investigation was to see whether the immune 
complexes bound to erythrocytes in a dose-dependent fashion, and 
to establish the complement dependency and temperature sensitivity
of this reaction.
At 37°C there was a dose-dependent binding reaction of 
thyroglobulin immune complexes to erythrocytes. Using 5^1 to 
100ul of complexes per ZOOjxl of erythrocytes ( 2. 5xlO®/ml ), 3 
individuals were tested and saturation of the receptors was never 
achieved with the doses of immune complex used. The binding 
reaction was greatly diminished when the experiments were per­
formed at 4°c (Pig. 33). Similar results were found by Pedersen 
et al (1980) using D M  immune complexes, and studies on the effects 
of temperature by Horgan and Taylor (1984) showed lower binding
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rates of DNA immune complexes to erythrocytes at low temperatures 
(less than 2 2 °C )  but above 2 2 °c  they assumed binding levels found 
at 37 C. The results of my work indicate that at 4°C the recep­
tors are not in a state which allows receptor binding, therefore 
increasing the temperature either allows the production of energy 
for membrane reorganisation or allows an increase in membrane 
fluidity. Horgan and Taylor (1984) favour the latter (especially 
as erythrocytes produce low levels of energy anaerobically), with 
the low temperature inducing membrane rigidity which would inhibit 
any "long range" receptor organization.
The complement dependency was next investigated. EDTA (lOmM) 
prevents both the turnover of the classical and the alternative 
pathways and Mg EGTA (20mM) prevents classical pathway turnover. 
Both these chemicals prevented the lysis of EAs by normal human 
serum and therefore were working effectively; however as can be 
seen in Fig. 34 they did not diminish the binding of the immune 
complexes to the erythrocytes. This raises the question of how 
the immune complexes were binding to the cell surface. The 
manner in which the immune complexes bound to the cell surface was 
presumed to be via G3b interacting with GR1 and evidence from 
other laboratories supported this assumption (Taylor et al, 1985; 
Medof and Oger 1982). However the experimental results attained 
using EDTA and Mg EGTA to specifically block complement turnover 
seem to suggest another binding mechanism. A recent paper by 
Virella, Shuler and Sherwood (1983) demonstrated the non-complement- 
dependent adsorption of soluble immune complexes to human erythro- 
eytes. Such results were found in these experiments (Pig. 34(a) 
immune complex plus buffer); however, the binding in the presence
of serum was greatly enhanced (Fig* 34(b).
An experiment quantitating the receptors using the monoclonal
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there was minimal binding. Analysis of the released immune 
complexes showed no size change but an increase in 03 breakdown 
products . A lack of size change may not be unexpected due to the 
nature of the DNA molecule but clearly there had been modifications 
of the C3b.
The effects of size on binding and release may reflect the 
amount of antibody bound and therefore complement fixation, with 
large complexes fixing more complement therefore binding with 
higher affinity and for longer to erythrocytes and vice versa.
Clearly the kinetics of binding and release are influenced 
by antigen and antigen size, resulting in different binding and 
processing by the erythrocytes. The different phases of binding 
and release from the erythrocytes seen with the thyroglobulin 
immune complexes (Fig. 32) was a constant finding and could represent 
handling of the immune complexes by the erythrocyte CR1 and the 
complement system, as described by Medof and Prince (1983 a and b); 
however this was not investigated further.
The next line of investigation was to see whether the immune 
complexes bound to erythrocytes in a dose-dependent fashion, and 
to establish the complement dependency and temperature sensitivity 
of this reaction.
At 37°C there was a dose-dependent binding reaction of 
thyroglobulin immune complexes to erythrocytes. Using 5^1 to 
10(ÿil of complexes per 200^1 of erythrocytes (2.5xlO®/ml), 3 
individuals were tested and saturation of the receptors was never 
achieved with the doses of immune complex used. The binding 
reaction was greatly diminished when the experiments were per­
formed at 4°C (Fig. 33). Similar results were found by Pedersen 
et al (1980) using DNA immune complexes, and studies on the effects 
of temperature by Horgan and Taylor (1984) showed lower binding
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rates of DNA immune complexes to erythrocytes at low temperatures 
(less than 22 C) but above 22 C they assumed binding levels found 
at 37 C. The results of my work indicate that at 4°C the recep­
tors are not in a state which allows receptor binding, therefore 
increasing the temperature either allows the production of energy 
for membrane reorganisation or allows an increase in membrane 
fluidity. Horgan and Taylor (1984) favour the latter (especially 
as erythrocytes produce low levels of energy anaerobically), with 
the low temperature inducing membrane rigidity which would inhibit 
any "long range" receptor organization.
The complement dependency was next investigated. EDTA (lOmM) 
prevents both the turnover of the classical and the alternative 
pathways and Mg EGTA (20mM) prevents classical pathway turnover. 
Both these chemicals prevented the lysis of EAs by normal human 
serum and therefore were working effectively; however as can be 
seen in Pig. 34 they did not diminish the binding of the immune 
complexes to the erythrocytes. This raises the question of how 
the immune complexes were binding to the cell surface. The 
manner in which the immune complexes bound to the cell surface was 
presumed to be via C3b interacting with CR1 and evidence from 
other laboratories supported this assumption (Taylor et al, 1983; 
Medof and Oger 1982). However the experimental results attained 
using EDTA and Mg EGTA to specifically block complement turnover 
seem to suggest another binding mechanism. A recent paper by 
Virella, Shuler and Sherwood (1983) demonstrated the non-complement- 
dependent adsorption of soluble immune complexes to human erythro­
cytes. Such results were found in these experiments (Pig. 34(a) 
immune complex plus buffer); however, the binding in the presence
of serum was greatly enhanced (Fig* 34(b).
An experiment quantitating the receptors using the monoclonal
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E11 pre- and post-incnbation with complexes alone, immnne
complexes plus serum and immune complexes plus EDTA (10mM) 
treated serum, showed that although the immune complexes had 
bound to the erythrocytes only immune complexes incubated with 
serum bound to and blocked CR1 (results page 259). , This restored 
faith in the view that the immune complexes were binding via C3b 
to CR1 and blocking the receptor, but this does not explain the 
results found using 10mM EDTA and 20mM Mg EGTA. A possible
explanation could be that although the C1 macromolecule would be 
dissociated due to the chelation of calcium ions (by EDTA and 
Mg EG-TA), the C1q moiety may still bind to the immune complexes, 
and it is possible that erythrocytes like lymphocytes, monocytes 
and neutrophils (Ross 1982) have C1q receptors allowing the binding 
of the complexes to the cell surface. The binding of the complexes 
in the absence of serum could be a non-specific "sticking" effect, 
or may be due to interactions with Fc^ receptors, although their 
presence on erythrocytes has not been described.
Based on the findings that opsonized immune complexes bound 
dose-dependently to erythrocytes and blocked receptor, it was 
decided to investigate whether this dose-dependent binding coin­
cided with dose-dependent blockade. The levels of cold immune 
complexes on the erythrocytes ' cell surface were monitored by the 
number of molecules of ^I-rabbit IgG anti-C3c, I-donkey IgG 
anti-rabbit IgG and ^^^I-rabbit anti-thyroglobulin bound. As is 
shown in Figures 35, 36 and 37, as the amount of immune complexes 
added to the system increased the receptor levels decreased and 
there was a concominant increase in the irwdber of Ig# molecules 
of the radiolabelled probes bound to the erythrocytes.
The results of the studies performed in this chapter do clearly 
show that in vitro opsonized immune complexes can reduce erythro­
cyte CR1 levels and perhaps this process could account for
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diminished receptor levels particularly in diseases where there 
is a high immune complex load such as SLE. If this was the 
case, one would perhaps expect to be able to detect immune 
complex associated IgG and/or C3 fragments bound to the erythro­
cyte surface of SLE patients.
The erythrocytes from six individuals (2 normals, 4 SLE 
patients) were examined for surface bound IgG and/or C3b/iC3b/C3c 
(as detected by anti-C3c antiserum, Table 32). Normal (1) had
constantly low CR1 levels, normal (2) had constantly high receptor
125
levels, there is a small difference in their levels of I-anti-
C3c bound (1098 cpm compared with 779 cpm respectively). Of the
four SLE patients only (4) had active disease at the time of
study, the remaining 3 having inactive disease. They showed little
125
variation in the levels of I-anti-IgG bound and this is not
significantly different from the normal value. The levels of 
125I-anti-C3c bound showed greater variation. The largest binding 
values were attained using the erythrocytes from patients (1)
(937 CR1 sites/erythrocyte) and (4) (1126 CR1 sites/erythrocyte) 
and indeed patient (1) with the lower receptor value does have a
higher level of ^^^I-anti-C3c binding (CR1 levels in patients (2)
and (3) were not evaluated). These results may indicate that 
there is an association between CR1 levels and amount of surface 
bound C3 fragments. However, the sample size was very small, 
more meaningful information would be gained by performing a 
prospective study, examining the erythrocyte cell surface of 
normals and patients for different immunoglobulin isotypes and 
for 03 and 04 which as well as being a CR1 ligand is adsorbed onto 
the erythrocyte cell surface to give the Chido and Rodgers blood
groups.
Various other workers have performed such studies to try and
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establish whether receptor blockade by complexes,
immunoglobulin or complement components could contribute to 
receptor reduction on erythrocytes. The results are con- 
flicting. In a study by Wilson et al (1982) they found no 
correlation between CR1 levels, bound 03 or auto-antibodies 
directed against CR1. In a later paper Wilson et al (1985) 
describe the case of an individual woman with SLE who had auto­
antibodies to CRi; 34 additional SLE patients and 28 healthy 
donors also tested had no such auto-antibodies. In two studies 
by Inada et al (1982, 1983), they found some of their patients with 
unspecified immune complex diseases to have erythrocyte bound IgG 
and/or 03 or 04 as detected by a direct Coombes’ test' however 
the significance of their results is questionable, as they point 
out in their own discussion (Inada et al 1982) the results could 
not be reproduced using more conventional serological techniques. 
Ross et al (1985) found no correlation between the presence of 
immune complexes or fixed C3b/iC3b with CR1 levels on the erythro­
cytes from active SLE patients. However, there was a correlation 
between CR1 levels and the levels of erythrocyte fixed C3d-g.
In 12 patients studied through periods of disease exacerbation 
there was an inverse relationship between the levels of fixed 
C3d-g and CR1. However, they do not believe that reduced receptor 
levels are caused by immune complexes blocking CR1 because they 
were unable to detect surface immunoglobulins or C3b/iC3b, and the 
in vitro incubation of DNA immune complexes with erythrocytes did 
not cause a receptor reduction. These results must be inter- 
preted with care. Firstly, the amount of immune complex required 
to bring about receptor blockade in vivo is unknown, this may be 
of particular importance in patients with phenotypically low CR1 
levels where very small quantities of immune complexes may cause
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blockade, and these levels may be undetectable by radiolabelled 
antisera to 03 and/or IgG. Secondly, C3d-g only binds very 
weakly to CR1 and therefore may not be bound to GR1 but another 
03 receptor and only coincidentally related, or maybe bound co­
valently to the cell membrane. Thirdly, it is difficult
to imagine by what means 03d-g alone becomes deposited on the 
erythrocyte cell surface*, perhaps the 03d-g is masking immune 
complexes bound to the cell surface. Fourthly, in the in vitro 
immune complex experiments performed, it is possible that the DNA 
complex used did not have 0R1 blocking characteristics. For 
example, the BSA complexes used for the blockade experiments 
described in this chapter bound to the erythrocytes and did not 
block the receptor,' this may be the case in the experiments per­
formed by Ross et al (1985). Walport et al (1985) also state 
that reduced receptor levels are not caused by receptor blockade 
as their monoclonal antibody to 0R1 (E11) can detect occupied 
receptors (i.e. binding of E11 is not affected by immune adherence) 
However, the results of the experiments reported in this chapter 
using E11 clearly show its inability to detect receptors to which 
immune complexes are bound (Fig. 35). Therefore, in the papers 
where the 0R1 levels have been quantitated using E11 (Walport et al 
1985; Ross et al 1985) low patient erythrocyte 0R1 levels could 
be attributed to blockade by immune complexes.
This chapter has dealt with possible mechanisms leading to 
the acquisition of low 0R1 levels on erythrocytes. There are 
two mechanisms which could be used to explain the reduction of 
receptor levels. Firstly, receptor removal,^this was not investi­
gated but has been discussed in this chapter^and secondly, receptor 
blockade. Preliminary studies were performed investigating this 
area. These encompassed an examination into whether circulating
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immime complexes could bind to erythrocytes and temporarily
(or otherwise) block the receptors. Using 3 types of antigens
(BSA, thyroglobulin and DNA) to form the immune complexes,
in vitro studies showed that although all these complexes when
opsonized bound to the erythrocytes only the larger thyroglobulin
and DNA immune complexes caused receptor blockade (as detected by 
125
I-F/ab')^ anti-CR1). Studies in vitro using thyroglobulin
immune complexes demonstrated the dose-dependent binding of the
complexes, and their subsequent dose-dependent blockade of the
125receptor (as detected by I-E11) and the temperature sensitivity
of the binding reaction. Binding kinetics showed multi-phasic
binding and release of the immune complex from the erythrocyte 
cell surface. This is unlike the binding curves of Medof and 
Oger (1982) using BSA anti-BSA complexes, or Horgan and Taylor
(1984) using DNA anti-DNA immune complexes; the differences 
observed may only reflect the different natures of the immune 
complexes studied. As pointed out by Taylor et al (1983 ) the 
fate of a circulating immune complex is largely governed by 
how they are recognised and processed by cells and tissues, 
consequently their physical properties play a major role in this 
recognition process. Influencing factors would be antibody iso­
type, antibody avidity, mode of antibody binding, antigen size, 
solubility, stability and composition of the immune complex and 
the degree of complement fixation (Pedersen et al 1980; Taylor 
et al 1985).
Initial in vitro studies have shown that immune complexes 
do bind to and block erythrocyte CR1 and this could be implicated 
as a possible means of low CR1 acquisition in diseases such as SLE 
where immune complexes are believed to manifest the disease process
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The possibility of receptor removal by proteolysis is 
another means of acquiring low receptor levels. Evidence from 
our laboratory suggests that proteolysis by plasma enzymes does 
not bring about a reduction in erythrocyte CR1 levels. How­
ever, in vivo studies performed by Brown and Nelson (1973) demon­
strated the sequestration of EC43 in the liver of rabbits after 
their intravenous injection. By dissecting out and fixing the 
liver at various time periods post-administration of the EC43, 
the fate of the EC43 could be followed. Within 2 mins of 
injection, the EC43 had adhered to the cell membrane of the 
Kupffer cells, from which protrusions were beginning to force 
their way into the red cell membrane. Seven to 25 mins later 
small red blood cell fragments were detected in the Kupffer cell 
cytoplasm. Thus cells bearing C3b or iC3b in the circulation
had bound to the Kupffer cells, and as the 03 ligands were
removed from the cell surface small fragments of membrane were
removed also. This process leads to immune spherocytosis.
Clearly when erythrocytes bearing C3b-coated complexes bind to the 
Kupffer cells, parts of the membrane could be removed including CR1
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The complement system consists of at least 20 chemi­
cally and immunologically distinct serum proteins, these are 
capable of interacting with one another, with antibody and with 
cell membranes and such interactions lead to biological activity,
The complement system has been shown to have a role in 
inflammation, opsonization of immune complexes, modulation of 
immune complexes, cell lysis and the inhibition of the activi­
ties of viruses and bacteria.
Together with the serum proteins of the complement system, 
there are also a group of membrane receptors for complement 
components found on the cell surfaces of both immune and non- 
immune cells. The subject of this thesis was CR1, the receptor 
for the major 03 cleavage fragment C3b. The first description 
of a 03 receptor was by Duke and Wallace in 1930; they described 
the adherence of human erythrocytes to trypanosomes in the 
presence of antibody and complement. Similarly, Nelson (1953) 
observed the preferential binding of antibody and complement 
coated Treponema pallidum to erythrocytes when added to whole 
blood, and termed this reaction immune adherence. It is now 
known that this reaction is mediated by the interaction of CR1 
on the erythrocytes with the 03 breakdown fragments on the
immune complex.
This receptor is not confined to human erythrocytes, but 
is also found on granulocytes, monocytes, macrophages, B lympho- 
oytes, some T lymphocytes, glomerular podocytes and mast cells 
(Amaout and Colten, 1984; Pearon, 1984). The ligand spe< 
floity of the receptor was originally thought to be for CJb,
ÏC1-
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iC3b and C4b (as described in Chapter 1) but it is now known
to bind G3b, C4b, iC3b, iC4b, C3i and C3c (personal communication 
Dr. G. Ross, 1986).
To date studies on CR1 have shown it to have 3 major 
functions; a) enhancing the phagocytosis of opsonized immune 
complexes by monocytes, macrophages and neutrophils, b) acting 
as an inhibitor of complement turnover and c) functioning as a 
transport mechanism carrying circulating immune complexes to 
the fixed mononuclear phagocytic system. The latter role was 
proposed by Siegel et al (1981) who believed that the role of 
the erythrocyte in the circulation was not purely respiratory, 
but that it also formed an integral and important part of the 
immune system. Experimental evidence both in vitro and in vivo 
support this hypothesis (Medof and Oger, 1982; Cornacoff et al, 
1983; Horgan and Taylor, 1984; Taylor et al, 1985; Jepsen 
et al, 1986). Bearing in mind the three aforementioned roles
of CR1, it is clear that a defect in GR1 would have major impli­
cations upon the functioning of the immune system.
CR1 levels have been evaluated on the erythrocytes of 
patients with immune complex diseases where there are often 
associated complement deficiencies, with particular attention 
being paid to the disease SLE. The first defect in the erythro­
cyte CR1 levels of SLE patients was described in 1981 by Miyakawa 
et al. They studied the erythrocytes from 56 SLE patients using 
IAEA and showed that 66% of their patients had no CR1 (lAHA 
negative) in comparison to 4°/ of the controls. Studies sub- 
sequent to this investigation from geographically widespread 
localities, have confirmed these findings (assays performed using 
IAEA and RIA, as discussed in Chapter 7). In addition the
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the defect was found not to be confined solely to the disease 
SLE, patients with other types of rheumatic disorders (RA and 
Sjogren's syndrome) and probable immune mediated disorders 
(cold agglutinating disease and paroxysmal nocturnal haemo- 
globinuria) also had reduced erythrocyte CR1 levels (lida et 
al, 1982; Ross et al, 1985).
Studies investigating erythrocyte CR1 levels in normals 
and SLE patients have striven to determine whether the low 
CR1 levels seen in SLE patients are an acquired secondary mani­
festation of a complex immunologically mediated disease process 
or a predisposing inherited defect. This distinction is clearly 
important as an acquired defect may be open for clinical treat­
ment. The data found by other workers in this field are 
extensively discussed in Chapter 7- Clearly, there are 
scientists who believe that CR1 levels are inherited (Miyakawa 
et al, 1981; Wilson et al, 1985; Minota et al, 1985) and those 
who believe that they can be acquired (Inada et al, 1982; lida 
et al, 1982; Walport et al, 1985). The results of the studies 
performed in this thesis suggest that genetic factors do play 
some role in the determination of/erythrocyte CR1 levels, this 
is indicated by the clustering of CR1 phenotypes (i.e. high, 
medium or low) within individual families, however, some of 
the patients studied may have acquired low erythrocyte CR1 
levels. The supportive evidence for this statement '.S ;
a) acquisition of low CR1 levels during periods of disease 
exacerbation as shown by serial studies (Pig. 27), b) lower 
mean CR1 levels in the SLE patients in an active disease phase 
(356 CR1 sites/erythrocyte) as opposed to an inactive disease 
phase (2428 CR1 sites/erythrocyte, p <0.001), c) SLE
285
patients with low CR1 levels belonging to families with 
medium to high CR1 levels (Figs. 29 and 30), d) identical 
twins with SLE had different CR1 levels. Therefore, some 
individuals with SLE seem to acquire low erythrocyte CR1 
levels and this seems to be associated with disease activity.
It is clearly well established that low erythrocyte CR1 
levels are associated with SLE and other immunologically 
mediated diseases and one can consider how this would affect 
the pathogenesis of the disease, for example in SLE. The 
potential consequences of low receptor levels could be con­
ceived to be the following: 1) Decreased carriage of circul­
ating immune complexes by the erythrocytes to the fixed mono­
nuclear phagocytic system of the liver and spleen? this could 
consequently affect the rate at which immune complexes were 
cleared and the amount left circulating. Therefore^immune 
complexes left in the circulation would have an enhanced chance 
of being deposited. A contributory factor would be the finding 
by Horgan and Taylor (1984) that DNA complexes bind less rapidly 
to erythrocytes from SLE patients than normals (30 mins as opposed 
to 4 mins), so there would be reduced binding which would occur 
more slowly, 2) Reduced cleavage of C3b on the immune complexes 
to the smaller breakdown fragments iC3b and finally C3d-g by 
the action of I and CR1 (Medof and Prince, 1983a; Horgan et 
al, 1984). This reduction in C3d-g bearing complexes would 
inhibit the interaction of immune complexes with phagocytic 
cells bearing CR3 and CR4 (C3d-g receptor ), and hence phago­
cytosis and immune complex clearance by this mechanism would 
be minimised. 3) As there would be reduced immune complex 
interaction with CR1, there would be less modulation of the 
circulating immune complexes size brought about by the inter­
action of CR1 and the complement system (Medof and Prince, 1983b).
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In addition, if one considers that the SLE patients 
may have already elevated circulating immune complexes and/or
hypocomplementaemia, the situation may become aggravated and 
a vicious circle could become established. For example, low 
CR1 levels would be unable to minimise the circulating 
immune complex load, this in turn would result in continuous 
complement activation and perhaps finally there would be 
deposition of the immune complexes and the subsequent init­
iation of an inflammatory response, all leading to tissue injury,
CR1 is not found solely on erythrocytes and the defect 
in erythrocyte CR1 levels seen in SLE patients may not be con­
fined to the erythrocyte alone. In this thesis the technique 
used to quantitate the erythrocyte CR1 levels was modified and 
performed without success on the human leucocyte populations 
(Chapter 4). Pursuing this work further Miss A. W. Fyfe 
successfully adapted the RIA method and has shown that the PMNs 
from SLE patients have lower CR1 levels than normal PMNs. She 
also observed a variation in the CR1 levels of PMNs with disease 
activity corresponding with changes in the erythrocyte CR1 
levels. Similar studies have not yet been performed on mono­
cytes, macrophages, lymphocytes or mast cells. A study by 
Kazatchkine et al (1982) however did show the lack of CR1 on the 
kidney podocytes of SLE patients with diffuse proliferative 
glomerulonephritis but not the non-proliferative form. It would 
therefore be of importance to establish whether this defect was 
restricted to certain cell types or a widespread defect, and 
what effects this would have on the immune system's ability 
to cope with circulating immune complexes.
The evidence supporting an acquired defect in CR1 levels 
has been presented as has the possible implications this may
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have on the fun,ctioning of the immune system and its ability 
to handle circulating immune complexes. However, the question 
which still remains to be answered is how low CR1 levels on 
erythrocytes are acquired? Three possibilities can be 
considered, firstly receptors may be lost during erythropoiesis, 
however in-depth studies examining CR1 levels at the different 
stages of erythrocyte differentiation would be required to 
answer this possibility. Secondly, receptor removal. This 
could possibly occur due to the action of plasma proteases on 
the erythrocyte CR1, or they may be removed together with the 
attached immune complexes by the fixed mononuclear phagocytic 
system during their passage through the liver and spleen. The 
finding by Yoon and Fearon (1985) of a soluble plasma form of 
CR1 proposed to be derived from the erythrocytes, supports 
the possibility that by some manner CR1 can be released and/or 
removed from the erythrocyte’s cell membrane. In addition,
Wilson et al (1982) found that older normal erythrocytes possessed 
fewer CR1 than younger ones and this data may also favour receptor 
removal. This area obviously requires further investigation; 
for example, does serum or serum factors (from normals and patients) 
affect receptor levels, do circulating soluble GR1 levels correspond 
with erythrocyte CR1 levels and can assay conditions be established 
which examine receptor loss? This area of receptor removal 
was not investigated in this thesis. Thirdly, receptor blockade.
In this thesis preliminary studies were undertaken to establish 
whether receptor blockade by immune complexes could contribute 
to receptor reduction. Opsonized immune complexes (BSA anti-BSA, 
thyroglobulin anti-thyroglobulin, DNA anti-DlA) were incubated 
in vitro with normal erythrocytes. All three complex types were 
shown to have bound to the erythrocyte cell surface, but only
tliose formed with thyroglobuliin or IMA broiaght about partial 
or total receptor blockade (as determined -m.Rüpg; both polyclonal 
.and monoclonal anti—GR1 ). Thus stressing the importance of
the immune complex size on its efficacy to block receptors, 
with the larger antigens forming complexes which sterically 
block the receptors more effectively than those formed with 
smaller antigens. An study on the effect of
immune complexes on receptor levels would be required to see 
whether parameters such as antibody isotype, avidity, type of 
antibody—antigen interaction, immune complex stability 
bility affect to different extents receptor blockade. For 
example, Pedersen et al (19©0] believe that in vitro
performed with small globular antigens such as BSA are irrelevant 
when studying diseases such as StE where the antigen (HiA)) is 
large and of variable size. Studies would also be required 
to confirm that the in vitro findings are not a test tube 
artifact. Tn vivo studies have been performed by Taylor et al
(1985) using DMA complexes and they examined their binding to 
guinea pig platelets (which bear CB1, whilst their erythrocytes 
do not ). They demonstrated binding and clearance of 75?^  of
the complexes within 5 mins, the reaction"s complement dependency 
and that the binding and release of DMA and BSA immune complexes 
were not the same. So more in-depth in vivo studies using 
different types of immune complexes may help elucidate whether 
iffliiune complex blockade in vivo could contribute to the acqui­
sition of low CE1 levels.
As mentioned earlier, if the defect of CB1 levels on 
erythrocytes in. some SDE patients is acquired, it opens up the 
possibility of developing means of increasing the circulating 
erythrocyte C11 levels. The most obvious remedy w
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transfusion of normal erythrocytes with a high CR1 level 
into an affected patient. This has been performed by 2 
groups, yielding conflicting results. Inada et al (1983) 
transfused a patient with normal erythrocytes with a high 
CR1 level, this brought about a reduction in the patient's 
circulating immune complex levels and an improvement of their 
condition. A similar study performed by Walport et al (1985b) 
caused a reduction in the CR1 levels on the transfused erythro­
cytes. Despite the conflicting results, this manner of 
treatment cannot be dismissed and further investigation into 
this area seems warranted.
A very evident problem with this means of treatment or 
any other means which may be used to try and rectify the CR1 
levels is in determining whether the patient has genetically 
or acquired low CR1 levels. To define this, serial studies 
and family studies would be required to assess whether the 
observed patient CR1 phenotype was inherited or acquired, 
as treatment of an inherited defect may have no potential benefit 
It is for the same reason that an individual's CR1 levels would 
be of no value as a diagnostic criteria for disease activity, 
unless the patient's normal inherited CR1 level was known, 
and continued serial studies performed to evaluate whether an 
acquired CR1 deficiency concorded with disease activity.
The aim of this thesis was to examine CR1 levels on the 
peripheral blood cells of normal individuals, SLE and RA patients, 
This was successfully performed on the erythrocytes but not the 
leucocytes. More in-depth studies performed on the SLE patients 
showed that some of these patients had acquired low erythrocyte 
CR1 levels. Preliminary investigations into the means of low
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CR1 acquisition concentrated on the possibility that 
opsonized circulating immune complexes could bind to erythro­
cytes and block the receptors. Personally I favour the 
view that acquired low CR1 levels are caused by receptor block­
ade. Although, CR1 is known to be very sensitive to proteo­
lysis (personal communication Dr. R. Sim), it is hence easy 
to believe that they could be removed from the erythrocyte, 
however, it is more difficult to explain why CR1 levels increase 
so rapidly in some individuals. For example, normal individual 
L.J. (Table 23) had a 1227% increase in her receptor levels 
in 5 weeks and SLE patient 8.8. (Table 26} increased her receptors 
by 677% in 3 weeks. It is difficult to explain these increases 
on the production of new erythrocytes possessing a higher CR1 
level, as the half-life of these cells is 120 days. However, 
blockade of receptors could explain such changes, with a removal 
of the blocking factor exposing more CR1 and vice versa. Daily 
serial studies would clarify how quickly and how often CR1 
levels change. It may also show whether there is any diurnal 
variation or any relationship with, for example, food intake, 
exercise or stress.
In conclusion, while the results of my study indicate that 
low CR1 levels could be due to receptor blockade, itWxs to be 
realised that^as with other biological systems, the exact 
mechanism whereby low CR1 numbers arise probably involves many 
other additional factors, the nature of which remains to be 
elucidated.
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